WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, September 22, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L10	L5 AND L8	82
☐	L9	L5 AND L6	249
☐	L8	cyclin	8181
☐	L7	CYCLIN	8181
☐	L6	SV40	26490
☐	L5	VP22	524
☐	L4	L3 AND VP22	79
☐	L3	530/300,350.CCLS.	16971
☐	L2	L1 AND VP22	70
☐	L1	(435/69.1.CCLS.)	19136

END OF SEARCH HISTORY

h e b b cg b chh e fb f c e c ch

Hit List

Search Forms
Search Results
Help
User Searches
Preferences
Logout

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 82 of 82 returned.

☐ 1. Document ID: US 20040151696 A1

Using default format because multiple data bases are involved.

L10: Entry 1 of 82 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151696
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040151696 A1

TITLE: Oncolytic adenovirus

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Johnson, Leisa	Lafayette	CA	US	
Fattaey, Ali	San Francisco	CA	US	
Hermiston, Terry	Corte Madera	CA	US	
Shen, Yuqiao	Orinda	CA	US	
Laquerre, Sylvie	Conshohocken	PA	US	

US-CL-CURRENT: 424/93.2; 435/235.1, 435/456

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20040146944 A1

L10: Entry 2 of 82 File: PGPB Jul 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040146944
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040146944 A1

TITLE: Reverse protein delivery into cells on coded microparticles

PUBLICATION-DATE: July 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fang, Ye	Painted Post	NY	US	
Webb, Brian L.	Painted Post	NY	US	

US-CL-CURRENT: 435/7.2

ABSTRACT:

Systems, methods and kits that utilize uniquely coded microparticles for performing protein assays are provided. The uniquely coded microparticles are used as a substrate for reverse protein delivery into cells. The microparticles and methods offer the possibility of studying the biological functions of either a single protein of interest in multiple cell types per assay or multiple proteins in a single cell type.

☐ 3. Document ID: US 20040142900 A1

L10: Entry 3 of 82 File: PGPB Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142900
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040142900 A1

TITLE: Uses of transport proteins

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Normand, Nadia Michelle	Surrey		GB	
Brewis, Neil Douglas	Surrey		GB	
Phelan, Anne	Kent		GB	

US-CL-CURRENT: 514/44; 435/455

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

☐ 4. Document ID: US 20040137622 A1

L10: Entry 4 of 82 File: PGPB Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040137622
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040137622 A1

TITLE: Modular transfection systems

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Schmidt, Hanns-Martin	Koln	DE
Altrogge, Ludger	Pulheim	DE
Lenz, Dietmar	Koln	DE
Riemen, Gudula	Langenfeld	DE
Brosterhus, Helmut	Kirchhunden	DE
Lorbach, Elke	Koln	DE
Helfrich, Juliana	Koln	DE
Hein, Katharina	Koln	DE
Gremse, Marion	Koln	DE
Males, Tarjana	Hilden	DE
Christine, Rainer	Koln	DE
Siebenkotten, Gregor	Freehen-Konigsdorf	DE
Ortmann, Bodo	Koln	DE
Klacs, Andrea	Koln	DE

US-CL-CURRENT: 435/455

ABSTRACT:

The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals. The present inventions also includes corresponding pharmaceutical preparations, especially for use in gene therapy as well as the use of such transfection agents as component in kits.

☐ 5. Document ID: US 20040072319 A1

L10: Entry 5 of 82 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072319
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072319 A1

TITLE: Molecules that modulate ubiquintin-dependent proteolysis and methods for identifying same

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Nash, Piers	Ontario		CA	
Pawson, Anthony	Ontario		CA	

Tang, Xiaojing	Ontario	CA
Tyers, Michael	Ontario	CA

US-CL-CURRENT: 435/226; 435/320.1, 435/325

ABSTRACT:

The invention relates to methods for identifying compounds that modulate ubiquitin-dependent proteolysis, and compounds identified using the methods. The invention also relates to a novel peptide motif referred to as the "CPD motif", molecules derived from the CPD motif, and uses of the CPD motif and molecules.

☐ 6. Document ID: US 20040038303 A1

L10: Entry 6 of 82 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038303
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038303 A1

TITLE: Biologic modulations with nanoparticles

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Unger, Gretchen M.	Chaska	MN	US	

US-CL-CURRENT: 435/7.1; 530/350, 530/387.1, 530/396, 536/123

ABSTRACT:

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth.

☐ 7. Document ID: US 20040028693 A1

L10: Entry 7 of 82 File: PGPB Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040028693
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040028693 A1

TITLE: Molecular vaccine linking intercellular spreading protein to an antigen

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wu, Tzyy Choou	Brookeville	MD	US	
Hung, Chien-Fu	Baltimore	MD	US	

US-CL-CURRENT: 424/185.1

ABSTRACT:

Superior molecular vaccines comprise nucleic acids, including naked DNA and replicon RNA, that encode a fusion polypeptide that includes an antigenic peptide or polypeptide against which an immune response is desired. Fused to the antigenic peptide is an intercellular spreading protein, in particular a herpes virus protein VP22 or a homologue or functional derivative thereof. Preferred spreading proteins are VP22 from HSV-1 and Marek's disease virus. The nucleic acid can encode any antigenic epitope of interest, preferably an epitope that is processed and presented by MHC class I proteins. Antigens of pathogenic organisms and cells such as tumor cells are preferred. Vaccines comprising HPV-16 E7 oncoprotein are exemplified. Also disclosed are methods of using the vaccines to induce heightened T cell mediated immunity, in particular by cytotoxic T lymphocytes, leading to protection from or treatment of a tumor.

☐ 8. Document ID: US 20040028607 A1

L10: Entry 8 of 82 File: PGPB Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040028607
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040028607 A1

TITLE: Methods of modulating tubulin deacetylase activity

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Verdin, Eric M.	San Francisco	CA	US	
North, Brian J.	San Francisco	CA	US	
Ulrich, Scott M.	Ithaca	NY	US	

US-CL-CURRENT: 424/1.11; 435/19

ABSTRACT:

The present invention provides methods for identifying agents that modulate a level or an activity of tubulin deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating tubulin deacetylase activity in a cell. The invention further provides methods of modulating cellular proliferation by modulating the activity of tubulin deacetylase.

☐ 9. Document ID: US 20040023391 A1

L10: Entry 9 of 82 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023391
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023391 A1

TITLE: Method and device for protein delivery into cells

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fang, Ye	Painted Post	NY	US	
Lai, Fang	Painted Post	NY	US	
Picard, Laurent A.G.	Corning	NY	US	
Webb, Brian L.	Painted Post	NY	US	

US-CL-CURRENT: 435/458; 435/366

ABSTRACT:

Methods for performing surface-mediated protein delivery into living cells, and fabricating protein-transfected cell cluster arrays are provided. The method comprises providing a protein-containing mixture; depositing said protein-containing mixture onto a surface at defined locations; affixing the protein-containing mixture to the surface as microspots; and plating cells onto the surface in sufficient density and under conditions for the proteins to be delivered into the cells. The protein-containing mixture comprises any suitable amino acid sequence, including peptides, proteins, protein-domains, antibodies, or protein-nucleic acid conjugates, etc., with a carrier reagent. Protein-transfected cell arrays may be used for rapid and direct, screening of protein or enzymatic functions or any given intracellular protein interaction in the natural environment of a living cell, as well as for high-throughput screening of other biological and chemical analytes, which affect the functions of these proteins.

☐ 10. Document ID: US 20040022769 A1

L10: Entry 10 of 82 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040022769
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040022769 A1

TITLE: Methods and compositions to induce antitumor response

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFace, Drake M.	San Diego	CA	US	

US-CL-CURRENT: 424/93.2; 435/235.1, 435/320.1, 435/456

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention invention is induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

☐ 11. Document ID: US 20040002455 A1

L10: Entry 11 of 82 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

☐ 12. Document ID: US 20030232781 A1

L10: Entry 12 of 82 File: PGPB Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030232781
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030232781 A1

TITLE: Modulation of gene expression using insulator binding proteins

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.			US	
Wolffe, Elizabeth J.			US	

US-CL-CURRENT: 514/44; 424/94.61, 435/455

ABSTRACT:

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions including insulator domains for targeted regulation of a gene or transgene are provided.

☐ 13. Document ID: US 20030229202 A1

L10: Entry 13 of 82 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030229202 A1

TITLE: Membrane penetrating peptides and uses thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guo, Yong	Fresh Meadows	NY	US	
Morse, Clarence C.	Asbury	NJ	US	
Yao, Zhengbin	Sugar Land	TX	US	
Keesler, George A.	Hillsborough	NJ	US	

US-CL-CURRENT: 530/350; 435/455

ABSTRACT:

The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More

particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 14. Document ID: US 20030199002 A1

L10: Entry 14 of 82 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199002
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030199002 A1

TITLE: Clk-2 nucleic acids, polypeptides and uses thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hekimi, Siegfried	Montreal	MD	CA	
Benard, Claire	Montreal		CA	
Jiang, Ning	Montreal		CA	
Kebir, Hania	Montreal		CA	
McCright, Brenton	Gaithersburg		US	
Lakowski, Bernard	Paris		FR	

US-CL-CURRENT: 435/7.2; 435/193, 435/320.1, 435/325, 435/69.7, 536/23.2

ABSTRACT:

The present invention relates to nucleotide sequences of clk-2 genes, particularly human clk-2, and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof. The present invention also relates to methods and compositions designed for the treatment, management, or prevention of disorders associated with abnormal expression and/or activity of clk-2 nucleic acids and/or proteins. In one embodiment, the invention encompasses a method of treating or preventing a disorder associated with decreased apoptosis (e.g., cancer, autoimmune disorders) or decreased telomere length (e.g., rapid aging or advanced age) by administering to a subject in need thereof an effective amount of an agent that promotes clk-2 activity. In another embodiment, invention encompasses a method of treating or preventing a disorder associated with increased apoptosis (e.g., neurodegenerative disorders) and increased telomere length (e.g., cancer) such as by administering to a subject in need thereof an effective amount of an agent that decreases clk-2 function. Diagnostic methods and methods for screening for therapeutically useful agents are also provided.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 15. Document ID: US 20030194727 A1

L10: Entry 15 of 82 File: PGPB Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kim, Jin-Soo	Yuseong-gu		KR	
Park, Kyung-Soon	Yuseong-gu		KR	
Lee, Dong-Ki	Yuseong-gu		KR	
Seol, Wongi	Yuseong-gu		KR	
Lee, Horim	Chungcheongnam-do		KR	
Lee, Seong-Il	Yuseong-gu		KR	
Yang, Hyo-Young	Yuseong-gu		KR	
Lee, Yangsoon	Yuseong-gu		KR	
Jang, Young-Soon	Yuseong-gu		KR	

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1, 435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

☐ 16. Document ID: US 20030180777 A1

L10: Entry 16 of 82 File: PGPB Sep 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030180777
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030180777 A1

TITLE: Rapid identification of transcriptional regulatory domains

PUBLICATION-DATE: September 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartsevich, Victor	Albany	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/7.2

ABSTRACT:

Compositions and methods for high-throughput assay for transcriptional regulatory domains in mammalian cells are provided. In certain embodiments, libraries of random amino acid sequences are assayed for transcriptional regulatory activity. In additional embodiments, cDNA libraries are assayed. Libraries are fused to a DNA-binding domain that is targeted to a reporter gene, and modulation of expression of the reporter gene is assayed. Accordingly, regulatory domains having both positive and negative transcriptional regulatory activity can be identified.

☐ 17. Document ID: US 20030170216 A1

L10: Entry 17 of 82 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170216
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170216 A1

TITLE: SYN3 compositions and methods

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ihnat, Peter M.	Brooklyn	NY	US	
Witchey-Lakshmanan, Leonore C.	Piscataway	NJ	US	
Sandweiss, Varda	Forest Hills	NY	US	
Ugwu, Sydney O.	Chicago	IL	US	

US-CL-CURRENT: 424/93.21; 514/44

ABSTRACT:

Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 18. Document ID: US 20030166141 A1

L10: Entry 18 of 82 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Case, Casey C.	San Mateo	CA	US
Cox, George N. III	Louisville	CO	US
Eisenberg, Stephen P.	Boulder	CO	US
Liu, Qiang	Foster City	CA	US
Rebar, Edward J.	El Cerrito	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

☐ 19. Document ID: US 20030152945 A1

L10: Entry 19 of 82 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152945 A1

TITLE: Cell cycle progression proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deak, Peter	Cambridge		GB	
Glover, David Moore	Sandy		GB	
Midgley, Carol	Milton Keynes		GB	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

☐ 20. Document ID: US 20030148973 A1

L10: Entry 20 of 82 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148973
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148973 A1

TITLE: MAGE-A1 peptides for treating or preventing cancer

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Emtage, Peter	Boston	MA	US	
Karunakaran, Liza	Toronto	NY	CA	
Pedyczak, Arthur	Toronto		CA	
Barber, Brian H.	Hawthorne		US	

US-CL-CURRENT: 514/44; 424/185.1, 424/93.2, 536/23.1

ABSTRACT:

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

☐ 21. Document ID: US 20030113919 A1

L10: Entry 21 of 82 File: PGPB Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030113919
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030113919 A1

TITLE: Immunogenic targets for melanoma

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Emtage, Peter	Sunnyvale	CA	US	
Karunakaran, Liza	Thornhill	NY	CA	
Pedyczak, Artur	Pickering		CA	
Barber, Brian	White Plains		US	

US-CL-CURRENT: 435/456; 435/235.1, 435/320.1

ABSTRACT:

The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.

☐ 22. Document ID: US 20030108880 A1

L10: Entry 22 of 82 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

☐ 23. Document ID: US 20030099944 A1

L10: Entry 23 of 82 File: PGPB May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030099944
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030099944 A1

TITLE: Combination therapy involving drugs which target cellular proteins and drugs which target pathogen-encoded proteins

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton		CA	

US-CL-CURRENT: 435/6; 424/204.1, 435/5, 514/263.38, 514/263.4

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of pathogen gene expression, replication and reactivation. The invention also relates to the identification of a combination therapy to inhibit pathogen replication in which a drug that inhibits pathogen replication by targeting a specific pathogen-encoded protein is administered in combination with a drug that inhibits pathogen replication by targeting host-encoded cdk proteins. Compositions and assays for the

identification and use of such inhibitors are provided as are methods of use of the inhibitors

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 24. Document ID: US 20030087817 A1

L10: Entry 24 of 82 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087817
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087817 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cox, George Norbert III	Louisville	CO	US	
Case, Casey Christopher	San Mateo	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric Edward	Boulder	CO	US	
Spratt, Sharon Kaye	Vacaville	CA	US	

US-CL-CURRENT: 514/12; 435/455

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 25. Document ID: US 20030087411 A1

L10: Entry 25 of 82 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	

Virca, George D. Bellevue WA US

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

☐ 26. Document ID: US 20030082552 A1

L10: Entry 26 of 82 File: PGPB May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082552
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030082552 A1

TITLE: Modulation of gene expression using localization domains

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	Richmond	CA	US	
Urnov, Fyodor	Richmond	CA	US	
Lai, Albert	Berkeley	CA	US	
Raschke, Eva	San Francisco	CA	US	
Wolffe, Elizabeth J.			US	

US-CL-CURRENT: 435/6; 435/317.1, 435/455

ABSTRACT:

Methods and compositions for regulating gene expression are provided. In particular, methods and compositions comprising localization domains, and fusions of localization domains with DNA binding domains and, optionally regulatory domains, are provided.

☐ 27. Document ID: US 20030060457 A1

L10: Entry 27 of 82 File: PGPB Mar 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030060457
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030060457 A1

TITLE: Cellular proteins as targets for the treatment of pathogens resistant to drugs

that target pathogen-encoded proteins

PUBLICATION-DATE: March 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton		CA	

US-CL-CURRENT: 514/211.08; 514/263.4, 514/285, 514/414, 514/456, 514/473, 514/518

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of gene expression, replication and reactivation in pathogenic agents. Compositions and assays for the identification and use of such inhibitors are provided, as are methods of use of the inhibitors

---

☐ 28. Document ID: US 20030059851 A1

L10: Entry 28 of 82 File: PGPB Mar 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030059851
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030059851 A1

TITLE: Protein quantitation with cell imaging densitometry

PUBLICATION-DATE: March 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Smith, Steven Jay	Bronx	NY	US	

US-CL-CURRENT: 435/7.2; 435/40.5, 435/7.23

ABSTRACT:

A method for quantitating cellular proteins in tissue, by means of a cell imaging densitometer in conjunction with immunohistological staining and a reference standard, is provided. Unlike prior art methods, which provide ordinal measures of relative amounts of protein among different cells, the method enables the quantitation of antigenic proteins in terms of absolute mass of protein/tumor or protein/patient, molecules of protein per cell, and volume or fraction of a tissue sample expressing the protein of interest. The method is useful for research purposes in the study of protein expression, and is shown to improve the accuracy of clinical histopathological analysis of tumor tissue sections for diagnosis and prognosis. The method is expected to be useful for prescribing in situ treatment dosages. The demonstrated resulting improvement in the correlation between tissue levels and blood levels of tumor-associated proteins should facilitate minimally-invasive monitoring of cancer progression and therapeutic response.

☐ 29. Document ID: US 20030054409 A1

L10: Entry 29 of 82 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054409
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054409 A1

TITLE: Novel complex-forming proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jerome, Valerie	Coelbe		DE	
Sedlacek, Hans-Harald	Marburg		DE	
Mueller, Rolf	Marburg		DE	

US-CL-CURRENT: 435/7.1; 435/183, 435/320.1, 435/325, 435/69.5, 435/69.7, 530/350, 530/351

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 30. Document ID: US 20030054000 A1

L10: Entry 30 of 82 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054000
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054000 A1

TITLE: Anti-pathogen system and methods of use thereof

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dowdy, Steven F.	Clayton	MO	US	

US-CL-CURRENT: 424/94.63; 435/226, 530/327, 530/350, 536/23.4, 536/24.33

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

☐ 31. Document ID: US 20030049649 A1

L10: Entry 31 of 82 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049649
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049649 A1

TITLE: Targeted modification of chromatin structure

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	San Pablo	CA	US	
Wolffe, Elizabeth J.	Richmond	CA	US	
Collingwood, Trevor			US	
Snowden, Andrew			US	

US-CL-CURRENT: 435/6; 435/199, 435/455, 435/468

ABSTRACT:

Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.

☐ 32. Document ID: US 20030049602 A1

L10: Entry 32 of 82 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

---

☐ 33. Document ID: US 20030036163 A1

L10: Entry 33 of 82 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

☐ 34. Document ID: US 20030022330 A1

L10: Entry 34 of 82 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022330
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022330 A1

TITLE: APOA2-interacting proteins and use thereof

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/183; 435/226, 435/7.1

ABSTRACT:

Protein complexes are provided comprising APOA2 and one or more APOA2-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA2 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des

☐ 35. Document ID: US 20030013169 A1

L10: Entry 35 of 82 File: PGPB Jan 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030013169
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030013169 A1

TITLE: Transcription factor E2F DNA-binding domain inhibitor peptides and their use

PUBLICATION-DATE: January 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Muller, Rolf	Marburg		DE	
Kontermann, Roland E.	Marburg		DE	
Montigiani, Silvia	Siena		IT	

US-CL-CURRENT: 435/184; 530/330

ABSTRACT:

The present invention provides peptides which bind to the DNA binding domain of transcription factor E2F, and inhibit cell cycle progression. Peptides include FWLRFT (SEQ ID NO:1); WVRWHF (SEQ ID NO:2); WHFIFW (SEQ ID NO:3); IWLSGLSRGVWVSFP (SEQ ID NO:4); and GSRILTFRSGSWYAS (SEQ ID NO:5) and derivatives based upon these sequences. Compositions and the use of the peptides in inhibiting cell cycle progression, such as in uncontrolled cell proliferation, are also provided.

☐ 36. Document ID: US 20030008373 A1

L10: Entry 36 of 82 File: PGPB Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008373
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030008373 A1

TITLE: APOA1-interacting proteins and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	
Szankasi, Philippe	Salt Lake City	UT	US	
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/226; 435/183, 435/7.1

ABSTRACT:

Protein complexes are provided comprising APOA1 and one or more APOA1-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA1 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 37. Document ID: US 20030008324 A1

L10: Entry 37 of 82 File: PGPB Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 38. Document ID: US 20020197691 A1

L10: Entry 38 of 82 File: PGPB Dec 26, 2002

PGPUB-DOCUMENT-NUMBER: 20020197691
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020197691 A1

TITLE: FLT4-interacting proteins and use thereof

PUBLICATION-DATE: December 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Janice	Salt Lake City	UT	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/7.23

ABSTRACT:

Protein complexes are provided comprising FLT4 and one or more FLT4-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with FLT4 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 39. Document ID: US 20020187143 A1

L10: Entry 39 of 82 File: PGPB Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187143
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187143 A1

TITLE: Methods and compositions for reducing immune response

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LaFace, Drake M.	San Diego	CA	US	
Rahman, Amena	San Diego	CA	US	
Shabram, Paul W.	Olivenhain	CA	US	
Tsai, Van T.	San Diego	CA	US	

US-CL-CURRENT: 424/140.1; 435/320.1, 536/23.72

ABSTRACT:

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.

☐ 40. Document ID: US 20020177692 A1

L10: Entry 40 of 82 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177692
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177692 A1

TITLE: BCL-XL-interacting protein and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/184, 435/287.2, 435/320.1, 435/325, 435/69.7

ABSTRACT:

Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting

members thereof are also provided.

☐ 41. Document ID: US 20020177207 A1

L10: Entry 41 of 82 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177207
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177207 A1

TITLE: Tsg101-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sugiyama, Janice	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/196; 435/199, 435/226

ABSTRACT:

Protein complexes are provided comprising Tsg101 and one or more protein interactors of Tsg101. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Tsg101 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 42. Document ID: US 20020177177 A1

L10: Entry 42 of 82 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177177
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177177 A1

TITLE: Interaction between cyclin D1 and steroid receptor co-activators and uses thereof in assays

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bernards, Rene	Alconde		NL	
Zwijsen, Renate	Utrecht		NL	

US-CL-CURRENT: 435/7.23; 514/14, 514/15, 514/16, 530/326, 530/327, 530/328

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumors, for assays for compounds useful in the prevention of tumors and compounds obtainable by such assays.

☐ 43. Document ID: US 20020177152 A1

L10: Entry 43 of 82 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opa1. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 44. Document ID: US 20020173026 A1

L10: Entry 44 of 82 File: PGPB Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/199; 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 45. Document ID: US 20020165352 A1

L10: Entry 45 of 82 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165352
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165352 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitis (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 46. Document ID: US 20020164666 A1

L10: Entry 46 of 82 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164666
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164666 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.23; 435/183, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 47. Document ID: US 20020164575 A1

L10: Entry 47 of 82 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164575
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164575 A1

TITLE: Gene identification

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Case, Casey C.	San Mateo	CA	US
Urnov, Fyodor	Richmond	CA	US

US-CL-CURRENT: 435/4; 435/6

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

☐ 48. Document ID: US 20020160940 A1

L10: Entry 48 of 82 File: PGPB Oct 31, 2002

PGPUB-DOCUMENT-NUMBER: 20020160940
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020160940 A1

TITLE: Modulation of endogenous gene expression in cells

PUBLICATION-DATE: October 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Wolffe, Alan	Richmond	CA	US	
Urnov, Fyodor	Richmond	CA	US	
Lai, Albert	Richmond	CA	US	
Snowden, Andrew	Alameda	CA	US	
Tan, Siyuan	El Cerrito	CA	US	
Gregory, Philip			US	

US-CL-CURRENT: 514/6; 435/455

ABSTRACT:

Disclosed herein are methods and compositions for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

☐ 49. Document ID: US 20020155988 A1

L10: Entry 49 of 82 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155988
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155988 A1

TITLE: Uses of transport proteins

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Normand, Nadia Michelle	Surrey		GB	
Brewis, Neil Douglas	Surrey		GB	
Phelan, Anne	Kent		GB	

US-CL-CURRENT: 514/2; 435/7.23

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

☐ 50. Document ID: US 20020155432 A1

L10: Entry 50 of 82 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	
Weichselbaum, Ralph R.	Chicago	IL	US	
Roizman, Bernard	Chicago	IL	US	

US-CL-CURRENT: 435/5; 424/199.1, 424/205.1, 424/229.1, 435/320.1, 435/69.1

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising

administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 51. Document ID: US 20020150557 A1

L10: Entry 51 of 82 File: PGPB Oct 17, 2002

PGPUB-DOCUMENT-NUMBER: 20020150557
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020150557 A1

TITLE: Selectively replicating viral vectors

PUBLICATION-DATE: October 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ramachandra, Muralidhara	San Diego	CA	US	
Shabram, Paul W.	Olivenhain	CA	US	

US-CL-CURRENT: 424/93.2; 424/456, 435/320.1

ABSTRACT:

The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 52. Document ID: US 20020115215 A1

L10: Entry 52 of 82 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115215
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115215 A1

TITLE: Targeted modification of chromatin structure

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Alan P.	Orinda	CA	US	
Collingwood, Trevor	San Pablo	CA	US	

US-CL-CURRENT: 435/455; 435/468, 435/6

ABSTRACT:

Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.

☐ 53. Document ID: US 20020106378 A1

L10: Entry 53 of 82 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106378
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106378 A1

TITLE: Materials and methods for intracellular transport and their uses

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Oxted		GB	
Elliott, Gillian Daphne	Oxted		GB	

US-CL-CURRENT: 424/186.1; 530/350

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

☐ 54. Document ID: US 20020094529 A1

L10: Entry 54 of 82 File: PGPB Jul 18, 2002

PGPUB-DOCUMENT-NUMBER: 20020094529
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020094529 A1

TITLE: Gene identification

PUBLICATION-DATE: July 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Urnov, Fyodor	Richmond	CA	US	

US-CL-CURRENT: 435/6; 435/4, 435/455

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

☐ 55. Document ID: US 20020081736 A1

L10: Entry 55 of 82 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081736
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081736 A1

TITLE: Nucleic acid delivery

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Conroy, Susan E.	London	CA	GB	
Engler, Heidrun	San Diego	CA	US	
Maneval, Daniel C.	San Diego		US	

US-CL-CURRENT: 435/455; 514/44, 514/53, 514/58

ABSTRACT:

The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression

vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 56. Document ID: US 20020081614 A1

L10: Entry 56 of 82 File: PGPB Jun 27, 2002

PGPUB-DOCUMENT-NUMBER: 20020081614
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020081614 A1

TITLE: Functional genomics using zinc finger proteins

PUBLICATION-DATE: June 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Zhang, Lei	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/7.21, 702/19

ABSTRACT:

0 The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

Full | Title | Cita | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 57. Document ID: US 20020072119 A1

L10: Entry 57 of 82 File: PGPB Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072119
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020072119 A1

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Laquerre, Sylvie	Walnut Creek	CA	US	
Hermiston, Terry	Corte Madera	CA	US	

US-CL-CURRENT: 435/456; 424/93.6, 435/235.1

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

☐ 58. Document ID: US 20020068706 A1

L10: Entry 58 of 82 File: PGPB Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068706
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020068706 A1

TITLE: INHIBITORS OF CELL-CYCLE PROGRESSION AND USES RELATED THERETO

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
GYURIS, JENO	WINCHESTER	MA	US	
LAMPHERE, LOU	BOSTON	MA	US	
BEACH, DAVID H.	HUNTINGTON BAY	NY	US	

US-CL-CURRENT: 514/44; 435/455, 536/23.4, 536/23.72, 536/24.1

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

☐ 59. Document ID: US 20020037280 A1

L10: Entry 59 of 82 File: PGPB Mar 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020037280
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020037280 A1

TITLE: Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

PUBLICATION-DATE: March 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lieber, Andre	Seattle	WA	US	

Steinwaerder, Dirk S.	Hamburg	WA	DE
Carlson, Cheryl A.	Seattle	WA	US
Mi, Jie	Seattle		US

US-CL-CURRENT: 424/93.21; 435/235.1, 435/320.1, 435/456

ABSTRACT:

This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).

☐ 60. Document ID: US 6780590 B2

L10: Entry 60 of 82 File: USPT Aug 24, 2004

US-PAT-NO: 6780590
DOCUMENT-IDENTIFIER: US 6780590 B2

TITLE: Gene identification

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6

ABSTRACT:

The present disclosure provides methods and compositions for identifying a particular genomic sequence as a gene and/or a coding region, once that sequence has been tentatively identified as a gene based on genomic analysis using one or more gene prediction algorithms. The methods include the use of exogenous molecules such as zinc finger proteins which are capable of binding to and modulating expression of gene transcription, targeted to putative gene sequences, followed by assay for one or more selected phenotypes.

30 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 61. Document ID: US 6777185 B2

L10: Entry 61 of 82 File: USPT Aug 17, 2004

US-PAT-NO: 6777185
DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 62. Document ID: US 6746848 B2

L10: Entry 62 of 82 File: USPT Jun 8, 2004

US-PAT-NO: 6746848
DOCUMENT-IDENTIFIER: US 6746848 B2

TITLE: Protein quantitation with cell imaging densitometry

DATE-ISSUED: June 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Smith; Steven Jay	Bronx	NY	10463	

US-CL-CURRENT: 435/7.23; 435/7.21, 435/960, 435/967, 436/518, 436/63, 436/64

ABSTRACT:

A method for quantitating cellular proteins in tissue, by means of a cell imaging densitometer in conjunction with immunohistological staining and a reference standard, is provided. Unlike prior art methods, which provide ordinal measures of

relative amounts of protein among different cells, the method enables the quantitation of antigenic proteins in terms of absolute mass of protein/tumor or protein/patient, molecules of protein per cell, and volume or fraction of a tissue sample expressing the protein of interest. The method is useful for research purposes in the study of protein expression, and is shown to improve the accuracy of clinical histopathological analysis of tumor tissue sections for diagnosis and prognosis. The method is expected to be useful for prescribing in situ treatment dosages. The demonstrated resulting improvement in the correlation between tissue levels and blood levels of tumor-associated proteins should facilitate minimally-invasive monitoring of cancer progression and therapeutic response.

21 Claims, 23 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17

☐ 63. Document ID: US 6734167 B2

L10: Entry 63 of 82 File: USPT May 11, 2004

US-PAT-NO: 6734167
DOCUMENT-IDENTIFIER: US 6734167 B2

TITLE: Uses of transport proteins

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Surry			GB
Normand; Nadia Michelle	Boulogne-Billancourt			FR
Brewis; Neil Douglas	Surry			GB
Phelan; Anne	Kent			GB

US-CL-CURRENT: 514/12; 424/204.1, 424/231.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 64. Document ID: US 6686196 B2

L10: Entry 64 of 82 File: USPT Feb 3, 2004

US-PAT-NO: 6686196
DOCUMENT-IDENTIFIER: US 6686196 B2

TITLE: Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof

DATE-ISSUED: February 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lieber; Andre	Seattle	WA		
Steinwaerder; Dirk S.	Hamburg			DE
Carlson; Cheryl A.	Seattle	WA		
Mi; Jie	Seattle	WA		

US-CL-CURRENT: 435/320.1; 424/93.2, 435/455, 435/456

ABSTRACT:

This invention provides modified recombinant Ad vectors (e.g., AdE1- vectors) undergoing defined homologous recombination in order to create predictably rearranged genomic derivatives in a host cell. Genomic rearrangements can be achieved, for example, by incorporating two IR sequences within one vector genome and enabling genomic rearrangement by coinfection with two parental vectors of one type (also referred to herein as a one vector system) or by homologous recombination of overlapping regions in two distinct types of parental vectors (with or without IR sequences) and enabling genomic rearrangement only upon coinfection of the host cell with the two distinct parental vectors (also referred to herein as two vector system).

26 Claims, 32 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

☐ 65. Document ID: US 6660259 B2

L10: Entry 65 of 82 File: USPT Dec 9, 2003

US-PAT-NO: 6660259
DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Laquerre; Sylvie	Walnut Creek	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is

cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 66. Document ID: US 6649158 B1

L10: Entry 66 of 82 File: USPT Nov 18, 2003

US-PAT-NO: 6649158
DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention invention is induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 67. Document ID: US 6645501 B2

L10: Entry 67 of 82 File: USPT Nov 11, 2003

US-PAT-NO: 6645501
DOCUMENT-IDENTIFIER: US 6645501 B2

TITLE: Anti-pathogen system and methods of use thereof

DATE-ISSUED: November 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dowdy; Steven F.	Clayton	MO		

US-CL-CURRENT: 424/192.1; 424/195.11, 424/196.11

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

27 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

☐ 68. Document ID: US 6635476 B1

L10: Entry 68 of 82 File: USPT Oct 21, 2003

US-PAT-NO: 6635476
DOCUMENT-IDENTIFIER: US 6635476 B1

TITLE: Targeted vectors

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murphy; Richard B.	San Diego	CA		

US-CL-CURRENT: 435/320.1; 424/199.1, 424/93.1, 424/93.2, 435/235.1

ABSTRACT:

This invention provides therapeutic and diagnostic agent delivery vehicles, including viral vectors, that are complexed to a targeting moiety by coordinate covalent linkages mediated by a transition metal ion. The complex is typically formed with a transition metal ion that is in a kinetically labile oxidation state; after the complex is formed, the oxidation state of the transition metal ion is changed to one that renders the complex kinetically stable. The use of a coordinate covalent linkage to attach the targeting moiety to the delivery vehicle provides the ability to readily attach a different targeting moiety to a delivery vehicle without modifying the delivery vehicle itself. This flexibility is achieved without sacrificing stability of the complex.

26 Claims, 2 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Cita | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des

☐ 69. Document ID: US 6607882 B1

L10: Entry 69 of 82 File: USPT Aug 19, 2003

US-PAT-NO: 6607882
DOCUMENT-IDENTIFIER: US 6607882 B1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

DATE-ISSUED: August 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox, III; George N.	Louisville	CO		
Case; Casey C.	San Mateo	CA		
Eisenberg; Stephen P.	Boulder	CO		
Jarvis; Eric E.	Boulder	CO		
Spratt; Sharon K.	Vacaville	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/455, 435/468, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

32 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Cita | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des

☐ 70. Document ID: US 6599692 B1

L10: Entry 70 of 82 File: USPT Jul 29, 2003

US-PAT-NO: 6599692
DOCUMENT-IDENTIFIER: US 6599692 B1

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	San Francisco	CA		

US-CL-CURRENT: 435/4; 435/6, 536/23.1

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

55 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 71. Document ID: US 6534261 B1

L10: Entry 71 of 82 File: USPT Mar 18, 2003

US-PAT-NO: 6534261
DOCUMENT-IDENTIFIER: US 6534261 B1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cox, III; George Norbert	Louisville	CO		
Case; Casey Christopher	San Mateo	CA		
Eisenberg; Stephen P.	Boulder	CO		
Jarvis; Eric Edward	Boulder	CO		
Spratt; Sharon Kaye	Vacaville	CA		

US-CL-CURRENT: 435/6; 435/29, 536/23.5, 536/24.1

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.

85 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 72. Document ID: US 6495526 B2

L10: Entry 72 of 82 File: USPT Dec 17, 2002

US-PAT-NO: 6495526
DOCUMENT-IDENTIFIER: US 6495526 B2

TITLE: Inhibitors of cell-cycle progression and uses related thereto

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gyuris; Jeno	Winchester	MA		
Lamphere; Lou	Boston	MA		
Beach; David H.	Huntington Bay	NY		

US-CL-CURRENT: 514/44; 536/23.4, 536/23.72, 536/24.1

ABSTRACT:

The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced.

42 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 73. Document ID: US 6495346 B1

L10: Entry 73 of 82 File: USPT Dec 17, 2002

US-PAT-NO: 6495346
DOCUMENT-IDENTIFIER: US 6495346 B1

TITLE: Complex-forming proteins

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jerome; Valerie	Colbe			DE
Sedlacek; Hans-Harald	Marburg			DE
Muller; Rolf	Marburg			DE

US-CL-CURRENT: 435/69.7; 424/85.1, 424/85.2, 435/69.5, 435/69.52, 530/351, 536/23.4, 536/23.5, 536/23.51

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the

component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

12 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 74. Document ID: US 6485977 B1

L10: Entry 74 of 82 File: USPT Nov 26, 2002

US-PAT-NO: 6485977
DOCUMENT-IDENTIFIER: US 6485977 B1

TITLE: Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collmer; Alan	Ithaca	NY		
Beer; Steven V.	Ithaca	NY		

US-CL-CURRENT: 435/455; 435/320.1, 435/325, 435/456, 435/69.1, 435/69.7, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.

11 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 75. Document ID: US 6464976 B1

L10: Entry 75 of 82 File: USPT Oct 15, 2002

US-PAT-NO: 6464976
DOCUMENT-IDENTIFIER: US 6464976 B1

TITLE: Methods and compositions for reducing immune response

DATE-ISSUED: October 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		
Rahman; Amena	San Diego	CA		
Shabram; Paul W.	Olivenhain	CA		
Tsai; Van T.	San Diego	CA		

US-CL-CURRENT: 424/140.1; 424/131.1, 424/159.1, 424/233.1, 424/278.1, 424/93.1, 435/7.1, 514/885, 530/351, 604/4.01, 604/5.01, 604/5.02

ABSTRACT:

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.

4 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 76. Document ID: US 6451579 B1

L10: Entry 76 of 82 File: USPT Sep 17, 2002

US-PAT-NO: 6451579
DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g.

alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 77. Document ID: US 6350572 B1

L10: Entry 77 of 82 File: USPT Feb 26, 2002

US-PAT-NO: 6350572
DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijsen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4; 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 78. Document ID: US 6251398 B1

L10: Entry 78 of 82 File: USPT Jun 26, 2001

US-PAT-NO: 6251398

DOCUMENT-IDENTIFIER: US 6251398 B1
**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 424/186.1; 424/192.1, 424/204.1, 424/208.1, 424/248.1, 424/263.1, 435/235.1, 435/252.3, 435/317.1, 435/325, 530/350, 530/826, 536/23.4

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

19 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 79. Document ID: US 6221355 B1

L10: Entry 79 of 82 File: USPT Apr 24, 2001

US-PAT-NO: 6221355
DOCUMENT-IDENTIFIER: US 6221355 B1

TITLE: Anti-pathogen system and methods of use thereof

DATE-ISSUED: April 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dowdy; Steven F.	Clayton	MO		

US-CL-CURRENT: 424/192.1; 424/204.1, 424/208.1, 530/387.3, 530/388.3, 536/23.4

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system

effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

21 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full | Title | Cita | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

---

☐ 80. Document ID: US 6086900 A

L10: Entry 80 of 82 File: USPT Jul 11, 2000

US-PAT-NO: 6086900
DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3, 435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Cita | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

---

☐ 81. Document ID: US 6017735 A

L10: Entry 81 of 82 File: USPT Jan 25, 2000

US-PAT-NO: 6017735
DOCUMENT-IDENTIFIER: US 6017735 A
**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/69.7; 435/252.3, 435/317.1, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.4, 536/23.5

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.

19 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 82. Document ID: US 20040142900 A1, WO 200147960 A1, AU 200122079 A, EP 1240190 A1, US 20020155988 A1, JP 2003519159 W, MX 2002006168 A1, US 6734167 B2

L10: Entry 82 of 82 File: DWPI Jul 22, 2004

DERWENT-ACC-NO: 2001-418224
DERWENT-WEEK: 200449

TITLE: Inhibiting cancer cell proliferation by exposing cells to a composition of fusion proteins comprising VP22 polypeptides coupled to cell cycle progression regulators, and further exposing cells to cell death stimulators

INVENTOR: BREWIS, N D; NORMAND, N M ; O'HARE, P F J ; PHELAN, A ; OHARE, P F J

PRIORITY-DATA: 1999GB-0030519 (December 24, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040142900 A1	July 22, 2004		000	A61K048/00
WO 200147960 A1	July 5, 2001	E	023	C07K014/035
AU 200122079 A	July 9, 2001		000	C07K014/035
EP 1240190 A1	September 18, 2002	E	000	C07K014/035
US 20020155988 A1	October 24, 2002		000	A01N037/18
JP 2003519159 W	June 17, 2003		024	A61K047/48
MX 2002006168 A1	January 1, 2003		000	A61K047/48
US 6734167 B2	May 11, 2004		000	A61K038/00

INT-CL (IPC): A01 N 37/18; A61 K 31/7088; A61 K 38/00; A61 K 47/48; A61 K 48/00; A61 P 9/10; A61 P 17/02; A61 P 17/06; A61 P 35/00; C07 K 14/035; C12 N 15/85; G01 N 33/574

ABSTRACTED-PUB-NO: WO 200147960A
BASIC-ABSTRACT:

NOVELTY - Reducing proliferation of cells by exposing them to proteins with the transport function of herpes virus VP22 coupled to cell cycle progression regulator, or to nucleic acids encoding the proteins, further exposing cells to an agent to stimulate cell death and optionally exposing cells to an agent that prevents export of administered agents from cell.

DETAILED DESCRIPTION - Reducing (M1) proliferation of cells comprises:

(a) exposing the cells to a composition comprising a polypeptide which comprises an amino acid sequence with the transport function of herpes viral VP22 protein, and is coupled to one or several functionally active proteins or peptides (P1) which can regulate cell cycle progression or their functional analogues, or exposing cells to therapeutic compositions comprising nucleic acids encoding the proteins(s);

(b) exposing the cells to an agent (A1) to further stimulate cell death, the agent being a drug which can induce cell cycle arrest, cytotoxic chemotherapeutic drug commonly used as a part of a treatment of malignant disease, DNA damaging agent, an agent which increases cellular sensitivity to DNA damage, or cytotoxic amounts of radiation; and optionally after the step (a) and/or step (b); and

(c) further exposing the cells to an agent (A2) that prevents export from the cell of any one of the agents administered in the above steps.

An INDEPENDENT CLAIM is also included for the preparation (I) which comprises a coupling product between a protein with the transport function of VP22 and a protein which can regulate cell cycle progression, (A1) and optionally (A2), in combination with an excipient.

ACTIVITY - Antipsoriatic; cytostatic; dermatological; virucidal.

MECHANISM OF ACTION - Apoptosis inducer; cyclin-dependent kinase inhibitor (claimed); cell proliferation suppressor.

No supporting data is given.

USE - Reducing proliferation of hyper-proliferating cells e.g., cancer cells. (I) is useful for manufacturing a medicament to reduce or treat cell proliferation e.g., cancer cell proliferation (claimed).

(I) is useful for reducing or treating cell proliferation, in tumor cells present in tumor cell mass, non-malignant cells e.g., benign tumor cells such as genital warts, smooth muscle cells present in restenosis, proliferating skin cells e.g., skin cancer, psoriasis or eczema skin cells, or proliferating cells of scar tissue.

Terms	Documents
L5 AND L8	82

Items 1 - 114 of 114 One

1: Chhabra A, Mehrotra S, Chakraborty NG, Mukherji B, Dorsky DI. Related Articles,

Cross-presentation of a human tumor antigen delivered to dendritic cells by H VP22-mediated protein translocation.
Eur J Immunol. 2004 Oct;34(10):2824.
PMID: 15368298 [PubMed - in process]

2: Cheng WF, Hung CF, Lee CN, Su YN, Chang MC, He L, Wu TC, Chen CA, Hsieh CY. Related Articles,

Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.
Eur J Immunol. 2004 Jul;34(7):1892-900.
PMID: 15214037 [PubMed - indexed for MEDLINE]

3: Jarver P, Langel U. Related Articles,

The use of cell-penetrating peptides as a tool for gene regulation.
Drug Discov Today. 2004 May 1;9(9):395-402. Review.
PMID: 15081956 [PubMed - indexed for MEDLINE]

4: Suzuki K, Murtuza B, Brand NJ, Varela-Carver A, Fukushima S, Yacoub MH. Related Articles,

Enhanced effect of myocardial gene transfection by VP22-mediated intercellu protein transport.
J Mol Cell Cardiol. 2004 Apr;36(4):603-6.
PMID: 15081320 [PubMed - in process]

5: Qiu Z, Harms JS, Zhu J, Splitter GA. Related Articles,

Bovine herpesvirus tegument protein VP22 enhances thymidine kinase/ganciclovir suicide gene therapy for neuroblastomas compared to herpe simplex virus VP22.
J Virol. 2004 Apr;78(8):4224-33.
PMID: 15047837 [PubMed - indexed for MEDLINE]

6: Falk K, Aspehaug V, Vlasak R, Endresen C. Related Articles,

Identification and characterization of viral structural proteins of infectious sali anemia virus.
J Virol. 2004 Mar;78(6):3063-71.
PMID: 14990725 [PubMed - indexed for MEDLINE]

7: Brady RO. Related Articles,

Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
Acta Paediatr Suppl. 2003 Dec;92(443):19-24.
PMID: 14989461 [PubMed - indexed for MEDLINE]

8: Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L, Boyd DA, Wu TC. Related Articles,

Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory

h cb h g e e e fcg e ch b e

cells and protective immunity.
Hum Gene Ther. 2004 Feb;15(2):167-77.
PMID: 14975189 [PubMed - in process]

9: Barbe-Tuana FM, Machado DC, Saitovitch D. Related Articles, I

Modified location of the major histocompatibility protein Kb by co-delivery w VP22 protein.
Biomol Eng. 2004 Jan;21(1):27-31.
PMID: 14715317 [PubMed - indexed for MEDLINE]

10: Roeder GE, Parish JL, Stern PL, Gaston K. Related Articles, I

Herpes Simplex Virus VP22-Human Papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death.
Biotechnol Appl Biochem. 2004 Jan 7 [Epub ahead of print]
PMID: 14709162 [PubMed - as supplied by publisher]

11: Zavaglia D, Normand N, Brewis N, O'Hare P, Favrot MC, Coll JL. Related Articles, I

VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mic
Mol Ther. 2003 Nov;8(5):840-5.
PMID: 14599818 [PubMed - indexed for MEDLINE]

12: Kueltzo LA, Middaugh CR. Related Articles, I

Nonclassical transport proteins and peptides: an alternative to classical macromolecule delivery systems.
J Pharm Sci. 2003 Sep;92(9):1754-72. Review.
PMID: 12949995 [PubMed - indexed for MEDLINE]

13: Stroh C, Held J, Samraj AK, Schulze-Osthoff K. Related Articles, I

Specific inhibition of transcription factor NF-kappaB through intracellular protein delivery of I kappaBalpha by the Herpes virus protein VP22.
Oncogene. 2003 Aug 14;22(34):5367-73.
PMID: 12917639 [PubMed - indexed for MEDLINE]

14: van Leeuwen H, Okuwaki M, Hong R, Chakravarti D, Nagata K, O'Hare P. Related Articles, I

Herpes simplex virus type 1 tegument protein VP22 interacts with TAF-I proteins and inhibits nucleosome assembly but not regulation of histone acetylation by INHAT.
J Gen Virol. 2003 Sep;84(Pt 9):2501-10.
PMID: 12917472 [PubMed - indexed for MEDLINE]

15: Kong BH, Wang WX, Liu CS, Ma DX, Qu X. Related Articles, I

[Tegument viral protein 22 enhanced cell-killing effect of the herpes simplex virus thymidine kinase/ganciclovir system on ovarian cancer in vivo]
Zhonghua Fu Chan Ke Za Zhi. 2003 Apr;38(4):195-8. Chinese.
PMID: 12885362 [PubMed - in process]

16: Rutjes SA, Bosma PJ, Rohn JL, Noteborn MH, Wesseling JG. Related Articles, I

Induction of insolubility by herpes simplex virus VP22 precludes intercellula trafficking of N-terminal Apoptin-VP22 fusion proteins.
J Mol Med. 2003 Sep;81(9):558-65. Epub 2003 Jul 16.
PMID: 12879152 [PubMed - indexed for MEDLINE]

17: Lundberg M, Wikstrom S, Johansson M. Related Articles, I

Cell surface adherence and endocytosis of protein transduction domains.
Mol Ther. 2003 Jul;8(1):143-50.

h cb h g e e e fcg e ch b e

PMID: 12842437 [PubMed - indexed for MEDLINE]

☐ **18:** Kong B, Wang W, Liu C, Song L, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Wang B, Wei MQ, Yang Q. Related Articles, I

Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.
In Vivo. 2003 Mar-Apr;17(2):153-6.
PMID: 12792977 [PubMed - indexed for MEDLINE]

☐ **19:** Namiki S, Tomida T, Tanabe M, Iino M, Hirose K. Related Articles, I

Intracellular delivery of glutathione S-transferase into mammalian cells.
Biochem Biophys Res Commun. 2003 Jun 6;305(3):592-7.
PMID: 12763035 [PubMed - indexed for MEDLINE]

☐ **20:** Kretz A, Wybranietz WA, Hermening S, Lauer UM, Isenmann S. Related Articles, I

HSV-1 VP22 augments adenoviral gene transfer to CNS neurons in the retina and striatum in vivo.
Mol Ther. 2003 May;7(5 Pt 1):659-69.
PMID: 12718909 [PubMed - indexed for MEDLINE]

☐ **21:** Boecnicke L, Chu K, Pauls R, Tams C, Kruse ML, Kurdow R, Schniewind B, Bohle A, Kremer B, Kalthoff H. Related Articles, I

Efficient dose-dependent and time-dependent protein transduction of pancreatic carcinoma cells in vitro and in vivo using purified VP22-EGFP fusion protein.
J Mol Med. 2003 Mar;81(3):205-13. Epub 2003 Mar 18.
PMID: 12682729 [PubMed - indexed for MEDLINE]

☐ **22:** Brignati MJ, Loomis JS, Wills JW, Courtney RJ. Related Articles, I

Membrane association of VP22, a herpes simplex virus type 1 tegument protein.
J Virol. 2003 Apr;77(8):4888-98.
PMID: 12663795 [PubMed - indexed for MEDLINE]

☐ **23:** Weitzman MD. Related Articles, I

VP22 flips the switch on cell death.
Mol Ther. 2003 Feb;7(2):146-7. No abstract available.
PMID: 12638542 [PubMed - indexed for MEDLINE]

☐ **24:** Walters JN, Sexton GL, McCaffery JM, Desai P. Related Articles, I

Mutation of single hydrophobic residue I27, L35, F39, L58, L65, L67, or L7 the N terminus of VP5 abolishes interaction with the scaffold protein and prevents closure of herpes simplex virus type 1 capsid shells.
J Virol. 2003 Apr;77(7):4043-59.
PMID: 12634364 [PubMed - indexed for MEDLINE]

☐ **25:** Brewis ND, Phelan A, Normand N, Choolun E, O'Hare P. Related Articles, I

Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis.
Mol Ther. 2003 Feb;7(2):262-70.
PMID: 12597915 [PubMed - indexed for MEDLINE]

☐ **26:** Zavaglia D, Favrot MC, Eymin B, Tenaud C, Coll JL. Related Articles, I

Intercellular trafficking and enhanced in vivo antitumour activity of a non-virally delivered P27-VP22 fusion protein.
Gene Ther. 2003 Feb;10(4):314-25.
PMID: 12595890 [PubMed - indexed for MEDLINE]

☐ **27:** Roy I, Holle L, Song W, Holle E, Wagner T, Yu X. Related Articles, I

Efficient translocation and apoptosis induction by adenovirus encoded VP22

h cb h g e e e fcg e ch b e

p53 fusion protein in human tumor cells in vitro.
Anticancer Res. 2002 Nov-Dec;22(6A):3185-9.
PMID: 12530063 [PubMed - indexed for MEDLINE]

28: Lyman MG, Demmin GL, Banfield BW. Related Articles, I

The attenuated pseudorabies virus strain Bartha fails to package the tegumen proteins Us3 and VP22.
J Virol. 2003 Jan;77(2):1403-14.
PMID: 12502856 [PubMed - indexed for MEDLINE]

29: Cashman SM, Sadowski SL, Morris DJ, Frederick J, Kumar-Singh R. Related Articles, I

Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors--implications for gene therapy.
Mol Ther. 2002 Dec;6(6):813-23.
PMID: 12498777 [PubMed - indexed for MEDLINE]

30: Kong B, Wang W, Liu C, Ma D, Qu X, Jiang J, Yang X, Zhang Y, Jiang S. Related Articles, I

[Anti-tumor effect of lentivirus-mediated MUC1 antibody-targeted gene ther with VP22-TK system on MUC1(+) human ovarian cancer transplanted intraperitoneally in nude mice]
Zhonghua Yi Xue Za Zhi. 2002 Sep 10;82(17):1207-10. Chinese.
PMID: 12475412 [PubMed - indexed for MEDLINE]

31: Sherman MP, Schubert U, Williams SA, de Noronha CM, Kreisberg JF, Henklein P, Greene WC. Related Articles, I

HIV-1 Vpr displays natural protein-transducing properties: implications for pathogenesis.
Virology. 2002 Oct 10;302(1):95-105.
PMID: 12429519 [PubMed - indexed for MEDLINE]

32: Ye D, Xu D, Singer AU, Juliano RL. Related Articles, I

Evaluation of strategies for the intracellular delivery of proteins.
Pharm Res. 2002 Sep;19(9):1302-9.
PMID: 12403066 [PubMed - indexed for MEDLINE]

33: Hutchinson I, Whiteley A, Browne H, Elliott G. Related Articles, I

Sequential localization of two herpes simplex virus tegument proteins to punctate nuclear dots adjacent to ICP0 domains.
J Virol. 2002 Oct;76(20):10365-73.
PMID: 12239313 [PubMed - indexed for MEDLINE]

34: Miranda-Saksena M, Boadle RA, Armati P, Cunningham AL. Related Articles, I

In rat dorsal root ganglion neurons, herpes simplex virus type 1 tegument for in the cytoplasm of the cell body.
J Virol. 2002 Oct;76(19):9934-51.
PMID: 12208970 [PubMed - indexed for MEDLINE]

35: Qian C, Sangro B, Prieto J. Related Articles, I

New strategies to enhance gene therapy efficiency.
Gastroenterology. 2002 Aug;123(2):639-42. No abstract available.
PMID: 12145817 [PubMed - indexed for MEDLINE]

36: Zender L, Kock R, Eckhard M, Frericks B, Gosling T, Gebhardt T, Drobek S, Galanski M, Kuhnel F, Manns M, Kubicka S. Related Articles, I

Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induc regression of liver tumors.
Gastroenterology. 2002 Aug;123(2):608-18.
PMID: 12145813 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

37: Fuchs W, Klupp BG, Granzow H, Hengartner C, Brack A, Mundt A, Enquist LW, Mettenleiter TC. Related Articles, I

Physical interaction between envelope glycoproteins E and M of pseudorabi virus and the major tegument protein UL49.
J Virol. 2002 Aug;76(16):8208-17.
PMID: 12134026 [PubMed - indexed for MEDLINE]

38: Sciortino MT, Taddeo B, Poon AP, Mastino A, Roizman B. Related Articles, I

Of the three tegument proteins that package mRNA in herpes simplex virion one (VP22) transports the mRNA to uninfected cells for expression prior to infection.
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8318-23.
PMID: 12060774 [PubMed - indexed for MEDLINE]

39: Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. Related Articles, I

VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and i vivo.
Cancer Gene Ther. 2002 Jun;9(6):489-96.
PMID: 12032659 [PubMed - indexed for MEDLINE]

40: Morris SJ, Smith H, Sweet C. Related Articles, I

Exploitation of the Herpes simplex virus translocating protein VP22 to carry influenza virus proteins into cells for studies of apoptosis: direct confirmatio that neuraminidase induces apoptosis and indications that other proteins may have a role.
Arch Virol. 2002 May;147(5):961-79.
PMID: 12021867 [PubMed - indexed for MEDLINE]

41: Martin A, O'Hare P, McLauchlan J, Elliott G. Related Articles, I

Herpes simplex virus tegument protein VP22 contains overlapping domains cytoplasmic localization, microtubule interaction, and chromatin binding.
J Virol. 2002 May;76(10):4961-70.
PMID: 11967313 [PubMed - indexed for MEDLINE]

42: Wybranietz WA, Gross CD, Phelan A, O'Hare P, Spiegel M, Graepler F, Bitzer M, Stahler P, Gregor M, Lauer UM. Related Articles, I

Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene.
Gene Ther. 2001 Nov;8(21):1654-64.
PMID: 11895004 [PubMed - indexed for MEDLINE]

43: Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M. Related Articles, I

Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccinatio
Virology. 2002 Mar 1;294(1):47-59.
PMID: 11886264 [PubMed - indexed for MEDLINE]

44: van Leeuwen H, Elliott G, O'Hare P. Related Articles, I

Evidence of a role for nonmuscle myosin II in herpes simplex virus type 1 egress.
J Virol. 2002 Apr;76(7):3471-81.
PMID: 11884571 [PubMed - indexed for MEDLINE]

45: Diefenbach RJ, Miranda-Saksena M, Diefenbach E, Holland DJ, Boadle RA, Armati PJ, Cunningham AL. Related Articles, I

Herpes simplex virus tegument protein US11 interacts with conventional kinesin heavy chain.
J Virol. 2002 Apr;76(7):3282-91.

h cb h g e e e fcg e ch b e

PMID: 11884553 [PubMed - indexed for MEDLINE]

46: O'Donnell LA, Clemmer JA, Czymmek K, Schmidt CJ. Related Articles, I

Marek's disease virus VP22: subcellular localization and characterization of carboxyl terminal deletion Mutations.
Virology. 2002 Jan 20;292(2):235-40.
PMID: 11878926 [PubMed - indexed for MEDLINE]

47: Soden J, Stevens A, Ray DW. Related Articles, I

Genetic engineering of the glucocorticoid receptor by fusion with the herpes viral protein VP22 causes selective loss of transactivation.
J Endocrinol. 2002 Mar;172(3):615-25.
PMID: 11874710 [PubMed - indexed for MEDLINE]

48: Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M, Wu TC. Related Articles, I

Cancer immunotherapy using Sindbis virus replicon particles encoding a VP antigen fusion.
Hum Gene Ther. 2002 Mar 1;13(4):553-68.
PMID: 11874633 [PubMed - indexed for MEDLINE]

49: Hung CF, He L, Juang J, Lin TJ, Ling M, Wu TC. Related Articles, I

Improving DNA vaccine potency by linking Marek's disease virus type 1 VP to an antigen.
J Virol. 2002 Mar;76(6):2676-82.
PMID: 11861834 [PubMed - indexed for MEDLINE]

50: Lundberg M, Johansson M. Related Articles, I

Positively charged DNA-binding proteins cause apparent cell membrane translocation.
Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71.
PMID: 11846414 [PubMed - indexed for MEDLINE]

51: Lai Z, Brady RO. Related Articles, I

Gene transfer into the central nervous system in vivo using a recombinanat lentivirus vector.
J Neurosci Res. 2002 Feb 1;67(3):363-71.
PMID: 11813241 [PubMed - indexed for MEDLINE]

52: Marples B, Greco O, Joiner MC, Scott SD. Related Articles, I

Molecular approaches to chemo-radiotherapy.
Eur J Cancer. 2002 Jan;38(2):231-9. Review.
PMID: 11803140 [PubMed - indexed for MEDLINE]

53: Dorange F, Tischer BK, Vautherot JF, Osterrieder N. Related Articles, I

Characterization of Marek's disease virus serotype 1 (MDV-1) deletion muta that lack UL46 to UL49 genes: MDV-1 UL49, encoding VP22, is indispensa for virus growth.
J Virol. 2002 Feb;76(4):1959-70.
PMID: 11799190 [PubMed - indexed for MEDLINE]

54: Bennett RP, Dalby B, Guy PM. Related Articles, I

Protein delivery using VP22.
Nat Biotechnol. 2002 Jan;20(1):20. No abstract available. Erratum in: Nat Biotechnol 2002 Apr;20(4):338.
PMID: 11753353 [PubMed - indexed for MEDLINE]

55: del Rio T, Werner HC, Enquist LW. Related Articles, I

h cb h g e e e fcg e ch b e

The pseudorabies virus VP22 homologue (UL49) is dispensable for virus growth in vitro and has no effect on virulence and neuronal spread in rodents
J Virol. 2002 Jan;76(2):774-82.
PMID: 11752167 [PubMed - indexed for MEDLINE]

☐ **56:** Morris MC, Depollier J, Mery J, Heitz F, Divita G. Related Articles, I

A peptide carrier for the delivery of biologically active proteins into mamma cells.
Nat Biotechnol. 2001 Dec;19(12):1173-6.
PMID: 11731788 [PubMed - indexed for MEDLINE]

☐ **57:** Derer W, Easwaran HP, Leonhardt H, Cardoso MC. Related Articles, I

A novel approach to induce cell cycle reentry in terminally differentiated mu cells.
FASEB J. 2002 Jan;16(1):132-3. Epub 2001 Nov 29.
PMID: 11729099 [PubMed - indexed for MEDLINE]

☐ **58:** Blouin A, Blaho JA. Related Articles, I

Assessment of the subcellular localization of the herpes simplex virus structu protein VP22 in the absence of other viral gene products.
Virus Res. 2001 Dec 4;81(1-2):57-68.
PMID: 11682125 [PubMed - indexed for MEDLINE]

☐ **59:** Geiss BJ, Tavis JE, Metzger LM, Leib DA, Morrison LA. Related Articles, I

Temporal regulation of herpes simplex virus type 2 VP22 expression and phosphorylation.
J Virol. 2001 Nov;75(22):10721-9.
PMID: 11602713 [PubMed - indexed for MEDLINE]

☐ **60:** Ren X, Harms JS, Splitter GA. Related Articles, I

Tyrosine phosphorylation of bovine herpesvirus 1 tegument protein VP22 correlates with the incorporation of VP22 into virions.
J Virol. 2001 Oct;75(19):9010-7.
PMID: 11533164 [PubMed - indexed for MEDLINE]

☐ **61:** Aints A, Guven H, Gahrton G, Smith CI, Dilber MS. Related Articles, I

Mapping of herpes simplex virus-1 VP22 functional domains for inter- and subcellular protein targeting.
Gene Ther. 2001 Jul;8(14):1051-6.
PMID: 11526452 [PubMed - indexed for MEDLINE]

☐ **62:** Wills KN, Atencio IA, Avanzini JB, Neuteboom S, Phelan A, Philopena J, Sutjipto S, Vaillancourt MT, Wen SF, Ralston RO, Johnson DE. Related Articles, I

Intratumoral spread and increased efficacy of a p53-VP22 fusion protein expressed by a recombinant adenovirus.
J Virol. 2001 Sep;75(18):8733-41.
PMID: 11507218 [PubMed - indexed for MEDLINE]

☐ **63:** Kotsakis A, Pomeranz LE, Blouin A, Blaho JA. Related Articles, I

Microtubule reorganization during herpes simplex virus type 1 infection facilitates the nuclear localization of VP22, a major virion tegument protein.
J Virol. 2001 Sep;75(18):8697-711.
PMID: 11507215 [PubMed - indexed for MEDLINE]

☐ **64:** Ren X, Harms JS, Splitter GA. Related Articles, I

Bovine herpesvirus 1 tegument protein VP22 interacts with histones, and the carboxyl terminus of VP22 is required for nuclear localization.
J Virol. 2001 Sep;75(17):8251-8.

h cb h g e e e fcg e ch b e

PMID: 11483770 [PubMed - indexed for MEDLINE]

☐ **65:** Lundberg M, Johansson M. Related Articles, l

Is VP22 nuclear homing an artifact?
Nat Biotechnol. 2001 Aug;19(8):713-4. No abstract available.
PMID: 11479552 [PubMed - indexed for MEDLINE]

☐ **66:** Oliveira SC, Harms JS, Afonso RR, Splitter GA. Related Articles, l

A genetic immunization adjuvant system based on BVP22-antigen fusion.
Hum Gene Ther. 2001 Jul 1;12(10):1353-9.
PMID: 11440628 [PubMed - indexed for MEDLINE]

☐ **67:** Ford KG, Souberbielle BE, Darling D, Farzaneh F. Related Articles, l

Protein transduction: an alternative to genetic intervention?
Gene Ther. 2001 Jan;8(1):1-4. Review.
PMID: 11402295 [PubMed - indexed for MEDLINE]

☐ **68:** Spengler M, Niesen N, Grose C, Ruyechan WT, Hay J. Related Articles, l

Interactions among structural proteins of varicella zoster virus.
Arch Virol Suppl. 2001;(17):71-9.
PMID: 11339553 [PubMed - indexed for MEDLINE]

☐ **69:** Liu CS, Kong B, Xia HH, Ellem KA, Wei MQ. Related Articles, l

VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced th level of ganciclovir needed to cause suicide cell death.
J Gene Med. 2001 Mar-Apr;3(2):145-52.
PMID: 11318113 [PubMed - indexed for MEDLINE]

☐ **70:** Hung CF, Cheng WF, Chai CY, Hsu KF, He L, Ling M, Wu TC. Related Articles, l

Improving vaccine potency through intercellular spreading and enhanced MI class I presentation of antigen.
J Immunol. 2001 May 1;166(9):5733-40.
PMID: 11313416 [PubMed - indexed for MEDLINE]

☐ **71:** Falnes PO, Wesche J, Olsnes S. Related Articles, l

Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment.
Biochemistry. 2001 Apr 10;40(14):4349-58.
PMID: 11284691 [PubMed - indexed for MEDLINE]

☐ **72:** Normand N, van Leeuwen H, O'Hare P. Related Articles, l

Particle formation by a conserved domain of the herpes simplex virus proteir VP22 facilitating protein and nucleic acid delivery.
J Biol Chem. 2001 May 4;276(18):15042-50. Epub 2001 Jan 18.
PMID: 11278656 [PubMed - indexed for MEDLINE]

☐ **73:** Schwartz JJ, Zhang S. Related Articles, l

Peptide-mediated cellular delivery.
Curr Opin Mol Ther. 2000 Apr;2(2):162-7. Review.
PMID: 11249637 [PubMed - indexed for MEDLINE]

☐ **74:** Donnelly M, Elliott G. Related Articles, l

Fluorescent tagging of herpes simplex virus tegument protein VP13/14 in vir infection.
J Virol. 2001 Mar;75(6):2575-83.
PMID: 11222680 [PubMed - indexed for MEDLINE]

☐ **75:** Rajcani J, Durmanova V. Related Articles, l

h cb h g e e e fcg e ch b e

Early expression of herpes simplex virus (HSV) proteins and reactivation of latent infection.
Folia Microbiol (Praha). 2000;45(1):7-28. Review.
PMID: 11200675 [PubMed - indexed for MEDLINE]

76: Cheng WF, Hung CH, Chai CY, Hsu KF, He L, Ling M, Wu TC. Related Articles, I

Enhancement of sindbis virus self-replicating RNA vaccine potency by linka of herpes simplex virus type 1 VP22 protein to antigen.
J Virol. 2001 Mar;75(5):2368-76.
PMID: 11160740 [PubMed - indexed for MEDLINE]

77: Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. Related Articles, I

CD4 T-cell responses to herpes simplex virus type 2 major capsid protein VI comparison with responses to tegument and envelope glycoproteins.
J Virol. 2000 Dec;74(23):11422-5.
PMID: 11070045 [PubMed - indexed for MEDLINE]

78: Lai Z, Han I, Zirzow G, Brady RO, Reiser J. Related Articles, I

Intercellular delivery of a herpes simplex virus VP22 fusion protein from cel infected with lentiviral vectors.
Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11297-302.
PMID: 11027330 [PubMed - indexed for MEDLINE]

79: Pomeranz LE, Blaho JA. Related Articles, I

Assembly of infectious Herpes simplex virus type 1 virions in the absence of full-length VP22.
J Virol. 2000 Nov;74(21):10041-54.
PMID: 11024133 [PubMed - indexed for MEDLINE]

80: Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF. Related Articles, I

Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL (VP22) and UL48 (VP16) genes: high-level expression and characterization MDV-1 VP22 and VP16.
J Gen Virol. 2000 Sep;81(Pt 9):2219-30.
PMID: 10950980 [PubMed - indexed for MEDLINE]

81: Kueltzo LA, Normand N, O'Hare P, Middaugh CR. Related Articles, I

Conformational lability of herpesvirus protein VP22.
J Biol Chem. 2000 Oct 27;275(43):33213-21.
PMID: 10913125 [PubMed - indexed for MEDLINE]

82: Aints A, Dilber MS, Smith CI. Related Articles, I

Intercellular spread of GFP-VP22.
J Gene Med. 1999 Jul-Aug;1(4):275-9.
PMID: 10738560 [PubMed - indexed for MEDLINE]

83: Wybranietz WA, Prinz F, Spiegel M, Schenk A, Bitzer M, Gregor M, Lauer UM. Related Articles, I

Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines.
J Gene Med. 1999 Jul-Aug;1(4):265-74.
PMID: 10738559 [PubMed - indexed for MEDLINE]

84: Harms JS, Ren X, Oliveira SC, Splitter GA. Related Articles, I

Distinctions between bovine herpesvirus 1 and herpes simplex virus type 1 VP22 tegument protein subcellular associations.
J Virol. 2000 Apr;74(7):3301-12.
PMID: 10708447 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

85: Elliott G, O'Hare P. Related Articles, I

Cytoplasm-to-nucleus translocation of a herpesvirus tegument protein during cell division.
J Virol. 2000 Mar;74(5):2131-41.
PMID: 10666242 [PubMed - indexed for MEDLINE]

86: Brewis N, Phelan A, Webb J, Drew J, Elliott G, O'Hare P. Related Articles, I

Evaluation of VP22 spread in tissue culture.
J Virol. 2000 Jan;74(2):1051-6.
PMID: 10623773 [PubMed - indexed for MEDLINE]

87: Derer W, Easwaran HP, Knopf CW, Leonhardt H, Cardoso MC. Related Articles, I

Direct protein transfer to terminally differentiated muscle cells.
J Mol Med. 1999 Aug;77(8):609-13.
PMID: 10543392 [PubMed - indexed for MEDLINE]

88: Luft FC. Related Articles, I

Can VP22 resurrect gene therapy?
J Mol Med. 1999 Aug;77(8):575-6. No abstract available.
PMID: 10543389 [PubMed - indexed for MEDLINE]

89: Pomeranz LE, Blaho JA. Related Articles, I

Modified VP22 localizes to the cell nucleus during synchronized herpes simplex virus type 1 infection.
J Virol. 1999 Aug;73(8):6769-81.
PMID: 10400775 [PubMed - indexed for MEDLINE]

90: Elliott G, O'Reilly D, O'Hare P. Related Articles, I

Identification of phosphorylation sites within the herpes simplex virus tegument protein VP22.
J Virol. 1999 Jul;73(7):6203-6.
PMID: 10364384 [PubMed - indexed for MEDLINE]

91: Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI, O'Hare P Related Articles, I

Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22.
Gene Ther. 1999 Jan;6(1):12-21.
PMID: 10341871 [PubMed - indexed for MEDLINE]

92: Elliott G, O'Hare P. Related Articles, I

Intercellular trafficking of VP22-GFP fusion proteins.
Gene Ther. 1999 Jan;6(1):149-51.
PMID: 10341888 [PubMed - indexed for MEDLINE]

93: Murphy AL, Murphy SJ. Related Articles, I

Catch VP22: the hitch-hiker's ride to gene therapy?
Gene Ther. 1999 Jan;6(1):4-5. No abstract available.
PMID: 10341869 [PubMed - indexed for MEDLINE]

94: Elliott G, O'Hare P. Related Articles, I

Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection.
J Virol. 1999 May;73(5):4110-9.
PMID: 10196307 [PubMed - indexed for MEDLINE]

95: Fang B, Xu B, Koch P, Roth JA. Related Articles, I

h cb h g e e e fcg e ch b e

Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultu mammalian cells.
Gene Ther. 1998 Oct;5(10):1420-4.
PMID: 9930348 [PubMed - indexed for MEDLINE]

96: Morrison EE, Stevenson AJ, Wang YF, Meredith DM. Related Articles, I

Differences in the intracellular localization and fate of herpes simplex virus tegument proteins early in the infection of Vero cells.
J Gen Virol. 1998 Oct;79 (Pt 10):2517-28.
PMID: 9780059 [PubMed - indexed for MEDLINE]

97: Koelle DM, Frank JM, Johnson ML, Kwok WW. Related Articles, I

Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cell infiltrating human genital herpes lesions.
J Virol. 1998 Sep;72(9):7476-83.
PMID: 9696844 [PubMed - indexed for MEDLINE]

98: Morrison EE, Wang YF, Meredith DM. Related Articles, I

Phosphorylation of structural components promotes dissociation of the herpe simplex virus type 1 tegument.
J Virol. 1998 Sep;72(9):7108-14.
PMID: 9696804 [PubMed - indexed for MEDLINE]

99: Elliott G, O'Hare P. Related Articles, I

Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules.
J Virol. 1998 Aug;72(8):6448-55.
PMID: 9658087 [PubMed - indexed for MEDLINE]

100: Phelan A, Elliott G, O'Hare P. Related Articles, I

Intercellular delivery of functional p53 by the herpesvirus protein VP22.
Nat Biotechnol. 1998 May;16(5):440-3.
PMID: 9592391 [PubMed - indexed for MEDLINE]

101: Liang X, Chow B, Babiuk LA. Related Articles, I

Study of immunogenicity and virulence of bovine herpesvirus 1 mutants deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in cat
Vaccine. 1997 Jul;15(10):1057-64.
PMID: 9269047 [PubMed - indexed for MEDLINE]

102: Elliott G, O'Hare P. Related Articles, I

Intercellular trafficking and protein delivery by a herpesvirus structural protein.
Cell. 1997 Jan 24;88(2):223-33.
PMID: 9008163 [PubMed - indexed for MEDLINE]

103: McLauchlan J. Related Articles, I

The abundance of the herpes simplex virus type 1 UL37 tegument protein in virus particles is closely controlled.
J Gen Virol. 1997 Jan;78 (Pt 1):189-94.
PMID: 9010303 [PubMed - indexed for MEDLINE]

104: Elliott G, O'Reilly D, O'Hare P. Related Articles, I

Phosphorylation of the herpes simplex virus type 1 tegument protein VP22.
Virology. 1996 Dec 1;226(1):140-5.
PMID: 8941333 [PubMed - indexed for MEDLINE]

105: Leslie J, Rixon FJ, McLauchlan J. Related Articles, I

h cb h g e e e fcg e ch b e

Overexpression of the herpes simplex virus type 1 tegument protein VP22 increases its incorporation into virus particles.
Virology. 1996 Jun 1;220(1):60-8.
PMID: 8659129 [PubMed - indexed for MEDLINE]

106: Elliott G, Mouzakitis G, O'Hare P. Related Articles, I

VP16 interacts via its activation domain with VP22, a tegument protein of herpes simplex virus, and is relocated to a novel macromolecular assembly coexpressing cells.
J Virol. 1995 Dec;69(12):7932-41.
PMID: 7494306 [PubMed - indexed for MEDLINE]

107: Dargan DJ, Patel AH, Subak-Sharpe JH. Related Articles, I

PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked.
J Virol. 1995 Aug;69(8):4924-32.
PMID: 7609061 [PubMed - indexed for MEDLINE]

108: Liang X, Chow B, Li Y, Raggo C, Yoo D, Attah-Poku S, Babiuk LA. Related Articles, I

Characterization of bovine herpesvirus 1 UL49 homolog gene and product: bovine herpesvirus 1 UL49 homolog is dispensable for virus growth.
J Virol. 1995 Jun;69(6):3863-7.
PMID: 7745736 [PubMed - indexed for MEDLINE]

109: Koptidesova D, Kopacek J, Zelnik V, Ross NL, Pastorekova S, Pastorek J. Related Articles, I

Identification and characterization of a cDNA clone derived from the Marel disease tumour cell line RPL1 encoding a homologue of alpha-transinducin factor (VP16) of HSV-1.
Arch Virol. 1995;140(2):355-62.
PMID: 7710361 [PubMed - indexed for MEDLINE]

110: Coulter LJ, Moss HW, Lang J, McGeoch DJ. Related Articles, I

A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted.
J Gen Virol. 1993 Mar;74 (Pt 3):387-95.
PMID: 8383174 [PubMed - indexed for MEDLINE]

111: Elliott GD, Meredith DM. Related Articles, I

The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49.
J Gen Virol. 1992 Mar;73 (Pt 3):723-6.
PMID: 1312128 [PubMed - indexed for MEDLINE]

112: Meredith DM, Lindsay JA, Halliburton IW, Whittaker GR. Related Articles, I

Post-translational modification of the tegument proteins (VP13 and VP14) o herpes simplex virus type 1 by glycosylation and phosphorylation.
J Gen Virol. 1991 Nov;72 (Pt 11):2771-5.
PMID: 1658203 [PubMed - indexed for MEDLINE]

113: Baker TS, Newcomb WW, Booy FP, Brown JC, Steven AC. Related Articles, I

Three-dimensional structures of maturable and abortive capsids of equine herpesvirus 1 from cryoelectron microscopy.
J Virol. 1990 Feb;64(2):563-73.
PMID: 2153224 [PubMed - indexed for MEDLINE]

114: Knopf KW, Kaerner HC. Related Articles, I

h cb h g e e e fcg e ch b e

Virus-specific basic phosphoproteins associated with herpes simplex virus t
a (HSV-1) particles and the chromatin of HSV-1-infected cells.
J Gen Virol. 1980 Feb;46(2):405-14.
PMID: 6247428 [PubMed - indexed for MEDLINE]

h cb h g e e e fcg e ch b e

1: Gene Ther. 1999 Jan;6(1):4-5.

nature publishing group

Catch VP22: the hitch-hiker's ride to gene therapy?

Murphy AL, Murphy SJ.

PMID: 10341869 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

h cb h g e e e fcg c e e e b b e b c

```
Connecting via Winsock to STN
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:26:57 ON 22 SEP 2004

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'AQUALINE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 14:27:08 ON 22 SEP 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 14:27:08 ON 22 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'CAPLUS' ENTERED AT 14:27:08 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:27:08 ON 22 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
```

FILE 'CROPB' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'FOMAD' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'HEALSAFE' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:27:08 ON 22 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'NIOSHTIC' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'NTIS' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'NUTRACEUT' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'OCEAN' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PASCAL' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PCTGEN' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PHAR' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PHARMAML' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PHIC' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PHIN' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PROMT' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'PROUSDDR' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'RDISCLOSURE' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'SCISEARCH' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'SYNTHLINE' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'TOXCENTER' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'USPATFULL' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'USPAT2' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'VETB' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'VETU' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'WATER' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'WPIDS' ENTERED AT 14:27:08 ON 22 SEP 2004

FILE 'WPIFV' ENTERED AT 14:27:08 ON 22 SEP 2004

```
FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s VP22
  49 FILES SEARCHED...
L1         2504 VP22

=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  51% COMPLETE FOR L1
PROCESSING IS APPROXIMATELY  94% COMPLETE FOR L1
PROCESSING COMPLETED FOR L1
L2          1383 DUP REM L1 (1121 DUPLICATES REMOVED)

=> S L2 AND PY<=1999
'1999' NOT A VALID FIELD CODE
   3 FILES SEARCHED...
   6 FILES SEARCHED...
   8 FILES SEARCHED...
  10 FILES SEARCHED...
  14 FILES SEARCHED...
  20 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  26 FILES SEARCHED...
  28 FILES SEARCHED...
  29 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  34 FILES SEARCHED...
L3          199 L2 AND PY<=1999

=> D L3 1-199

L3   ANSWER 1 OF 199  AGRICOLA  Compiled and distributed by the National
     Agricultural Library of the Department of Agriculture of the United States
     of America.  It contains copyrighted materials.  All rights reserved.
     (2004) on STN
AN   95:59072  AGRICOLA
DN   IND20479688
TI   Identification and characterization of a cDNA clone derived from the
     Marek's disease tumour cell line RPL1 encoding a homologue of
     alpha-transinducing factor (VP16) of HSV-1.
AU   Koptidesova, D.; Kopacek, J.; Zelnik, V.; Ross, N.L.J.; Pastorekova, S.;
     Pastorek, J.
CS   Slovak Academy of Sciences, Bratislava, Slovak Republic.
AV   DNAL (448.3 Ar23)
SO   Archives of virology,   ***1995.***   Vol. 140, No. 2. p. 355-362
     Publisher: Wien, Austria : Springer-Verlag.
     CODEN: ARVIDF; ISSN: 0304-8608
NTE  Includes references
CY   Austria
DT   Article
FS   Non-U.S. Imprint other than FAO
LA   English

L3   ANSWER 2 OF 199  BIOBUSINESS  COPYRIGHT (c) 1998 The Thomson Corporation.
     on STN
AN   1998:53870  BIOBUSINESS
DN   1005693
TI   Intercellular delivery of functional p53 by the herpesvirus protein
       ***VP22***  .
AU   Phelan A  Elliott G  O'Hare P
CS   Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 0TL, UK.
SO   Nature Biotechnology, (  ***1998***  ) Vol.16, No.5, p.440-443.
     ISSN: 1087-0156.
DT   ARTICLE
FS   NONUNIQUE
LA   English

L3   ANSWER 3 OF 199  BIOBUSINESS  COPYRIGHT (c) 1998 The Thomson Corporation.
     on STN
AN   1998:48224  BIOBUSINESS
DN   1000047
TI   Delivering p53 with herpesvirus protein.
```

AU Anon
SO Applied Genetics News, (***1998***) Vol.18, No.11, June, p.2.
ISSN: 0271-7107.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 4 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 1998:48128 BIOBUSINESS
DN 0999951
TI Invitrogen gets cell transport molecule from Phogen.
AU Anon
SO Pharmaceutical Business News, (***1998***) Vol.14, No.316, May 11, p.26.
ISSN: 0956-0661.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 5 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 1998:44319 BIOBUSINESS
DN 0996142
TI Phogen's ***VP22*** tech piggy-backs proteins into target cells.
AU Anon
SO European Biotechnology Newsletter, (***1998***) No.267, May 21, p.12.
ISSN: 0765-2046.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 6 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 97:33268 BIOBUSINESS
DN 0890803
TI Phogen JV explores potential of herpesvirus drug delivery.
AU Anon
SO Genetic Engineering News, (***1997***) Vol.17, No.6, March 15, p.4.
ISSN: 0270-6377.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 7 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 97:32996 BIOBUSINESS
DN 0890531
TI Cantab and MCCC will develop herpesvirus drug delivery.
AU Anon
SO Genetic Technology News, (***1997***) Vol.17, No.4, April, p.12.
ISSN: 0272-9032.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 8 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 97:30348 BIOBUSINESS
DN 0887883
TI Cantab joins forces with MCCC to form biotech company.
AU Anon
SO Pharmaceutical Business News, (***1997***) Vol.13, No.287, March 12, p.18.
ISSN: 0956-0661.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 9 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 97:27599 BIOBUSINESS
DN 0885134
TI ***VP22*** : A new movement in protein transport.
AU Marshall A; Castellino A
CS Dep. Cell Biol. Anatomy, Cornell Univ. Med. Coll., 1300 York Ave., New

York, NY 10021, USA.
SO Nature Biotechnology, (***1997***) Vol.15, No.3, March, p.205.
ISSN: 1087-0156.
DT ARTICLE
FS UNIQUE
LA English

L3 ANSWER 10 OF 199 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 97:24738 BIOBUSINESS
DN 0882273
TI Could cold sores be gene therapy's best friend?
AU Coghlan A
SO New Scientist, (***1997***) Vol.153, No.2069, Feb. 15, P.25.
ISSN: 0262-4079.
FS UNIQUE
LA ENGLISH

L3 ANSWER 11 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0183317 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Washington University (3086), USA
Idun Pharmaceuticals Inc (28890), USA
SO Pharmaceutical Business News, 10 SEP 1999, vol. 349, Page(s) 22.
TC (Company information)

L3 ANSWER 12 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0180669 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Cantab Pharmaceuticals plc (26256), UK
Marie Curie Cancer Care (MCCC) (41041), UK
Xenova Group plc (29007), UK
SO Scrip, 26 MAY 1999, vol. 2440, Page(s) 14.
Pharma Marketletter, 24 MAY 1999, vol. 2621, Page(s) 6.
TC (Company information)

L3 ANSWER 13 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0178060 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Cantab Pharmaceuticals plc (26256), UK
Marie Curie Cancer Care (MCCC) (41041), UK
Xenova Group plc (29007), UK
SO Scrip, 22 JAN 1999, vol. 2405, Page(s) 22.
Pharmaceutical Business News, 22 JAN 1999, vol. 15334, Page(s) 26.
TC (Company information)

L3 ANSWER 14 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0177649 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Karolinska Institute (KI) (602), Sweden
Marie Curie Cancer Care (MCCC) (41041), UK
Cantab Pharmaceuticals plc (26256), UK
NASDAQ Stock Market (33303), USA
Xenova Group plc (29007), UK
SO Phogen Press Release, 11 JAN 1999
TC (Company information)

L3 ANSWER 15 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0176533 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Cantab Pharmaceuticals Research Ltd (26181), UK
Marie Curie Cancer Care (MCCC) (41041), UK
Chemo-Sero-Therapeutic Research Institute, The (Kaketsuken) (2351), Japan
Xenova Research Ltd (49192), UK
SO Genetic Engineering News, 01 NOV 1998, vol. 1819, Page(s) 1,22,39,42.
TC General Review

L3 ANSWER 16 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0173423 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Cantab Pharmaceuticals plc (26256), UK
Marie Curie Cancer Care (MCCC) (41041), UK
Invitrogen Corp (17791), USA
Marie Curie Research Institute (15418), UK
Xenova Group plc (29007), UK
SO Pharm Science & Technology Today, JUN 1998, vol. 13, Page(s) 92-93.

TC General Review

L3 ANSWER 17 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0171772 BIOCOMMERCE FS Abstract
CO Marie Curie Research Institute (15418), UK
Texas A&M University (4987), USA
SO Nature Biotechnology, MAY 1998, vol. 165, Page(s) 418-419,440-43.
Chemistry in Britain, AUG 1998, vol. 348, Page(s) 19.
TC (Institute information)

L3 ANSWER 18 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0170624 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Invitrogen Corp (17791), USA
SO Scrip, 15 MAY 1998, vol. 2335, Page(s) 29.
Genetic Technology News, 13 MAY 1998, vol. 1819, Page(s) 3.
In Vivo, MAY 1998, vol. 165, Page(s) 74-75.
TC (Company information)

L3 ANSWER 19 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0169739 BIOCOMMERCE FS Abstract
CO Phogen Ltd (41282), UK
Cantab Pharmaceuticals plc (26256), UK
Marie Curie Research Institute (15418), UK
Xenova Group plc (29007), UK
SO Cantab Pharmaceuticals Press Release, 08 MAY 1998, vol. 320, Page(s) 1,8.
BioWorld International, 20 MAY 1998, vol. 165, Page(s) 440-443.
Nature Biotechnology, MAY 1998, vol. 2335, Page(s) 29.
Scrip, 15 MAY 1998, vol. 136, Page(s) 30.
BioVenture View, JUN 1998, vol. 267, Page(s) 12.
European Biotechnology Newsletter, 21 MAY 1998, vol. 2,340, Page(s) 724.
Gene Therapy, 03 JUN 1998, vol. 1811, Page(s) 2.
Applied Genetics News, JUN 1998
TC (Company information)

L3 ANSWER 20 OF 199 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN
AN 0152695 BIOCOMMERCE FS Abstract
CO Cantab Pharmaceuticals plc (26256), UK
Marie Curie Cancer Care (MCCC) (41041), UK
Phogen Ltd (41282), UK
Xenova Group plc (29007), UK
SO Cantab Pharmaceuticals Press Release, 27 FEB 1997, vol. 210, Page(s) 24.
Times, 28 FEB 1997, vol. 2213, Page(s) 1,3.
BioWorld International, 05 MAR 1997, vol. 43, Page(s) 10.
Scrip, 11 MAR 1997, vol. 2410, Page(s) 178.
Gene Therapy, MAR 1997, vol. 68, Page(s) 28.
Marketletter, 10 MAR 1997, vol. 13287, Page(s) 8-9.
R&D Focus Drug News, 10 MAR 1997, vol. 6, Page(s) 18.
Pharmaceutical Business News, 12 MAR 1997, vol. 710, Page(s) 202.
Chemistry and Industry, 17 MAR 1997, vol. 611, Page(s) 8.
BIA Bulletin, MAY 1997, vol. 2412, Page(s) 28.
Marketletter, 04 MAY 1998, vol. 421, Page(s) 6-7.
Pharmaceutical Ventures, 10 MAR 1997, vol. 176, Page(s) 10.
R&D Focus Drug News, 31 MAR 1997, vol. 44, Page(s) 4.
Marketletter, 24 MAR 1997, vol. 519, Page(s) 7.
European Biotechnology Newsletter, 20 MAR 1997, vol. 174, Page(s) 14.
Biotechnology Newswatch, 03 MAR 1997, vol. 335, Page(s) 13.
Cancer Weekly, 10 MAR 1997, vol. 95, Page(s) 9-10.
Gene Therapy Weekly, 10 MAR 1997, vol. 104, Page(s) 4.
Genetic Engineering News, 15 MAR 1997, Page(s) 272.
Gene Therapy, APR 1997, Page(s) 3.
BioWorld Financial Watch, 12 MAY 1997, Page(s) 8.
Pharmaceutical Times, APR 1997, Page(s) 12.
Genetic Technology News, APR 1997, Page(s) 10.
Chemistry in Britain, MAY 1997, Page(s) 10.
Pharmaceutical Technology Europe, MAY 1997, Page(s) 11.
BioPharm, APR 1997, Page(s) 4.
Nature UK Product Review, MAY 1997, Page(s) 8.
BIA Bulletin, MAY 1998, Page(s) 10.
BioPharm Showcase, JUL 1998
TC (Company information)

L3 ANSWER 21 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004383604 BIOENG
DN 4597965
TI Intercellular Spread of GFP- ***VP22***

AU Aints, A; Dilber, MS; Smith, CIE*
CS Center for Biotechnology, Department of Biosciences at Novum, Karolinska Institutet, Haelsovaegen 7, S-14157, Huddinge, Sweden, [mailto:edvard.smith@cbt.ki.se]
SO Journal of Gene Medicine [J. Gene Med.]. Vol. 1, no. 4, pp. 275-279. Jul-Aug 1999.
ISSN: 1099-498X
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 22 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004383603 BIOENG
DN 4597964
TI Quantification of ***VP22*** -GFP Spread by Direct Fluorescence in 15 Commonly Used Cell Lines
AU Wybranietz, WA; Prinz, F; Spiegel, M; Schenk, A; Bitzer, M; Gregor, M; Lauer, UM
CS Internal Medicine I, Medical University Clinic Tuebingen, Otfried Mueller-Str. 10, D-72076 Tuebingen, Germany, [mailto:wolfgang.wybranietz@uni-tuebingen.de]
SO Journal of Gene Medicine [J. Gene Med.]. Vol. 1, no. 4, pp. 265-274. Jul-Aug 1999.
ISSN: 1099-498X
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 23 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004373949 BIOENG
DN 4449126
TI Intercellular trafficking of ***VP22*** -GFP fusion proteins
AU Elliott, G; O'Hare, P*
CS Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 0TL, UK
SO Gene Therapy [Gene Ther.]. Vol. 6, no. 1, pp. 149-151. Jan 1999.
ISSN: 0969-7128
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 24 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004373932 BIOENG
DN 4449109
TI Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, ***VP22***
AU Dilber, MS; Phelan, A; Aints, A; Mohamed, AJ; Elliott, G; Edvard Smith, CI; O'Hare, P*
CS Marie Curie Research Institute, The Chart, Oxted, Surrey, RH8 0TL, UK
SO Gene Therapy [Gene Ther.]. Vol. 6, no. 1, pp. 12-21. Jan 1999.
ISSN: 0969-7128
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 25 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004371099 BIOENG
DN 4424908
TI Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27 super(Kip1) induces cell migration
AU Nagahara, H; Vocero-Akbani, AM; Snyder, EL; Ho, A; Latham, DG; Lissy, NA; Becker-Hapak, M; Ezhevsky, SA; Dowdy, SF*
CS Howard Hughes Medical Institute and Division of Molecular Oncology, Depts of Pathology and Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA, [mailto:dowdy@pathology.wustl.edu]
SO Nature Medicine [Nat. Med.]. Vol. 4, no. 12, pp. 1449-1452. Dec 1998.
ISSN: 1078-8956
DT Journal
LA English
OS Medical and Pharmaceutical Biotechnology Abstracts; Oncogenes & Growth Factors Abstracts

L3 ANSWER 26 OF 199 BIOENG COPYRIGHT on STN 2004 CSA

AN 2004366843 BIOENG
DN 4633200
TI Protein therapy - delivery guaranteed
AU Bayley, H
CS Department of medical biochemistry and genetics at the Texas A&M Health Science Center, College Station, TX 77843-1114, USA, [mailto:bayley@tamu.edu]
SO Nature Biotechnology [Nat. Biotechnol.]. Vol. 17, no. 11, pp. 1066-1067. Nov 1999.
ISSN: 1087-0156
DT Journal; General Review
LA English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 27 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004359291 BIOENG
DN 4411655
TI Intercellular trafficking of ***VP22*** -GFP fusion proteins is not observed in cultured mammalian cells
AU Fang, B; Xu, B; Koch, P; Roth, JA
CS Section of Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Box 109, 1515 Holcombe Boulevard, Houston, TX 77030, USA
SO Gene Therapy [Gene Ther.]. Vol. 5, no. 10, pp. 1420-1424. Oct 1998.
ISSN: 0969-7128
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 28 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004356753 BIOENG
DN 4344192
TI Intercellular delivery of functional p53 by the herpesvirus protein ***VP22***
AU Phelan, A; Elliott, G; O'Hare, P*
CS Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 OTL, UK
SO Nature Biotechnology [NAT. BIOTECHNOL.]. Vol. 16, no. 5, pp. 440-443. May 1998.
ISSN: 1087-0156
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 29 OF 199 BIOENG COPYRIGHT on STN 2004 CSA
AN 2004356752 BIOENG
DN 4344191
TI Ferrying proteins to the other side [Drug delivery through the plasma membrane]
AU Fernandez, Tania; Bayley, Hagan*
CS Department of Medical Biochemistry and Genetics at the Texas A&M Health Science Center, College Station, TX 77843, USA
SO Nature Biotechnology [NAT. BIOTECHNOL.]. Vol. 16, no. 5, pp. 418-420. May 1998.
ISSN: 1087-0156
DT Journal; General Review
LA English
OS Medical and Pharmaceutical Biotechnology Abstracts

L3 ANSWER 30 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:277810 BIOSIS
DN PREV200000277810
TI Herpesvirus pre-(viral DNA replication) enveloped particles.
AU Dargan, Derrick James [Inventor, Reprint author]; Patel, Arvind Hirabhai [Inventor]; Subak-Sharpe, John Herbert [Inventor]
CS Glasgow, UK
ASSIGNEE: Medical Research Council
PI US 5994116 November 30, 1999
SO Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 30, 1999) Vol. 1228, No. 5. e-file.
CODEN: OGUPE7. ISSN: 0098-1133.
DT Patent
LA English
ED Entered STN: 6 Jul 2000

Last Updated on STN: 7 Jan 2002

L3 ANSWER 31 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2000:792 BIOSIS
DN PREV200000000792
TI Direct protein transfer to terminally differentiated muscle cells.
AU Derer, Wolfgang; Easwaran, Hariharan P.; Knopf, Charles W.; Leonhardt, Heinrich; Cardoso, M. Cristina [Reprint author]
CS Franz Volhard Clinic, Max Delbrueck Center, Wiltbergstrasse 50, D-13125, Berlin, Germany
SO Journal of Molecular Medicine (Berlin), (Aug., 1999) Vol. 77, No. 8, pp. 609-613. print.
ISSN: 0946-2716.
DT Article
LA English
ED Entered STN: 23 Dec 1999
Last Updated on STN: 31 Dec 2001

L3 ANSWER 32 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:345893 BIOSIS
DN PREV199900345893
TI Modified ***VP22*** localizes to the cell nucleus during synchronized herpes simplex virus type 1 infection.
AU Pomeranz, Lisa E.; Blaho, John A. [Reprint author]
CS Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY, 10029-6574, USA
SO Journal of Virology, (Aug., 1999) Vol. 73, No. 8, pp. 6769-6781. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

L3 ANSWER 33 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:323440 BIOSIS
DN PREV199900323440
TI Identification of phosphorylation sites within the herpes simplex virus tegument protein ***VP22*** .
AU Elliott, Gillian [Reprint author]; O'Reilly, Dawn; O'Hare, Peter
CS Virus Assembly Group, Marie Curie Research Institute, The Chart, Oxted, Surrey, RH1 OTL, UK
SO Journal of Virology, (July, 1999) Vol. 73, No. 7, pp. 6203-6206. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 24 Aug 1999
Last Updated on STN: 24 Aug 1999

L3 ANSWER 34 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:310764 BIOSIS
DN PREV199900310764
TI ***VP22*** translocates heterologous proteins into tissue culture cells.
AU Bennett, Robert P. [Reprint author]; Dalby, Brian [Reprint author]; Guy, Pamela M. [Reprint author]
CS Invitrogen Corporation, Carlsbad, CA, USA
SO FASEB Journal, (April 23, 1999) Vol. 13, No. 7, pp. A1555. print.
Meeting Info.: Annual Meeting of the American Societies for Experimental Biology on Biochemistry and Molecular Biology 99. San Francisco, California, USA. May 16-20, 1999. American Societies for Experimental Biology.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 17 Aug 1999
Last Updated on STN: 17 Aug 1999

L3 ANSWER 35 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:298221 BIOSIS
DN PREV199900298221

TI Preliminary structural characterization of ***VP22*** , a protein expressing novel intercellular trafficking activity.
AU Kueltzo, L. [Reprint author]; O'Hare, P.; Middaugh, C. R. [Reprint author]
CS Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, 66047, USA
SO FASEB Journal, (April 23, 1999) Vol. 13, No. 7, pp. A1393. print.
Meeting Info.: Annual Meeting of the American Societies for Experimental Biology on Biochemistry and Molecular Biology 99. San Francisco, California, USA. May 16-20, 1999. American Societies for Experimental Biology.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 12 Aug 1999
Last Updated on STN: 12 Aug 1999

L3 ANSWER 36 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:238923 BIOSIS
DN PREV199900238923
TI Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection.
AU Elliott, Gillian [Reprint author]; O'Hare, Peter
CS Marie Curie Research Institute, The Chart, Oxted, Surrey, RH1 0TL, UK
SO Journal of Virology, (May, 1999) Vol. 73, No. 5, pp. 4110-4119. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 17 Jun 1999
Last Updated on STN: 17 Jun 1999

L3 ANSWER 37 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:490859 BIOSIS
DN PREV199800490859
TI Differences in the intracellular localization and fate of herpes simplex virus tegument proteins early in the infection of Vero cells.
AU Morrison, Ewan E.; Steven, Alex J.; Wang, Yi-Fen; Meredith, David M. [Reprint author]
CS Mol. Med. Unit, Univ. Leeds, St. James's Univ. Hosp., Beckett St., Leeds LS9 7TF, UK
SO Journal of General Virology, (Oct., 1998) Vol. 79, No. 10, pp. 2517-2528. print.
CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
LA English
ED Entered STN: 18 Nov 1998
Last Updated on STN: 18 Nov 1998

L3 ANSWER 38 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:411472 BIOSIS
DN PREV199800411472
TI Phosphorylation of structural components promotes dissociation of the herpes simplex virus type 1 tegument.
AU Morrison, Ewan E.; Wang, Yi-Fen; Meredith, David M. [Reprint author]
CS Molecular Med. Unit, Univ. Leeds, Clinical Sci. Build., St. James Univ. Hosp., Leeds LS9 7TF, UK
SO Journal of Virology, (Sept., 1998) Vol. 72, No. 9, pp. 7108-7114. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 21 Sep 1998
Last Updated on STN: 21 Sep 1998

L3 ANSWER 39 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:405088 BIOSIS
DN PREV199800405088
TI Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions.
AU Koelle, David M. [Reprint author]; Frank, Jeannine M.; Johnson, Matthew L.; Kwok, William W.
CS Fred Hutchinson Cancer Res. Center, Room D3-100, 1100 Fairview Ave. North, P.O. Box 19024, Seattle, WA 98109, USA

SO Journal of Virology, (Sept., 1998) Vol. 72, No. 9, pp. 7476-7483. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 21 Sep 1998
Last Updated on STN: 21 Sep 1998

L3 ANSWER 40 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:372651 BIOSIS
DN PREV199800372651
TI Herpes simplex virus type 1 tegument protein ***VP22*** induces the stabilization and hyperacetylation of microtubules.
AU Elliott, Gillian [Reprint author]; O'Hare, Peter
CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 OTL, UK
SO Journal of Virology, (Aug., 1998) Vol. 72, No. 8, pp. 6448-6455. print.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 27 Aug 1998
Last Updated on STN: 27 Aug 1998

L3 ANSWER 41 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:290802 BIOSIS
DN PREV199799590005
TI Protein transport: The nonclassical ins and outs.
AU Cleves, Ann E.
CS Dep. Biochemistry Biophysics, Univ. California, San Francisco, CA 94143-0534, USA
SO Current Biology, (1997) Vol. 7, No. 5, pp. R318-R320.
CODEN: CUBLE2. ISSN: 0960-9822.
DT Article
LA English
ED Entered STN: 9 Jul 1997
Last Updated on STN: 9 Jul 1997

L3 ANSWER 42 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:118416 BIOSIS
DN PREV199799417619
TI The abundance of the herpes simplex virus type 1 UL37 tegument protein in virus particles in closely controlled.
AU McLauchlan, John
CS MRC Virol. Unit, Church St., Glasgow G11 5JR, UK
SO Journal of General Virology, (1997) Vol. 78, No. 1, pp. 189-194.
CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
LA English
ED Entered STN: 10 Mar 1997
Last Updated on STN: 10 Mar 1997

L3 ANSWER 43 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:107423 BIOSIS
DN PREV199799406626
TI Intercellular trafficking and protein delivery by a herpesvirus structural protein.
AU Elliott, Gillian; O'Hare, Peter
CS Marie Curie Res. Inst., The Chart, Oxted, Surrey RH8 OTL, UK
SO Cell, (1997) Vol. 88, No. 2, pp. 223-233.
CODEN: CELLB5. ISSN: 0092-8674.
DT Article
LA English
ED Entered STN: 10 Mar 1997
Last Updated on STN: 10 Mar 1997

L3 ANSWER 44 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:30445 BIOSIS
DN PREV199799336848
TI Phosphorylation of the herpes simplex virus type 1 tegument protein ***VP22***.
AU Elliott, Gillian [Reprint author]; O'Reilly, Dawn; O'Hare, Peter
CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 OTL, UK
SO Virology, (1996) Vol. 226, No. 1, pp. 140-145.

CODEN: VIRLAX. ISSN: 0042-6822.
DT Article
LA English
ED Entered STN: 28 Jan 1997
Last Updated on STN: 25 Mar 1997

L3 ANSWER 45 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1996:341870 BIOSIS
DN PREV199699064226
TI Overexpression of the herpes simplex virus type 1 tegument protein ***VP22*** increases its incorporation into virus particles.
AU Leslie, J.; Rixon, F. J.; McLauchlan, J. [Reprint author]
CS MRC Virology Unit, Inst. Virology, Church Street, Glasgow G11 5JR, UK
SO Virology, (1996) Vol. 220, No. 1, pp. 60-68.
CODEN: VIRLAX. ISSN: 0042-6822.
DT Article
LA English
ED Entered STN: 26 Jul 1996
Last Updated on STN: 26 Jul 1996

L3 ANSWER 46 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1996:30491 BIOSIS
DN PREV199698602626
TI VP16 interacts via its activation domain with ***VP22*** , a tegument protein of herpes simplex virus, and is relocated to a novel macromolecular assembly in coexpressing cells.
AU Elliott, Gillian [Reprint author]; Mouzakitis, Gerasimos; O'Hare, Peter
CS Marie Curie Res. Inst., Chart, Oxted, Surrey RH8 0TL, UK
SO Journal of Virology, (1995) Vol. 69, No. 12, pp. 7932-7941.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 12 Jan 1996
Last Updated on STN: 12 Jan 1996

L3 ANSWER 47 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1995:364073 BIOSIS
DN PREV199598378373
TI PREPs: Herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked.
AU Dargan, D. J. [Reprint author]; Patel, A. H.; Subak-Sharpe, J. H.
CS Med. Res. Council, Virol Unit, Univ. Glasgow, Church St., Glasgow G11 5JR, UK
SO Journal of Virology, (1995) Vol. 69, No. 8, pp. 4924-4932.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
LA English
ED Entered STN: 30 Aug 1995
Last Updated on STN: 30 Aug 1995

L3 ANSWER 48 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1994:272819 BIOSIS
DN PREV199497285819
TI Detection and identification of Vibrio parahaemolyticus in fecal samples of outbreak patients by in vitro amplification of thermostable direct haemolysin gene fragment.
AU Lee, Chiayin [Reprint author]; Pan, Shwu-Fen; Lee, Yeong-Sheng; Lee, Chih-Lung
CS Graduate Inst. Agric. Chem., Natl. Taiwan Univ., Taipei, Taiwan
SO Journal of the Chinese Agricultural Chemical Society, (1994) Vol. 32, No. 1, pp. 103-112.
CODEN: CKNHAA. ISSN: 0578-1736.
DT Article
LA Chinese
ED Entered STN: 24 Jun 1994
Last Updated on STN: 24 Jun 1994

L3 ANSWER 49 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1993:235606 BIOSIS
DN PREV199395126781
TI A mutant of herpes simplex virus type 1 in which the UL13 protein kinase

gene is disrupted.
AU Coulter, L. J.; Moss, H. W. M.; Lang, J.; McGeoch, D. J. [Reprint author]
CS Inst. Virology, Univ. Glasgow, Church Street, Glasgow G11 5JR, UK
SO Journal of General Virology, (1993) Vol. 74, No. 3, pp. 387-395.
CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
LA English
ED Entered STN: 7 May 1993
Last Updated on STN: 7 May 1993

L3 ANSWER 50 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1992:234456 BIOSIS
DN PREV199293122481; BA93:122481
TI THE HERPES SIMPLEX VIRUS TYPE 1 TEGUMENT PROTEIN ***VP22*** IS ENCODED BY GENE UL49.
AU ELLIOTT G D [Reprint author]; MEREDITH D M
CS DEP MICROBIOL, UNIV OF LEEDS, LEEDS LS2 9JT, UK
SO Journal of General Virology, (1992) Vol. 73, No. 3, pp. 723-726.
CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 10 May 1992
Last Updated on STN: 10 May 1992

L3 ANSWER 51 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1992:56110 BIOSIS
DN PREV199293036085; BA93:36085
TI POST-TRANSLATIONAL MODIFICATION OF THE TEGUMENT PROTEINS VP13 AND VP14 OF HERPES SIMPLEX VIRUS TYPE 1 BY GLYCOSYLATION AND PHOSPHORYLATION.
AU MEREDITH D M [Reprint author]; LINDSAY J A; HALLIBURTON I W; WHITTAKER G R
CS DEP MICROBIOL, UNIV LEEDS, LEEDS LS2 9JT, UK
SO Journal of General Virology, (1991) Vol. 72, No. 11, pp. 2771-2776.
CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 13 Jan 1992
Last Updated on STN: 13 Jan 1992

L3 ANSWER 52 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1990:139691 BIOSIS
DN PREV199089078502; BA89:78502
TI THREE-DIMENSIONAL STRUCTURES OF MATURABLE AND ABORTIVE CAPSIDS OF EQUINE HERPESVIRUS 1 FROM CRYOELECTRON MICROSCOPY.
AU BAKER T S [Reprint author]; NEWCOMB W W; BOOY F P; BROWN J C; STEVEN A C
CS LAB PHYSIOL BIOL, NATL INST ARTHRITIS MUSCULOSKELETAL SKIN DIS, BUILDING 6, ROOM 114, BETHESDA, MD 20892, USA
SO Journal of Virology, (1990) Vol. 64, No. 2, pp. 563-573.
CODEN: JOVIAM. ISSN: 0022-538X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 13 Mar 1990
Last Updated on STN: 13 Mar 1990

L3 ANSWER 53 OF 199 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1980:179973 BIOSIS
DN PREV198069054969; BA69:54969
TI VIRUS SPECIFIC BASIC PHOSPHO PROTEINS ASSOCIATED WITH HERPES SIMPLEX VIRUS TYPE 1 PARTICLES AND THE CHROMATIN OF HERPES SIMPLEX VIRUS TYPE 1 INFECTED CELLS.
AU KNOPF K-W [Reprint author]; KAERNER H C
CS GER CANCER RES CENT, INST VIRUS RES, 6900 HEIDELBERG, W GER
SO Journal of General Virology, (1980) Vol. 46, No. 2, pp. 405-414.
CODEN: JGVIAY. ISSN: 0022-1317.
DT Article
FS BA
LA ENGLISH

L3 ANSWER 54 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1999-05246 BIOTECHDS

TI Intercellular trafficking of ***VP22*** -GFP fusion proteins;
      VP22 -green fluorescent protein fusion protein with the
    ability to mediate intercellular protein transport
AU Elliot G; *O'Hare P
CS Marie-Curie-Res.Inst.Oxted
LO Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 OTL, UK.
SO Gene Ther.; (***1999***) 6, 1, 149-51
    CODEN: GETHEC ISSN: 0969-7128
DT Journal
LA English

L3 ANSWER 55 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1999-02756 BIOTECHDS
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex
    virus;
      herpes simplex virus recombinant ***VP22*** protein preparation,
    virus vector-mediated gene transfer and expression in host cell, used
    for infection recombinant vaccine or nucleic acid vaccine
AU Burke R L; Tigges M A
PA Chiron
LO Emeryville, CA, USA.
PI WO 9855145 ***10 Dec 1998***
AI WO 1998-US10664 26 May 1998
PRAI US 1997-47359 2 Jun 1997
DT Patent
LA English
OS WPI: 1999-059878 [05]

L3 ANSWER 56 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1999-01646 BIOTECHDS
TI Using baculo virus to deliver nucleic acid to hepatocytes;
      thymidine-kinase gene transfer, antisense and ribozyme for virus
    infection and liver cancer gene therapy
AU McGarvey M J; Thomas H C
PA Imperial-Coll.Innovations
LO London, UK.
PI WO 9848842 ***5 Nov 1998***
AI WO 1998-GB1249 29 Apr 1998
PRAI GB 1997-8698 29 Apr 1997
DT Patent
LA English
OS WPI: 1999-009390 [01]

L3 ANSWER 57 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1998-11220 BIOTECHDS
TI Use of the microtubule binding function and transport properties of
    herpes virus ***VP22*** protein;
      to study and manipulate mammal cell structure, growth, division and
    death in vitro and in vivo
AU Elliot G D
PA Phogen
LO Cambridge, UK.
PI WO 9842742 ***1 Oct 1998***
AI WO 1998-GB873 23 Mar 1998
PRAI GB 1997-5903 21 Mar 1997
DT Patent
LA English
OS WPI: 1998-531948 [45]

L3 ANSWER 58 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1998-09556 BIOTECHDS
TI New coupled or fusion polypeptides;
      herpes virus ***VP22*** protein and p53 fusion protein preparation
    by plasmid p49532p+10 vector expression in microorganism or mammal
    cell, used for disease therapy or gene therapy, etc.
AU O'Hare P F J; Elliott G D
PA Marie-Curie-Cancer-Care
LO London, UK.
PI WO 9832866 ***30 Jul 1998***
AI WO 1998-GB207 23 Jan 1998
PRAI GB 1997-16398 1 Aug 1997; GB 1997-1363 23 Jan 1997
DT Patent
LA English
OS WPI: 1998-427962 [36]

L3 ANSWER 59 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN

AN 1998-08690 BIOTECHDS
TI Ferrying proteins to the other side;
membrane translocating protein fusion protein for potential use in gene therapy or as recombinant vaccine
AU Fernandez T; Bayley H
CS Univ.Texas-A+M
LO Department of Medical Biochemistry and Genetics, Texas A+M Health Science Center, College Station, TX 77843, USA.
Email: bayley@tamu.edu
SO Nat.Biotechnol.; (***1998***) 16, 5, 418-20
CODEN: NABIF ISSN: 1087-0156
DT Journal
LA English

L3 ANSWER 60 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1998-04880 BIOTECHDS
TI New antiviral agent against herpes, disrupts binding of ***VP22*** to VP16 or gB;
virucide causing disruption of herpes simplex virus type-1 protein association
AU McLaughlan J; McGeoch D J; Hope R G; Rixon H W M
PA Med.Res.Counc.
LO London, UK.
PI WO 9804708 ***5 Feb 1998***
AI WO 1997-GB2036 28 Jul 1997
PRAI GB 1996-15726 26 Jul 1996
DT Patent
LA English
OS WPI: 1998-130696 [12]

L3 ANSWER 61 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1997-06513 BIOTECHDS
TI Use of herpes simplex virus type-1 major tegument portion, ***VP22*** ;
as a transport protein in a fusion protein, for tissue-specific gene expression, using a virus vector, lipofection, transfection or microinjection, in e.g. gene therapy
AU O'Hare P F J; Elliott G D
PA O'Hare P F J; Elliott G D
LO Oxted, UK.
PI WO 9705265 ***13 Feb 1997***
AI WO 1996-GB1831 25 Jul 1996
PRAI GB 1996-1570 26 Jan 1996; GB 1995-15568 28 Jul 1995
DT Patent
LA English
OS WPI: 1997-145701 [13]

L3 ANSWER 62 OF 199 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
AN 1985-05303 BIOTECHDS
TI Construction of a shuttle vector which replicates stably in Vibrio parahemolyticus and Escherichia coli;
plasmid characterization (conference paper)
AU Ando T; Arai T
LO Department of Microbiology, Keio University School of Medicine Tokyo, Japan.
SO Transferable Antibiot.Resist.; (***1984***) 5 Meet., 347-52
DT Journal
LA English

L3 ANSWER 63 OF 199 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1999:29479978 BIOTECHNO
TI Can ***VP22*** resurrect gene therapy?
AU Luft F.C.
CS F.C. Luft, Franz-Volhard-Klinik, Humboldt University of Berlin, Wiltbergstrasse 50, D-13125 Berlin-Buch, Germany.
E-mail: luft@fvk-berlin.de
SO Journal of Molecular Medicine, (***1999***), 77/8 (575-576), 6 reference(s)
CODEN: JMLME8 ISSN: 0946-2716
DT Journal; (Short Survey)
CY Germany, Federal Republic of
LA English

L3 ANSWER 64 OF 199 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1999:29043687 BIOTECHNO
TI Catch ***VP22*** : The hitch-hiker's ride to gene therapy?

AU Murphy A.L.; Murphy S.J.
SO Gene Therapy, (***1999***), 6/1 (4-5), 7 reference(s)
CODEN: GETHEC ISSN: 0969-7128
DT Journal; (Short Survey)
CY United Kingdom
LA English

L3 ANSWER 65 OF 199 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 1998:29043337 BIOTECHNO
TI New strategies for the genetic therapy of primary liver carcinoma
AU Lauer U.; Spiegel M.; Bitzer M.; Wybranietz W.A.; Gross Ch.D.; Prinz F.; Graepler F.; Neubert W.J.; Gregor M.
CS Dr. U. Lauer, Abteilung Innere Medizin I, Med. Universitatsklinik Tubingen, Otfried-Muller-Str. 10, D-72076 Tubingen, Germany.
SO Minimally Invasive Therapy and Allied Technologies, (***1998***), 7/6 (567-571), 26 reference(s)
CODEN: MITAFI ISSN: 1364-5706
DT Journal; Article
CY United Kingdom
LA English
SL English

L3 ANSWER 66 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:753364 CAPLUS
DN 131:347510
TI Gene therapy vectors utilizing recombination and their use in antitumor therapy
IN Margison, Geoffrey Paul; Marples, Brian; Scott, Simon; Hendry, Jolyon Hindson
PA Cancer Research Campaign Technology Limited, UK
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9960142	A2	19991125	WO 1999-GB1362	19990517 <--
	WO 9960142	A3	20000713		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2374248	AA	19991125	CA 1999-2374248	19990517 <--
	AU 9939375	A1	19991206	AU 1999-39375	19990517 <--
	AU 763714	B2	20030731		
	EP 1078091	A2	20010228	EP 1999-922263	19990517
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	NZ 508671	A	20030530	NZ 1999-508671	19990517
PRAI	GB 1998-10423	A	19980515		
	WO 1999-GB1362	W	19990517		

L3 ANSWER 67 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:390423 CAPLUS
DN 131:39724
TI Cytotoxin fusion proteins for use in killing of cells infected by pathogens
IN Dowdy, Steven F.
PA Washington University, USA
SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929721	A1	19990617	WO 1998-US26358	19981210 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				

UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2314267	AA	19990617	CA 1998-2314267	19981210 <--
AU 9918182	A1	19990628	AU 1999-18182	19981210 <--
EP 1037911	A1	20000927	EP 1998-963079	19981210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6221355	B1	20010424	US 1998-208966	19981210
JP 2002505077	T2	20020219	JP 2000-524312	19981210
PRAI US 1997-69012P	P	19971210		
US 1998-82402P	P	19980420		
WO 1998-US26358	W	19981210		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 68 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:166641 CAPLUS
DN 130:205911
TI Fusion proteins of transcriptional activators carrying peptides promoting cell uptake and a regulated expression system using them
IN Dowdy, Steven F.; Jessee, Joel A.
PA Washington University, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9910376	A1	19990304	WO 1998-US16887	19980814 <--
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1005486	A1	20000607	EP 1998-939402	19980814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001513987	T2	20010911	JP 2000-507702	19980814
US 2003040038	A1	20030227	US 1998-134793	19980814
US 2004146889	A1	20040729	US 2003-680576	20031006
PRAI US 1997-56713P	P	19970822		
US 1998-134793	A1	19980814		
WO 1998-US16887	W	19980814		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 69 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:621324 CAPLUS
DN 129:240848
TI Increasing the efficiency of uptake of transforming DNA complexes with polycations using peptides
IN Hawley-Nelson, Pamela; Lan, Jianqing; Shih, Pojen; Jessee, Joel A.; Ciccarone, Valentina C.; Evans, Krista L.; Schifferli, Kevin P.; Gebeyehu, Guililat
PA Life Technologies, Inc., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9840502	A1	19980917	WO 1998-US5232	19980316 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6051429	A	20000418	US 1997-818200	19970314
AU 9865622	A1	19980929	AU 1998-65622	19980316 <--
EP 1007699	A1	20000614	EP 1998-911737	19980316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI
JP 2001517939 T2 20011009 JP 1998-539899 19980316
PRAI US 1997-818200 A 19970314
US 1995-477354 B2 19950607
US 1996-658130 A2 19960604
WO 1998-US5232 W 19980316
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 70 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:175378 CAPLUS
TI ***VP22*** : A new movement in protein transport
AU Marshall, Andrew; Castellino, Alexander
CS Dep. Cell Biol. Anatomy, Cornell Univ. Med. Coll., New York, NY, 10021, USA
SO Nature Biotechnology (***1997***), 15(3), 205
CODEN: NABIF9; ISSN: 1087-0156
PB Nature Publishing Co.
DT Journal; News Announcement
LA English

L3 ANSWER 71 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:571796 CAPLUS
DN 121:171796
TI Nucleotide sequence of a 55 kbp region from the right end of the genome of a pathogenic African swine fever virus isolate (malawi LIL20/1)
AU Dixon, Linda K.; Twigg, Stephen R. F.; Baylis, Sally A.; Vydelingum, Soopayah; Bristow, Christine; Hammond, Jef M.; Smith, Geoffrey L.
CS AFRC Inst. Animal Health, Pirbright Lab., Woking, GU24 0NF, UK
SO Journal of General Virology (***1994***), 75(7), 1655-84
CODEN: JGVIAY; ISSN: 0022-1317
DT Journal
LA English

L3 ANSWER 72 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:320903 CAPLUS
DN 120:320903
TI Analysis of antibody responses to predominant linear epitopes of Theiler's murine encephalomyelitis virus
AU Inoue, Atsushi; Choe, Yong Kyung; Kim, Byung S.
CS Med. Sch., Northwest. Univ., Chicago, IL, 60611, USA
SO Journal of Virology (***1994***), 68(5), 3324-33
CODEN: JOVIAM; ISSN: 0022-538X
DT Journal
LA English

L3 ANSWER 73 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:445358 CAPLUS
DN 115:45358
TI Purification of the structural proteins of herpes simplex virus type 1 by reversed-phase high-performance liquid chromatography
AU Whittaker, G. R.; Meredith, D. M.
CS Dep. Microbiol., Univ. Leeds, Leeds, LS2 9JT, UK
SO Archives of Virology (***1990***), 114(3-4), 271-6
CODEN: ARVIDF; ISSN: 0304-8608
DT Journal
LA English

L3 ANSWER 74 OF 199 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:403337 CAPLUS
DN 99:3337
TI Important role of protease of baculovirus inclusion bodies in the infection process
AU Kozlov, E. A.; Levitina, T. L.; Gusak, N. M.; Unguryanu, N.; Serebryanyi, S. B.
CS Inst. Mol. Biol. Genet., Kiev, USSR
SO Molekulyarnaya Biologiya (Kiev) (***1982***), 31, 32-5
CODEN: MLKBAQ; ISSN: 0375-9415
DT Journal
LA Russian

L3 ANSWER 75 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1999(06):5040 CEABA-VTB FS B
DN CEABA: 1999:3212891
TI Phogen s herpes protein technology boosts anticancer gene therapy
CS Phogen, Cambridge, UK

SO Pharm. Bus. News (***1999***) 15(334), p.26
CODEN: PBNEEH ISSN: 0956-0661
DT Journal
LA English

L3 ANSWER 76 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1998(07):0028 CEABA-VTB FS B
DN CEABA: 1998:5225896
TI Invitrogen gets cell transport molecule from Phogen
CS Invitrogen, USA
SO Pharm. Bus. News (***1998***) 14(316), p.26
CODEN: PBNEEH ISSN: 0956-0661
DT Journal
LA English

L3 ANSWER 77 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1998(06):5537 CEABA-VTB FS B
DN CEABA: 1998:2431892
TI Cancer gene therapy: guardian gene restored
AU Newell, J. (UK)
SO Chem. Br. (***1998***) 34(8), p.19
CODEN: CHMBAY ISSN: 0009-3106
DT Journal
LA English

L3 ANSWER 78 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1997(07):5539 CEABA-VTB FS B
DN CEABA: 1997:7484891
TI Could cold sores be gene therapy s best friend?
AU Coghlan, A.
SO New Sci. (***1997***) 153(2069), p.25
CODEN: NWSCAL ISSN: 0028-6664
DT Journal
LA English

L3 ANSWER 79 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1997(06):8691 CEABA-VTB FS B
DN CEABA: 1997:3712899
TI Hitchhiker s guide to gene therapy
CS Phogen, UK
SO Chem. Ind. (London) (***1997***) (6), p.202
CODEN: CHINAG ISSN: 0009-3068
DT Journal
LA English

L3 ANSWER 80 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1997(06):7870 CEABA-VTB FS B
DN CEABA: 1997:3336891
TI Phogen to focus on herpes drug delivery
CS Phogen, Cambridge, UK
SO Biotechnol. Newswatch (***1997***), p.14
ISSN: 0275-3685
DT Journal
LA English

L3 ANSWER 81 OF 199 CEABA-VTB COPYRIGHT 2004 DECHEMA on STN
AN 1997(06):4294 CEABA-VTB FS B
DN CEABA: 1997:1558891
TI Drug delivery by herpes virus protein
SO Lab. News (London) (***1997***), p.5
ISSN: 0266-7169
DT Journal
LA English

L3 ANSWER 82 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 28(23):23048P CIN
TI Deals
SO BioCentury, 24 May 1999 (19990524), 7(30, Pt. 2), p. B3. ISSN: 1097-7201;
CODEN: BICEFS.
LA English

L3 ANSWER 83 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 28(5):4140W CIN
TI Other research news
SO BioCentury, 18 Jan 1999 (19990118), 7(5, Pt. 2), p. B16. ISSN: 1097-7201;
CODEN: BICEFS.

LA English

L3 ANSWER 84 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 27(27):30609E CIN
TI Phogen's ***VP22*** tech piggy-backs proteins into target cells
SO Eur. Biotechnol. Newsl., 21 May 1998 (19980521), 267, p. 12. ISSN: 0765-2046; CODEN: EBNWEI.
LA English

L3 ANSWER 85 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 27(20):23072W CIN
TI Other research news
SO BioCentury, 4 May 1998 (19980504), 6(39, Pt. 2), p. B13. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L3 ANSWER 86 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 27(20):22759P CIN
TI Sales & marketing
SO BioCentury, 4 May 1998 (19980504), 6(39, Pt. 2), p. B6. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L3 ANSWER 87 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(18):20632X CIN
TI Phogen JV explores potential of herpesvirus drug delivery
SO Genet. Eng. News, 15 Mar 1997 (970315), 17(6), p. 4. ISSN: 0270-6377; CODEN: GENNDX.
LA English

L3 ANSWER 88 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(14):16215W CIN
TI Hitchhiker's guide to gene therapy
SO Chem. Ind. (London), 17 Mar 1997 (970317), (6), p. 202. ISSN: 0009-3068; CODEN: CHINAG.
LA English

L3 ANSWER 89 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(13):15349F CIN
TI Cantab joins forces with MCCC to form biotech company
SO Pharm. Bus. News, 12 Mar 1997 (970312), 13(287), p. 18. ISSN: 0956-0661; CODEN: PBNEEH.
LA English

L3 ANSWER 90 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(13):15271Z CIN
TI Cantab forms joint venture to develop protein for drug and gene delivery
SO Biotechnol. News, 6 Mar 1997 (970306), 17(6), p. 4. ISSN: 0273-3226; CODEN: BINWEY.
LA English

L3 ANSWER 91 OF 199 CIN COPYRIGHT 2004 ACS on STN
AN 26(12):13742E CIN
TI ***VP22*** : a new movement in protein transport
SO Nat. Biotechnol., Mar 1997 (970300), 15(3), p. 205. ISSN: 1087-0156; CODEN: NABIF9.
LA English

L3 ANSWER 92 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY78333 peptide DGENE
TI New membrane permanent peptide complexes for medical imaging, diagnostics and therapy -
IN Piwnica-Worms D
PA (UNIW) UNIV WASHINGTON.
PI ***WO 9967284 A2 19991229 65p***
AI WO 1999-US13660 19990618
PRAI US 1998-90087 19980620
DT Patent
LA English
OS 2000-160576 [14]
DESC Herpes simplex virus ***VP22*** protein SEQ ID NO:5.

L3 ANSWER 93 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW67755 Protein DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce

a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***
AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
CR N-PSDB: AAV81471
DESC HSV-2 ***VP22*** protein.

L3 ANSWER 94 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW95100 peptide DGENE
TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI ***WO 9906540 A2 19990211 88p***
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR N-PSDB: AAX26228
DESC HIV-1 ***VP22*** polypeptide C-terminal domain.

L3 ANSWER 95 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW95099 Protein DGENE
TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI ***WO 9906540 A2 19990211 88p***
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR N-PSDB: AAX26227
DESC HIV-1 ***VP22*** polypeptide.

L3 ANSWER 96 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY27404 Protein DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors or inflammation -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945126 A2 19990910 149p***
AI WO 1999-GB672 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-540852 [45]
CR N-PSDB: AAZ07807
DESC HSV-1 tegument protein ***VP22*** .

L3 ANSWER 97 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAY42292 Protein DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945127 A2 19990910 187p***
AI WO 1999-GB674 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129

DT Patent
LA English
OS 1999-551046 [46]
CR N-PSDB: AAZ19784
DESC Herpes simplex virus type 1 (HSV-1) ***VP22*** tegument protein.

L3 ANSWER 98 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47199 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide D.

L3 ANSWER 99 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47198 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide C.

L3 ANSWER 100 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47197 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide B.

L3 ANSWER 101 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47196 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide A.

L3 ANSWER 102 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47195 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726

DT Patent
LA English
OS 1998-130696 [12]
DESC Herpes simplex virus truncated tegument protein ***VP22*** .

L3 ANSWER 103 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47194 Protein DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
CR N-PSDB: AAV17085
DESC Herpes simplex virus tegument protein ***VP22*** .

L3 ANSWER 104 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47205 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide J.

L3 ANSWER 105 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47204 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide I.

L3 ANSWER 106 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47203 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide H.

L3 ANSWER 107 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47202 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726

DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide G.

L3 ANSWER 108 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47201 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide F.

L3 ANSWER 109 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW47200 peptide DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
DESC HSV truncated tegument protein ***VP22*** derived peptide E.

L3 ANSWER 110 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW69718 protein DGENE
TI Coupled or fusion polypeptides, for transporting proteins into cells - contain an amino acid sequence with the transport function of herpesviral ***VP22*** protein
IN Elliott G D; O'Hare P F J
PA (CURI-N) CURIE CANCER CARE MARIE.
PI ***WO 9832866 A1 19980730 39p***
AI WO 1998-GB207 19980123
PRAI GB 1997-16398 19970801
GB 1997-1363 19970123
DT Patent
LA English
OS 1998-427962 [36]
DESC Human p53 used in coupled proteins and fusion proteins.

L3 ANSWER 111 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAW69717 protein DGENE
TI Coupled or fusion polypeptides, for transporting proteins into cells - contain an amino acid sequence with the transport function of herpesviral ***VP22*** protein
IN Elliott G D; O'Hare P F J
PA (CURI-N) CURIE CANCER CARE MARIE.
PI ***WO 9832866 A1 19980730 39p***
AI WO 1998-GB207 19980123
PRAI GB 1997-16398 19970801
GB 1997-1363 19970123
DT Patent
LA English
OS 1998-427962 [36]
DESC Herpesviral ***VP22*** protein used in coupled proteins and fusion proteins.

L3 ANSWER 112 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV81473 DNA DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***

AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
DESC Primer GPUL49 3' for HSV-2 ***VP22*** gene.

L3 ANSWER 113 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV81472 DNA DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***
AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
DESC Primer GPUL49 5' for HSV-2 ***VP22*** gene.

L3 ANSWER 114 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV81471 DNA DGENE
TI Subunit vaccine containing ***VP22*** polypeptide of herpes simplex virus - and vaccines containing vector encoding this polypeptide, induce a cytotoxic T cell response
IN Burke R L; Tigges M A
PA (CHIR) CHIRON CORP.
PI ***WO 9855145 A1 19981210 94p***
AI WO 1998-US10664 19980526
PRAI US 1997-47359 19970602
DT Patent
LA English
OS 1999-059878 [05]
CR P-PSDB: AAW67755
DESC HSV-2 ***VP22*** gene.

L3 ANSWER 115 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAX26227 DNA DGENE
TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI ***WO 9906540 A2 19990211 88p***
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR P-PSDB: AAW95099
DESC HIV-1 ***VP22*** polypeptide encoding DNA.

L3 ANSWER 116 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAX26228 DNA DGENE
TI Fusion and chimaeric proteins including cyclin-dependent kinase binding motif - used for regulation of cell proliferation and differentiation, for treatment of, e.g. vascular injury, cancers, fibrosis and neurodegeneration
IN Beach D H; Gyuris J; Lamphere L
PA (MITO-N) MITOTIX INC.
PI ***WO 9906540 A2 19990211 88p***
AI WO 1998-US15759 19980729
PRAI US 1997-902572 19970729
DT Patent
LA English
OS 1999-153770 [13]
CR P-PSDB: AAW95100
DESC HIV-1 ***VP22*** polypeptide C-terminal domain encoding DNA.

L3 ANSWER 117 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ07807 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors or inflammation -

IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945126 A2 19990910 149p***
AI WO 1999-GB672 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-540852 [45]
CR P-PSDB: AAY27404
DESC HSV-1 tegument protein ***VP22*** encoding DNA.

L3 ANSWER 118 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ07770 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors or inflammation -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945126 A2 19990910 149p***
AI WO 1999-GB672 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-540852 [45]
DESC HSV-1 tegument protein ***VP22*** 3' primer.

L3 ANSWER 119 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ07769 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors or inflammation -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945126 A2 19990910 149p***
AI WO 1999-GB672 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-540852 [45]
DESC HSV-1 tegument protein ***VP22*** 5' primer.

L3 ANSWER 120 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ19804 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945127 A2 19990910 187p***
AI WO 1999-GB674 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-551046 [46]
DESC Herpes simplex type 1 (HSV-1) tegument protein ***VP22*** 3' PCR primer.

L3 ANSWER 121 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ19803 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945127 A2 19990910 187p***
AI WO 1999-GB674 19990305
PRAI GB 1998-4841 19980306

GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-551046 [46]
DESC Herpes simplex type 1 (HSV-1) tegument protein ***VP22*** 5' PCR primer.

L3 ANSWER 122 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ19796 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945127 A2 19990910 187p***
AI WO 1999-GB674 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-551046 [46]
DESC Human anchorless P450R 3' PCR primer.

L3 ANSWER 123 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ19795 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945127 A2 19990910 187p***
AI WO 1999-GB674 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-551046 [46]
DESC Human anchorless P450R 5' PCR primer.

L3 ANSWER 124 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAZ19784 DNA DGENE
TI New prodrug activating agent targeted to selected cells or tissues, particularly hypoxic cells, for treating e.g. tumors -
IN Stratford I J; Patterson A V; Kingsman S M; Kan O; Griffiths L; Mitrophanous K
PA (OXFO-N) OXFORD BIOMEDICA UK LTD.
PI ***WO 9945127 A2 19990910 187p***
AI WO 1999-GB674 19990305
PRAI GB 1998-4841 19980306
GB 1998-18103 19980819
GB 1999-2081 19990129
DT Patent
LA English
OS 1999-551046 [46]
CR P-PSDB: AAY42292
DESC Herpes simplex virus type 1 (HSV-1) ***VP22*** DNA.

L3 ANSWER 125 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAV17085 DNA DGENE
TI New antiviral agent disrupting binding of ***VP22*** to VP16 or gB - useful for treating infections caused by herpes simplex, e.g. cold sores and chicken-pox
IN Hope R G; McGeoch D J; McLaughlan J; Rixon H W M
PA (MEDI-N) MEDICAL RES COUNCIL.
PI ***WO 9804708 A1 19980205 75p***
AI WO 1997-GB2036 19970728
PRAI GB 1996-15726 19960726
DT Patent
LA English
OS 1998-130696 [12]
CR P-PSDB: AAW47194
DESC Herpes simplex virus UL49 gene.

L3 ANSWER 126 OF 199 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAT10200 DNA DGENE
TI Amplification and detection of specific gene fragment of Vibrio parahaemolyticus - using two oligo:nucleotide(s) as a primer set to amplify the thermostable direct haemolysin gene
IN Lii J; Pan S
PA (LIIJ-I) LII J.
PI ***TW 265366 A 19951211 9p***
AI TW 1993-110632 19931215
PRAI TW 1993-110632 19931215
DT Patent
LA Chinese
OS 1996-086449 [09]
DESC Thermostable direct haemolysin primer, ***VP22*** .

L3 ANSWER 127 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 1999:1564 IMSDRUGNEWS
TITLE: drug delivery system, ***VP22*** herpesvirus protein Phogen agreement extended
SOURCE: R&D Focus Drug News (***7 Jun 1999***).
WORD COUNT: 38

L3 ANSWER 128 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 1998:1629 IMSDRUGNEWS
TITLE: drug delivery system, ***VP22*** herpesvirus protein Phogen preclinical data
SOURCE: R&D Focus Drug News (***25 May 1998***).
WORD COUNT: 179

L3 ANSWER 129 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 97:894 IMSDRUGNEWS
TITLE: drug delivery system, ***VP22*** herpesvirus protein Phogen preclinical data
SOURCE: R&D Focus Drug News (***31 Mar 1997***).
WORD COUNT: 154

L3 ANSWER 130 OF 199 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 97:685 IMSDRUGNEWS
TITLE: drug delivery system, ***VP22*** herpesvirus protein Phogen Cantab, Marie Curie Cancer Care joint venture
SOURCE: R&D Focus Drug News (***10 Mar 1997***).
WORD COUNT: 110

L3 ANSWER 131 OF 199 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BVH1LFT31 GenBank (R)
GenBank ACC. NO. (GBN): Z54206
GenBank VERSION (VER): Z54206.1 GI:995626
CAS REGISTRY NO. (RN): 169022-06-4
SEQUENCE LENGTH (SQL): 31444
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Viruses
DATE (DATE): 23 Jan 1997
DEFINITION (DEF): Bovine herpesvirus type 1 31-kb DNA (left genome end).
SOURCE: Bovine herpesvirus 1.
ORGANISM (ORGN): Bovine herpesvirus 1
Viruses; dsDNA viruses, no RNA stage; Herpesviridae; Alphaherpesvirinae; Varicellovirus
NUCLEIC ACID COUNT (NA): 4507 a 10913 c 11443 g 4581 t
REFERENCE: 1 (bases 1 to 1354)
AUTHOR (AU): Fraefel,C.; Wirth,U.V.; Vogt,B.; Schwyzer,M.
TITLE (TI): Immediate-early transcription over covalently joined genome ends of bovine herpesvirus 1: the circ gene
JOURNAL (SO): Journal of virology., 67 (3), 1328-1333 (***1993***)
OTHER SOURCE (OS): CA 118:227339
REFERENCE: 2 (bases 1601 to 3100)
AUTHOR (AU): Singh,M.; Fraefel,C.; Bello,L.J.; Lawrence,W.C.; Schwyzer,M.
TITLE (TI): Identification and characterization of BICP27, an early protein of bovine herpesvirus 1 which may stimulate mRNA 3' processing

JOURNAL (SO): The Journal of general virology., 77 (Pt 4), 615-625 (***1996***)
OTHER SOURCE (OS): CA 124:282366
REFERENCE: 3 (bases 3101 to 8000)
AUTHOR (AU): Letchworth,G.J.; Lowery,D.E.; Schwyzer,M.
TITLE (TI): Sequence of the BHV-1 UL53 (gK), UL52 (helicase/primase), and UL51 genes
JOURNAL (SO): Unpublished
REFERENCE: 4 (bases 7818 to 9667)
AUTHOR (AU): Liang,X.; Tang,M.; Manns,B.; Babiuk,L.A.; Zamb,T.J.
TITLE (TI): Identification and deletion mutagenesis of the bovine herpesvirus 1 dUTPase gene and a gene homologous to herpes simplex virus UL49.5
JOURNAL (SO): Virology., 195 (1), 42-50 (***1993***)
OTHER SOURCE (OS): CA 119:153149
REFERENCE: 5 (bases 9662 to 11962)
AUTHOR (AU): Carpenter,D.E.; Misra,V.
TITLE (TI): Sequences of the bovine herpesvirus 1 homologue of herpes simplex virus type-1 alpha-trans-inducing factor (UL48)
JOURNAL (SO): Gene., 119 (2), 259-263 (***1992***)
OTHER SOURCE (OS): CA 119:42360
REFERENCE: 6 (bases 11963 to 15012)
AUTHOR (AU): LaBoissiere,S.; Trudel,M.; Simard,C.
TITLE (TI): Characterization and transcript mapping of a bovine herpesvirus type 1 gene encoding a polypeptide homologous to the herpes simplex virus type 1 major tegument proteins VP13/14
JOURNAL (SO): The Journal of general virology., 73 (Pt 11), 2941-2947 (***1992***)
OTHER SOURCE (OS): CA 119:89230
REFERENCE: 7 (bases 15007 to 22448)
AUTHOR (AU): Vlcek,C.; Paces,V.; Schwyzer,M.
TITLE (TI): Sequence of BHV-1 UL46 to UL41 genes
JOURNAL (SO): Unpublished
REFERENCE: 8 (bases 22099 to 23813)
AUTHOR (AU): Simard,C.; Bastien,N.; Trudel,M.
TITLE (TI): Sequencing and 5'- and 3'-end transcript mapping of the gene encoding the small subunit of ribonucleotide reductase from bovine herpesvirus type-1
JOURNAL (SO): Virology., 190 (2), 689-701 (***1992***)
OTHER SOURCE (OS): CA 119:89863
REFERENCE: 9 (bases 23481 to 31444)
AUTHOR (AU): Simard,C.; Langlois,I.; Styger,D.; Vogt,B.; Vlcek,C.; Chalifour,A.; Trudel,M.; Schwyzer,M.
TITLE (TI): Sequence analysis of the UL39, UL38 and UL37 homologs of bovine herpesvirus 1 and expression studies of UL40 and UL39, the subunits of ribonucleotide reductase
JOURNAL (SO): Virology (1995) In press
REFERENCE: 10 (bases 1 to 31444)
AUTHOR (AU): Schwyzer,M.; Styger,D.; Vogt,B.; Lowery,D.E.; Simard,C.; LaBoissiere,S.; Misra,V.; Vlcek,C.; Paces,V.
TITLE (TI): Gene contents in a 31-kb segment at the left genome end of bovine herpesvirus-1
JOURNAL (SO): Unpublished
REFERENCE: 11 (bases 1 to 31444)
AUTHOR (AU): Schwyzer,M.
TITLE (TI): Direct Submission
JOURNAL (SO): Submitted (21-SEP-1995) Martin Schwyzer, Institute of Virology, Faculty of Veterinary, Medicine, University of Zurich, Winterthurerstr. 266a, Zurich, CH-8057, Switzerland

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..31444	/organism="Bovine herpesvirus 1" /strain="Cooper" /db-xref="taxon:10320" /clone="HindIII fragments N, J, M, I, E"
misc-signal	200..207	/note="octamer box"
repeat-region	235..430	/rpt-type=DIRECT /rpt-unit=235..248
mRNA	466..1280	/gene="circ" /standard-name="LR1.1"

```
                                     /note="transcribed from
                                     alternative late promoter"
                                     /evidence=experimental
gene            466..1280
exon            473..1280            /gene="circ"
                                     /gene="circ"
                                     /standard-name="IER1.5"
                                     /note="IE transcription over
                                     covalently joined genome ends"
                                     /number=2
                                     /evidence=experimental
CDS             486..1229            /gene="circ"
                                     /note="product of IER1.5 and
                                     LR1.1; homolog of VZV ORF2 and
                                     EHV-1 ORF3"
                                     /codon-start=1
                                     /product="circ"
                                     /protein-id="CAA90913.1"
                                     /db-xref="GI:995627"
                                     /db-xref="SPTREMBL:Q01342"
                                     /translation="MGARASAPAAGPPPAHAVLL
                                     DALSGGTIDLPGGDEAVFVSCPTT
                                     RPVYHHMRRGRTAHTTPVHFVGRAYAILPCRKFM
                                     LYLMRGGAVYGYEPTTGLHRLADS
                                     LHDFLTTAGLQQRDLHCLDVTVLDAQMDPVTFTT
                                     PEILIELEADPAFPPPPSARARRS
                                     TLRRASMRRPARTFCPHQLLAEGSILDLCSPEQA
                                     AAPGCSLLPACDSGDAACPCDAGE
                                     TARDCTADAARAPSPGALSRYSSVRSVFF"
polyA-signal    1259..1264           /gene="circ"
                                     /note="IER1.5 and LR1.1"
polyA-signal    complement(1649..1654)  /note="BICP27, UL53, UL52"
CDS             complement(1658..2860)  /function="early protein affecting
                                     3'mRNA processing"
                                     /note="homolog of ICP27 (UL54) of
                                     HSV-1"
                                     /codon-start=1
                                     /product="BICP27"
                                     /protein-id="CAA90914.1"
                                     /db-xref="GI:995628"
                                     /db-xref="SPTREMBL:Q01354"
                                     /translation="MADPEIATLSTASESDDLSL
                                     FGSDREEDDEAPSLAPALRSVVGQ
                                     VRKRKLEGAEDEPMPAEPPGEGAASGDGGPAEAP
                                     PARRARVRPRRPRRRPRRRQPAGE
                                     QRSRGPAAKREAALATSSHGGGGAAARSIGSSLR
                                     LARSLAEAAQRATAERVTAVFAGA
                                     RLDLMRPVQNGGFRAAGVSPWAAVLDFGAEQFVP
                                     EGRRVTWETLMFHGRDLYRMFEVR
                                     PHAAQAARALRDLVLRSANLVDALASADECLTWC
                                     KFIATKNLRLRTKDPIVATAGAVL
                                     ENLRLKLAPFLRCYLRGRGLPSLEELCAARRLSL
                                     ATCPASYMFVMLARLSRAVRSGAE
                                     CVPLLEVTVGDAPFEEYIPGTCVAGLIDALDTHK
TATA-signal     complement(2985..2991)  QACDSMTCKLVANFTLVPVYMHGK YFYCNEIF"
CDS             complement(3040..4038)  /note="BICP27"
                                     /note="glycoprotein K"
                                     /codon-start=1
                                     /product="UL53"
                                     /protein-id="CAA90915.1"
                                     /db-xref="GI:995629"
                                     /db-xref="SPTREMBL:Q65816"
                                     /translation="MLLGGRTVNLAALALLTAHL
                                     ALALWVALAARCQRCACVRATARN
                                     GSLRWELRSPGAVYVWGGANNATLAADAPCRHAV
                                     VQHIPPGLLDGDEALHGRVRAVAG
                                     ARDCRAYLWCAQARGGLLAWLLYVAFVYLRQERR
                                     MFGLCRNDADFLSPGGYTLNYAAA
                                     ALAAVVGHGPYTKLARLMCELSARRRALAVDFRL
                                     DPLGCAWRPRAALPLLAEGFARLG
                                     ARIAAAGSVGITHPCAAAYPLYLKIWAWVHVALF
                                     AGLELVSLLYRKPRRRGGTCAGDG
                                     GDGGESGIRKVCVNCCSTLLAGLLVKALYLAAIV
                                     GGVIALLHYEHNLRLRLLGAQT"
CDS             complement(4013..7237)  /note="component of DNA
                                     helicase/primase complex"
                                     /codon-start=1
```

```
                                    /product="UL52"
                                    /protein-id="CAA90916.1"
                                    /db-xref="GI:995630"
                                    /db-xref="SPTREMBL:Q65817"
                                    /translation="MDGPAALEDALQILYATDGC
                                    AIGFSLMLLTGQEEPGRGAYVVSY
                                    NWPGRLAACLGGESPNDVALALADARPLVAFYLL
                                    GGPPGGSAAATPRLARLRVHLQQR
                                    AGRARARRRTAPRQGPTRARAARAPRRGRHLCAA
                                    RGHDHALLVATEQLAPRTGRTADD
                                    ARYVEGQTTVRSALRARPAGRRGLASLYIHHEHK
                                    TVAAYRRLYSNSGATPFWFLSKFG
                                    PGEKTLVLATRFYVFQAERAGDAATYDLQAVRDC
                                    LATYAVAAPPNPSGLAFPDLVSFA
                                    ALAAFCCRSGYARGAVAAGAPAYVAARIEADLAE
                                    VRCLREYIDHDRRSLKVADPEFVA
                                    YVYLAYFEGFNRRQITEHLRAVTATEPPDGGEAL
                                    APRLAGVSRLRERAVDAFFRHVRA
                                    QFNVQSYIEQNVAVAVVRLPPATAEAYARARTYA
                                    RLLAATANGPGRTICDGAAALRAA
                                    LDHLEGQAARFGWVLHAPGAPSASAVPGPGLDAA
                                    LRVGAPDGGASPDATPACCGVSKR
                                    LLELAAAAAARDGAHPLDGLFGARGTAAPTPVYRV
                                    ELPRGHQAFAVADGDDWAAVTSVA
                                    ALDPDEVAVEVAAAAAAAAESGRDALVERDARLT
                                    ALLTERAACAAGRSDRRSLGPAAP
                                    RDQYYVNRNELFNARLAVTNIVLDVDFRLKRPLP
                                    RGDLHGAMRSFRRGALAALAALFP
                                    EIAADAWPAHPCFFYKSACPSAAASNLGDGDASP
                                    SWAAPDRDAGWDEYESALAREGEA
                                    QYSCEDVSDPAGARPEETGGAEGAGSAAALTTAC
                                    GCDDKMGFRVAVPVPAPYIIAGGP
                                    TLKGIARLVQHAVMLERPFAEAMSRYLRDFAFVD
                                    AAVYTHGHSLRLPFFGKPDAASNV
                                    GRWLLPFYVVPERCDDVAAFVAAHRDPHHFHFHA
                                    APPAGGRREARRAHVGGEYVSFFE
                                    RKAAVNRAAFHGVRVSLRRALAAVGVDGGDRGAV
                                    EEFIADVIEAELAPYMAEHYPQAA
                                    REYQGAGARLVAAKADWLLAQLVPARAGTAQGFG
                                    CLRAAHGRAAQNKARSLVSLSVDS
                                    HDRLCASLIQQCFATKCGSNRLGTVFTVDLSGRA
                                    ARYAARGADC"
CDS                 7236..7967      /codon-start=1
                                    /product="UL51"
                                    /protein-id="CAA90917.1"
                                    /db-xref="GI:995631"
                                    /db-xref="SPTREMBL:Q65818"
                                    /translation="MALQRLVGWLCGRGGGTRDA
                                    PQYEPLARRLSGPTLFRLQEAVVA
                                    VSALLPAPLTVEDVARSADGTRRLAKAQSLARTY
                                    YICQRNIECLSKHQAACSDASITA
                                    VVTKHIQDAQRMRDTCLAALLQMYHSVGAVEGTT
                                    DSMVDQAIRMAAESNIVMADVAVL
                                    ERALGIQAQGAGAEAAARASPTAVGAEARAPPPL
                                    PRQPAASAPVAVSPAPPVAPAEAA
                                    ATKPPSRAGRAAAAAASSPAVLQLAA"
polyA-signal        7976..7981      /note="UL51"
misc-feature        7982..8028      /note="intergenic region between
                                    convergent UL51 and UL50"
polyA-signal        complement(8029..8034)  /note="UL50; noncanonical"
CDS                 complement(8045..9022)  /function="deoxyuridine
                                    triphosphatase"
                                    /codon-start=1
                                    /product="UL50"
                                    /protein-id="CAA90918.1"
                                    /db-xref="GI:995632"
                                    /db-xref="SPTREMBL:Q89932"
                                    /translation="MANSAAATTATMSGDRGILV
                                    VELNAEAAPWRLESCCEPDSLALW
                                    GPIAPAAKRDETAPSGSLLYSRLINLNMKAAAPG
                                    GYAIIMSQMRSGDTHMPRPPAVAV
                                    GIVDSGYSGILRAIVWAPESAAAAPPAGLALRLT
                                    LARLTTTLPRLIAVDDDANAGTEA
                                    GVEVPFFATFAPKRDEDAGYDIAMPYTAVLAPGE
                                    NLHVRLPVAYAADAHAAAPYVFGR
                                    SSCNLRGLIVLPTAWPPGEPCRFVLRNVTQEPLV
```

```
                                  AAAGQRVAQLLLLARRLEWLPSGL
                                  NDREPFPTSPRAAPPAPGAPRLRWRRVADLAAAV
                                  PPSARGPRGFGSTGL"
CDS               8970..9260      /codon-start=1
                                  /product="UL49.5"
                                  /protein-id="CAA90919.1"
                                  /db-xref="GI:995633"
                                  /db-xref="SPTREMBL:Q89806"
                                  /translation="MPRSPLIVAVVAAALFAIVR
                                  GRDPLLDAMRREGAMDFWSAGCYA
                                  RGVPLSEPPQALVVFYVALTAVMVAVALYAYGLC
                                  FRLMGASGPNKKESRGRG"
polyA-signal      9231..9236      /note="UL49.5"
TATA-signal       9288..9294      /note="UL49"
CDS               9384..10160     /note="homolog of HSV-1 VP22
                                  (tegument protein)"
                                  /codon-start=1
                                  /product="UL49"
                                  /protein-id="CAA90920.1"
                                  /db-xref="GI:995634"
                                  /db-xref="SWISS-PROT:P30022"
                                  /translation="MARFHRPSEDEDDYEYSDLW
                                  VRENSLYDYESGSDDHVYEELRAA
                                  TSGPEPSGRRASVRACASAAAVQPAARGRDRAAA
                                  AGTTVAAPAAAPARRSSSRASSRP
                                  PRAAADPPVLRPATRGSSGGAGAVAVGPPRPRAP
                                  PGANAVASGRPLAFSAAPKTPKAP
                                  WCGPTHAYNRTIFCEAVALVAAEYARQAAASVWD
                                  SDPPKSNERLDRMLKSAAIRILVC
                                  EGSGLLAAANDILAARAQRPAARGSTSGGESRLR
                                  GERARP"
polyA-signal      10224..10229    /note="UL49"
CDS               10275..11792    /function="tegument protein which
                                  transactivates IE genes"
                                  /note="homolog of HSV-1 alphaTIF
                                  (Vmw65, VP16)"
                                  /codon-start=1
                                  /product="BTIF"
                                  /protein-id="CAA90921.1"
                                  /db-xref="GI:995635"
                                  /db-xref="SPTREMBL:Q65819"
                                  /translation="MSGRIKTAGRALASQCGGAA
                                  AATMDPYDAIEAFDDSLLGSPLAA
                                  GPLYDGPSPARFALPPPRPAPLAALLERMQAELG
                                  FPDGPALLRAMERWNEDLFSCLPT
                                  NADLYADAALLSADADAVVGAMYLAVPGDAERLD
                                  LNAHANQPLPAPPASEEGLPEYVA
                                  GVQAHFLAELRAREERYAGLFLGYCRALLQHLRA
                                  TAARGRGAAGAGAQADRLRQLVAA
                                  RYYREASRLARLAFAHMYVATAREVSWRLHSQQS
                                  QAQGVFVSLYYAWPQRRQFTCLFH
                                  PVLFNHGVVALEDGFLDAAELRRLNYRRRELGLP
                                  LVRAGLVEVEVGPLVEEPPFSGSL
                                  PRALGFLNYQVRAKMGAPAEAGGRLAPEREHSYA
                                  RPRGAINYGTTPEAMLRPPSPSEV
                                  LPCDPAPAATVRVASPATHLAQAPSAKGAAPAEF
                                  AALAGLAKPGPAPLAAAPAQAPFA
                                  AALALAEPAAALAPAPLAAAPAEPAAAVAGPSPA
                                  NPFGGTYDALLGDRLNQLLDF"
TATA-signal       11892..11898    /note="UL47"
polyA-signal      11892..11897    /note="UL48; noncanonical"
CDS               11963..14182    /note="Major tegument protein
                                  (VP8)"
                                  /codon-start=1
                                  /product="UL47"
                                  /protein-id="CAA90922.1"
                                  /db-xref="GI:995636"
                                  /db-xref="SWISS-PROT:P36338"
                                  /translation="MDAARDGRPERRRAVSGTYR
                                  THPFQRPSARRSAGRPARCGRRGR
                                  GAPRVRRPRPYFQRPPDEDTSEDENVYDYIDGDS
                                  SDSADDYDSDYFTANRGPNHGAGD
                                  AMDTDAPPERAPEGGAPQDYLTAHLRAIEVLPES
                                  APHRSLLERTARTVYAQQFPPRDL
                                  SAGSKAPAQRARRSLRGFPRGGGGGQEPGPDDEG
                                  DDAADLREDLVPDEAYAHLERDER
```

```
                                                LSEGPPLLNMEAAAAAAGERSVVEELFTYAPAQP
                                                QVEVPLPRILEGRVRPSAFFAQMS
                                                LDALCRTPPNDQRVARERRAWEMAGTPHGLLITT
                                                WSTVDPEFSIGGMYVGAPEGTRPR
                                                LVWRRAMKQAMALQYRLGVGGLCRAVDGAACRPL
                                                RRCSFWRDALLRECATAIFCRGRG
                                                ARAAPRRLPRPAVGLLAATQFTPPDASPHATLFR
                                                GSMGSLIYWHELRVMLTAVPALCA
                                                RYAGAGLQSAELYLLALRHSEAPGYTANERYALS
                                                AYLTLFVALAERGLRWLYLAGAHL
                                                LGPHPTAAAFREVRAKIPYERLPLGSATLHDAEV
                                                ETVDSATFQEALAFSALAHVYGEA
                                                YVAVRTATTLLMAEYAVHAERRDVRQMTAAFLGV
                                                GLIAQRLMGSLNLLLNCVAGAAVY
                                                GGRRVTVREGTLARYSLLADAALPLVRPVFLVEF
                                                REARDGVMRELRLRPVASPPLAGK
                                                RRVMELYLSLDSIEALVGREPLGSRPVLGPLVDI
                                                AEALADHPHLVTGDGRGPRLGGR"
TATA-signal     14263..14269                    /note="UL46"
CDS             14314..16560                    /note="tegument protein"
                                                /codon-start=1
                                                /product="UL46"
                                                /protein-id="CAA90923.1"
                                                /db-xref="GI:995637"
                                                /db-xref="SPTREMBL:Q65820"
                                                /translation="MAWPAASRGLIERRAEKGCL
                                                LPTLADATAAAVVALQEATEPLCG
                                                APLFGAERAAALLGVRSNAVPEALVLSDSAKDAD
                                                DEYRLEYDRAAARVLAGARLSKDA
                                                VWRAVIGSYWKYLKASSGADVNIDGAAGGAAMEQ
                                                AQLTNVMLFAPTYARRASRSPFKH
                                                KQDNAAYKTAAAELRGALRAVEKYMYYMRPGDPM
                                                VESPDTEARLQEILAYAATAYRWL
                                                LWFMDALDGTVLRKLGKRPSAAVGPREPRPPGEL
                                                CERHLTGGPGIACGSGAALMLTAL
                                                TAAVLALLLRVGAAWTESSWKSNTQGVTGAIVAA
                                                VELASAVHHHLQYLLNMAFVGYAC
                                                WLRAGVRDPYMIAAIRAQCRFAHFTGQLMPTMTS
                                                ASWAALERGTASWFKLALLKSVAA
                                                HGAQTRYYSNIVESMRLGGSRGLLAPVRARPSGR
                                                GRRCPQSLAARPLPSLPAAAAAPP
                                                GSGSGSGSGSDSDSDLDLGFAPAVGVYASMRNLE
                                                GAYADAGGPLSPAASAARREAAVY
                                                ENEGEGEFAPLPSAFAEDGSSDSADELAIDGPMP
                                                APPPRGGRGADELAIDGPMPAPPP
                                                RGGRGADELAIDGPMPAPPPRGGRGASAGRLQYA
                                                DSRAVSSDDDEDEGKDEDENKAGA
                                                TAPLAADPESELARAMRRCSLRVPASAPAPAPAP
                                                CTERPGNPTRSYSRSRPRLRALDD
                                                RHGLEALAAAGAAHTARHNRDVWQRFSRVCEAGD
                                                DYENYDEARGAERGHLSCASRARP EVERVTSL"
polyA-signal    16594..16599                    /note="UL47, UL46"
misc-feature    16600..16612                    /note="intergenic region between
                                                convergent UL46 and UL44; no BHV-1
                                                homolog of HSV-1 UL45 found"
polyA-signal    complement(16613..16618         /note="UL43, UL44"
                )
CDS             complement(16683..18209         /function="glycoprotein C"
                )
                                                /codon-start=1
                                                /product="UL44"
                                                /protein-id="CAA90924.1"
                                                /db-xref="GI:995638"
                                                /db-xref="SPTREMBL:Q65821"
                                                /translation="MGPLGRAWLIAAIFAWALLS
                                                ARRGLAEEAEASPSPPPSPSPTET
                                                ESSAGTTGATPPTPNSPDATPEDSTPGATTPVGT
                                                PEPPSVSEHDPPVTNSTPPPAPPE
                                                DGRPGGAGNASRDGRPSGGGRPRPPRPSKAPPKE
                                                RKWMLCEREAVAASYAEPLYVHCG
                                                VADNATGGARLELWFQRVGRFRSTRGDDEAVRNP
                                                FPRAPPVLLFVAQNGSIAYRSAEL
                                                GDNYIFPSPADPRNLPLTVRSLTAATEGVYTWRR
                                                DMGTKSQRKVVTVTTHRAPAVSVE
                                                PQPALEGAGYAAVCRAAEYYPPRSTRLHWFRNGY
                                                PVEARHARDVFTVDDSGLFSRTSV
```

```
                                     LTLEDATPTAHPPNLRCDVSWFQSANMERRFYAA
                                     GTPAVYRPPELRVYFEGGEAVCEA
                                     RCVPEGRVSLRWTVRDGIAPSRTEQTGVCAERPG
                                     LVNLRGVRLLSTTDGPVDYTCTAT
                                     GYPAPLPEFSATATYDASPGLIGSPVLVSVVAVA
                                     CGLGAVGLLLVAASCLRRKARARL "
TATA-signal          complement(18301..18307 /note="UL44"
                     )
CDS                  complement(18388..19524 /codon-start=1
                     )
                                     /product="UL43"
                                     /protein-id="CAA90925.1"
                                     /db-xref="GI:995639"
                                     /db-xref="SPTREMBL:Q65822"
                                     /translation="MFASVRVSGCAGARAGCGPC
                                     ALAATGALVAMGTHTGLMAAALAT
                                     VGRAQDPAAALALTATAAAALVCWRPAAQTLRRR
                                     LAPLGRLAQALAVAAALAVWATDP
                                     APAVLRGVTTGAAAAYVVCGVPVHCAHFVTAASG
                                     TGAHFRTALLTMTCGLLLGLSAGR
                                     WGARPEALAAAGAAAALVVAATDAAAALEDTCHY
                                     KIWRYAALRTLAPLGEAACPADPC
                                     GAREDAVPMRALARAAAAELALSAAALAAAAALW
                                     APGRALGLEGGGRWRTRGAVLLSV
                                     AGGHGVALAEHLCLRYARADAADGALMAHVGICA
                                     LGAALPLCGADGGAPAALASAAAG
                                     TLVACVWVRRCGRGTARLAAAHVAKALHAALCFC
                                     VGACWVCADE"
polyA-signal         complement(19582..19587 /note="UL42"
                     )
CDS                  complement(19597..20823 /function="processivity factor for
                     )                       DNA polymerase"
                                     /codon-start=1
                                     /product="UL42"
                                     /protein-id="CAA90926.1"
                                     /db-xref="GI:995640"
                                     /db-xref="SPTREMBL:Q65823"
                                     /translation="MLQPPSHLRADEGEARLTAG
                                     LSDGGNGNPIASASLIGRQLADVS
                                     ALLSPFGASLRNAFLVFSREGMLVHSGLYDEQVY
                                     VAVPAEKFTSFQWAPARDDARAVF
                                     LANVDSRRGLLDAFRADKTRTVQNVAFLITGEPP
                                     ASVLTQVTYFREADALLQASLVKH
                                     ELGEYSIMLPTRGADLAVSLSRPQLSKLQAVAKD
                                     PNEAVVFAYRRARCLSAESASGRA
                                     SFAARHEGGESGAELQLALAPSAGSERIFARAQG
                                     GGRRAALLEVRCSGGAPDFRLELE
                                     SPSGFRRLLQKVRQVGGDALVRFYLAPASAAMMS
                                     VSTAAPEGLTVFFFCRPATATASA
                                     DDADDCAEPAPRLPAKRPAASGQPRRGAGAGIQT
                                     DGAHPVAVSGGRARKRPRADAGAP
                                     GPSSGPDRGGEGGETP"
TATA-signal          complement(20903..20909 /note="UL42"
                     )
CDS                  21068..22447            /function="virion host shutoff
                                             factor"
                                     /codon-start=1
                                     /product="UL41"
                                     /protein-id="CAA90927.1"
                                     /db-xref="GI:995641"
                                     /db-xref="SPTREMBL:Q65824"
                                     /translation="MGLFKLLRYAYGNRLVKHDA
                                     ITTPPGVMTPIAVDLWNVMYTLLE
                                     RFCGDAPGGVGDAAATARCFLSLLRMLLKRSYYP
                                     IFVADRGIHGDRRATRGAKAIVAQ
                                     TMRAVGGSGRLGRLVSDDYTSEDEVLGAYEYPVP
                                     HADAAADDDEEATAKEFAGRASAG
                                     AARANAPKLAHRVCVSLIRFLGYAYVDAAEMEAD
                                     DVCANLFHTNTVAHIYTTDTDMIL
                                     MGCDLILDAAPLFPPTLRCRDVLASLGLTYGQFL
                                     ATFVRCHTDLHQPPMLRSVQQVVR
                                     GLRRAAEAEPATTETESGSEREPESELGRPGAGP
                                     RRRLPPAVDDPLKTTTPATVEAHS
                                     VRMKYTSRYPPIAQTCADALRLLPASQTRGGVLE
                                     RKFVKHVVDTIAPRMRGRWAVLKR
                                     VPIAQDAPDPRLVYDTIVSAVGSAAEADTLMGLF
```

```
                                        WKHIPTPPPFAKVLADYWDEAPAG
                                        PGSRRTTRQ"
polyA-signal    22443..22448            /note="UL41"
mRNA            complement(22475..23602 /gene="UL40"
                )
                                        /evidence=experimental
gene            complement(22475..23602 /gene="UL40"
                )
polyA-signal    complement(22494..22499 /gene="UL40"
                )
                                        /note="UL39, UL40"
mRNA            complement(22495..26048 /gene="UL39"
                )
                                        /evidence=experimental
gene            complement(22495..26048 /gene="UL39"
                )
CDS             complement(22563..23507 /gene="UL40"
                )
                                        /function="ribonucleotide
                                        reductase small subunit"
                                        /codon-start=1
                                        /product="UL40"
                                        /protein-id="CAA90928.1"
                                        /db-xref="GI:995642"
                                        /db-xref="SWISS-PROT:Q01319"
                                        /translation="MAEAADAATLTRKYKYFYET
                                        ECPDLDHLRSLSVANRWLETEFPL
                                        ADDAKDVARLSGAELEFYRFLFAFLSAADDLVNV
                                        NLGDLSELFTQKDILHYYIEQESI
                                        EVVHSRVYSAIQLLLFRNDAVARAGYVEGALGDP
                                        AVRRKVDWLERRVAAAESVAEKYV
                                        LMILIEGIFFSSSFAAIAYLRTHNLFVVTCQTND
                                        LISRDEAVHTAASCCIFDNYLGGE
                                        RPPPARIYELFREAWKLSASLFGCAPRGSHILDV
                                        EAISAYVEYSADRLLAAIQLPPLF
                                        GTPPPGTDFPLALMTAEKHTNFFERRSTNYTGTV
                                        INDL"
CDS             complement(23526..25889 /gene="UL39"
                )
                                        /function="ribonucleotide
                                        reductase large subunit"
                                        /codon-start=1
                                        /product="UL39"
                                        /protein-id="CAA90929.1"
                                        /db-xref="GI:995643"
                                        /db-xref="SWISS-PROT:P50646"
                                        /translation="MASDAFMQTACPADAAEQLE
                                        AEHAEWAQLGCGAVPPPPAAASRP
                                        SRAAVAAYVGEVVDRMRAQSRADERVYVKCGQLV
                                        HLRVRARSVPLDDWLTSAELALVS
                                        EVAEPVRANRAFVEVSLRYFELTEYATLRALGLQ
                                        SALKYEEMYLAKLEGGAIESMGQF
                                        FVRIAATAATWTMREPAFGRALVGEGATWCAVFN
                                        AYLTALYRQLVVPATPIMLFAGRA
                                        RGSLASCYLLNPQVSSSTEAVEAITTEVARILLN
                                        RGGIGISFQSFDRAVSRDCKRGIM
                                        GALKLLDSMAMAINSDSERPTGICVYLEPWHCDV
                                        RAVLNMRGLLARDESTRCDNLFSC
                                        LWVPDLLFDRYLAHLEGREGVVWTLFDDRASHLS
                                        RLHGPAFTAEYERLEREGLGVETV
                                        PVQDLAFLIVRSIVMTGSPFVMFKDACNRHYHMD
                                        TAGDALTGSNLCTEIVQRASPDAH
                                        GVCNLASVNLPRCVREGEGGALAFDFAALSTAAA
                                        TAAIFVNAMMLGGQYPTEKAARGV
                                        ARHRSLGIGFQGLHTLLLELGMDMLSPAARRLNV
                                        EIAERLLLAVMATSATLCEYGCAP
                                        FEDFARSKFARGLMPFDGYEGVVLSLPRAWARLR
                                        EKVARHGLYNAQFVALMPTVSSSQ
                                        VTEGSEGFSPVFTNMFSKVTMSGELLRPNLPLMR
                                        ALRKHFTREASRLGAVRALDREQW
                                        SVAAALGDLAPGHPLAKFKTAFEYDQERLIDLCA
                                        DRAPFVDQSQSMSLFVTEPMDGKV
                                        PASQIMNLLVYAYKKGLKTGLYYCKIRKATNNGV
                                        FTGGDLVCSGCHL"
TATA-signal     complement(26119..26125 /note="UL39"
                )
```

```
polyA-signal     complement(26202..26207 /note="UL38"
                 )
CDS              complement(26231..27655 /note="homolog of HSV-1 capsid
                 )                       protein VP19C"
                                         /codon-start=1
                                         /product="UL38"
                                         /protein-id="CAA90930.1"
                                         /db-xref="GI:995644"
                                         /db-xref="SPTREMBL:Q89542"
                                         /translation="MAAPNGSSSYIQIGNHLRMR
                                         LPAAAPPFSGVPAAAAAAAEASAA
                                         EAGVQSVTAPAVGGARGRAPRGYNPWAGGMLHVS
                                         DATVTIQNMSGIQIVTPRQIAVDT
                                         PAGTAVLSPGGQPHIRLSRQVTLTDFCDPQLERP
                                         GAPVLTLKHPADIIGLAAAAAPPG
                                         RQFRDVEEAWRDLGDASSVGAVPPGGLRASLVSF
                                         SFLAAACAAEYGNRAAADALRAHL
                                         ISNSGDRRMALRLDRFYACLQAMIRCRAFPHQAL
                                         GCLGGLLSWTTQDKLASVTAVVCG
                                         AQEGARTDQAAHPRSTAHVPACAFLDVDAELRLE
                                         PAGVKFVYLVFVYTQRLEHEGFRA
                                         HVAVSKLNETTFASGLSYLLHRTRAENVLRGTAG
                                         DAAEVAGAADEFPLPALANSRAAY
                                         RCPVSRLGDCDATAFLPRWAPDAAGRPTRESCMY
                                         AAFARLGTLPHDSPRVTCRSERYQ
                                         SCDVPVVKIEGLVWGTGDWVECFY"
TATA-signal      complement(27720..27726 /note="UL37"
                 )
CDS              27871..30945            /note="tegument protein"
                                         /codon-start=1
                                         /product="UL37"
                                         /protein-id="CAA90931.1"
                                         /db-xref="GI:995645"
                                         /db-xref="SPTREMBL:Q89815"
                                         /translation="MSGDPVRALWAALERLDGEV
                                         AGPAALAEARAAVSEFLLASGPSS
                                         LDFVAPRWAALQRAACRAYERLHTPDAALLAENL
                                         PGLVLWRLPGAARDTADFMAGVRD
                                         LANSMIAEAPLGYLAAARLRATAAFGPVNMQRVV
                                         VEWASLFLEIYAREDAACVGVLGP
                                         DPACRSPAGSAAVIRPLLQSRFRLLYDMPFFQAG
                                         LSALAHAANWKVPMAAVARRAADA
                                         AAPPLARALFAVALVDEYFPEPDDEDTAPGLAEA
                                         FAEIADLVPPEALVPAGEANAFAR
                                         SSHDVRVSAALAYRDPFVRGAAAGSVAARVRADA
                                         GLLADDTLLGRDAVAVHAGAVVRL
                                         LERAAARATPAALGRVAEHAAAVWDAVQASATPD
                                         QAVETLAAAGFTPGTCAMLERAVL
                                         AQLSRPEPRAPADVLQAVGCVAVAGGVLFKLFDA
                                         YGPSADYLAHYTATIANLHPYYAD
                                         VLPLLGLPDGGLEQTIRHCMAPRPRTDYVAAIRA
                                         ALAAEAAAADKRAASASARAAVEN
                                         SGDRAAAGAAAREALLTWFDLRASERWGVAPPAA
                                         EAPPAAEAARSPAAGGASAAELAR
                                         AARALEFPRTDAVPAAVLRDPAFAPHFAAAVLSD
                                         VLVAADALPFSANGVAQLMALIAW
                                         ARDCGAGAVANVDGYRTKLSALAAGLWPFVDASA
                                         PAPTTTQVRNAEAVLGELHTVATT
                                         AAECLPPEVRPPVPARPRVGGCVFLASMYLHAAF
                                         ARLQGYVAETEALAASMAAAVGDV
                                         AGAVARLGVLFDCHFASVPGQQMLAIYATRGAPC
                                         ALGAWRSADLADAVRGARAEAARA
                                         RAEVRVSLAALQRAAAQTTQALQECEAADARPPG
                                         GGLDDEHRALLAGHSALVRAQTAL
                                         ALAAGKLVAGAEAPGLHEVGRFLQRWDAIGAALG
                                         RALDDSAGERDVAELVARLRGVWD
                                         EVQEDRRVAAPGPPRSAANAAAAEEAVLALLEGY
                                         PEVRGDEGSPALLDARADVADWAG
                                         VDRGPLQRRASAGADAAASAAAANTAAGPWLTTE
                                         DLLAEVDGVCASRPAAAR"

SEQUENCE (SEQ):
     1 ggcccagccc ccgcgcgggg ggcgcggaga aaaaaaaaat tttttccgcg cggcgcgtgc
    61 attgcggcgg gcgggggcgg ggtgggggat gggcgcggag cgcgagggta gggttggcac
   121 actgccaaga tcaccaagca tgtgcgcggc catcttgctt ccaaactcat tagcataccc
   181 cgcccattat tccattctca tttgcatacc caccgttgca catgccgcca tattgctcct
```

241 cctccctcgc tcctcctccc tcgctcctcc tccctcgctc ctcctccctc gctcctcctc
301 cctcgctcct cctccctcgc tcctcctccc tcgctcctcc tccctcgctc ctcctccctc
361 gctcctcctc cctcgctcct cctccctcgc tcctcctccc tcgctcctcc tccctcgctc
421 ctcctccctc gctcctcttc aaaacactac cgcgggcgtc cgctctcact agcttcggcg
481 ccgtcatggg tgcccgcgcc tccgcgcctg ctgccggccc gcccccagcc cacgctgttc
541 tactagatgc gctctccggg ggcacgattg acctgcctgg cggcgacgag gccgtctttg
601 tgtcctgccc gacgacgcgc cccgtgtacc accacatgcg ccgcggccgc acggcccaca
661 ctacacccgt gcacttcgtt ggccgcgcct atgccatctt gccctgccgc aagtttatgc
721 tgtatctgat gcgcggtggt gccgtttacg gctacgagcc caccactggc ctgcaccgcc
781 tcgccgattc actgcacgac tttcttacta ctgccggact acagcagcga gacctacact
841 gcctcgatgt cacggtgctt gacgcgcaga tggacccggt gacgttcacc accccgaga
901 tcctcatcga gctcgaggcg gacccggcct tcccaccgcc gccctcggcc cgcgcgcgcc
961 gctccacgct gcgccgggcg tctatgcgcc ggcccgcacg caccttctgc ccccaccagc
1021 tgctagcaga gggctccatt ctggacctct gctcgccaga gcaagcggcg gcgccgggct
1081 gttcgctgct ccccgcctgt gactctggag acgccgcgtg cccctgcgac gctggcgaga
1141 ccgcccgtga ctgtactgcc gatgccgcgc gcgctcccag ccccggcgcc ttatctcgct
1201 atagctccgt gcgctcggtg ttcttttagc gcgcgggcgc ccgtgtggga catacattaa
1261 taaatgcagc gtttcttact ctactgtagt ggctggccgt ttgcttcttt ttgggattgg
1321 caatttagcg ttccgtcgac gccacatctt ttgcctttct gtttcccgtt gcgtgcgcgt
1381 gtgtcgccga gccgacttgc cccgacaaca caggcaggca cgcggccccg cgccccgcca
1441 ggcactattt gcgctcgggt gcattgagct tgactttgac tcgcttttgt gccgacgccc
1501 aattatttgc cttggcccgt tgtgttcccc ccgcgcgcgc ttgtgccgcc caagcccgcc
1561 cgcccgatag cgcgcccgcg cctgtgtccc caacaagtac tatacacact cgagtatatc
1621 gggttcaaat caatgttgac aggttgactt tattagctta gaagatctcg ttgcagtaaa
1681 agtattttcc gtgcatgtac acgggaacca gggtgaaatt agcgacgagc ttgcacgtca
1741 tgctgtcgca agcctgtttg tgtgtgtcca gggcatcgat gaggcccgcc acgcaggtcc
1801 cggggatgta ctcctcgaaa ggcgcgtcgc ccacagtcac ctccaacagc ggcacgcact
1861 ctgcgccgga gcgcaccgcg cggcttagac gcgccaacat cacgaacatg tacgatgcgg
1921 ggcaggtggc gaggcttagc cggcgcgcgg cgcagagctc ctccagcgag ggcagcccgc
1981 gcccgcgcag gtagcagcgc agaaaaggcg ctagcttcag ccgcaggttt tccagcacgg
2041 cgccggccgt ggccacgata gggtctttgg tgcgcaggcg caagttcttg gtggcgatga
2101 acttgcacca cgttaggcac tcgtcggccg aggccagtgc gtctaccagg tttgcgctgc
2161 gcagcaccag gtctcgcagc gcccgcgccg cctgggcggc gtgcgggcgc acctcaaaca
2221 tgcggtagag gtcgcggccg tggaacatga gcgtctccca ggtgacgcgg cggccctcgg
2281 gaacgaattg ctccgcgcca aagtccaaga cggctgccca tggcgacacg cccgctgcgc
2341 ggaacccgcc gttttgcacg ggccgcatga ggtccagtcg cgcgcccgcg aagacggcgg
2401 tgacgcgctc ggccgtggct cgctgcgccg cttcggccaa gcttcgcgcc agccgcagcg
2461 agctcccgat cgagcgggcg gcggcgcccc cgccgccgtg tgaagacgtc gcgagggccg
2521 cctcgcgctt tgctgccggg ccgcgggacc gctgctctcc ggcgggctgt cttcggcgcg
2581 ggcgcctgcg cggccgccgc ggccgcacgc gagcccgccg cgccggaggt gcttcggcgg
2641 gaccgccgtc gccgcttgcg gcgccttcgc ccggcggctc ggccggcatc ggctcgtcct
2701 ccgcgccctc cagcttgcgc ttgcgaacct gccccaccac ggagcgcagg gcgggagcga
2761 gcgagggcgc ctcgtcgtct tcttcgcggt cagagccgaa gaggctcaag tcgtcgctct
2821 cgctggccgt gctgagggtt gcgatctcgg ggtccgccat gccgctgcga ctcgcgggcg
2881 tcgtcgtcgg gccgggtgcg tcgccgttcg ggccggacgg tcggtgtctc gcgtttctaa
2941 aagagggctc gcactccggc gccgtgttcg cactgagacc ggcattttat gttcgccggc
3001 cccaccctgc gcggcagcag cgccgcccaa taggggcggt cacgtctgcg cgcccagcag
3061 ccgcaggcgc aggttgtgct cgtagtgcag cagcgcgatg acgccccca cgatagcggc
3121 caggtagagc gcctttacga gcagccccgc gagcagcgtg gagcagcagt taacgcacac
3181 ctttctgatc ccgctctcgc cgccgtcgcc gccatcgccg gcgcacgtgc ctccgcgccg
3241 ccgcggcttg cggtacagca gcgagaccag ttccaatccg gcaaagaggg cgacgtgaac
3301 ccacgcccag attttcaggt acagcgggta ggcggccgcg caggggtgcg ttatgccgac
3361 gctgccggcc gccgcaatcc gcgcgccgag ccgcgcaaag ccctccgcaa gcagcgggag
3421 agcagcccgg gggcgccagg cgcagcccag ggggtcgagg cggaagtcga cagcaagcgc
3481 gcgccggcgc gccgagagct cgcacatgag ccgcgcgagc ttcgtgtacg ggccgtggcc
3541 gactacggcc gcgagcgcgg cggcggcgta gttgagggtg tagccgccgg ggctgaggaa
3601 gtcggcgtcg ttgcggcaaa gaccaaacat gcgccgctcc tggcgcaggt acacgaacgc
3661 gacgtacagc agccatgcca gcaggccgcc gcgagcctgc gcgcaccaca ggtaggcgcg
3721 gcaatcgcgc gcgccggcca cggcgcgcac gcggccgtgc agcgcttcgt cgccgtcgag
3781 cagcccgggc gggatgtgct gcacgacggc gtgccggcac ggggcgtcgg ccgcgagcgt
3841 ggcgttgttc gcgccgcccc agacgtagac ggcgccgggg ctgcgcagct cccagcggag
3901 cgagccgttg cgcgcggtgg cgcggacgca cgcacagcgc tggcagcggg cggcgagcgc
3961 gacccacagc gccagcgcga ggtgggccgt gagcagcgcc agcgcggcca agttaacagt
4021 ccgccccccg agcagcatac cgcgccgcgc gccccgagag atccacggtg aacacggtac
4081 cgaggcggtt gctgccgcac ttggtagcga agcactgctg gatgagcgag gcacacaggc
4141 ggtcgtgcga gtcgacactg agggacacca gcgagcgggc cttgttttgg gccgcgcgcc
4201 cgtgggccgc gcgcaggcag ccaaagccct gcgcggtgcc ggcgcgcgcc ggcacgagct
4261 gcgccagcag ccagtcggct ttggcggcca cgaggcgcgc gccggcgcct tggtactcgc
4321 gcgccgcctg cgggtagtgc tccgccatgt agggcgccag ctcggcctcg attacgtcag
4381 caataaactc ttcgacggcg ccacggtcgc cgccgtcgac gccgacggcg gcgagcgcgc
4441 gccgcaggga aacgcgcacg ccgtgaaagg ccgcgcggtt gacggcggcc ttgcgctcaa
4501 aaaagctaac gtattcgccg ccaacgtgcg cacgacgtgc ctcgcggcgg ccgcccgcgg
4561 gtggcgcggc gtggaagtgg aagtggtgcg ggtcgcggtg cgcggcgacg aaggcggcca
4621 cgtcgtcgca gcgctctggg accacgtaga agggcaggag ccaccgcccg acgttgcttg
4681 cggcgtctgg cttgccaaaa aagggcaaac gcaggctgtg cccgtgcgtg tagacagccg
4741 cgtcaacgaa ggcaaagtcg cgcaagtagc ggctcatggc ctcggcgaag gggcgttcca

4801 gcatgacggc atgctggacg aggcgcgcga tgcccttgag cgtggggccg ccggcgataa
4861 tgtatggcgc cgggacgggc acagccacgc ggaagcccat tttgtcgtcg catccgcacg
4921 cggtcgttag ggccgccgcg cttcccgcgc cctccgcgcc gcccgtctct tcaggccggg
4981 cgcccgcggg gtcgctgacg tcctcgcagc tgtattgcgc ctcgccctcg cgcgcgaggg
5041 cgctctcgta ctcgtcccag cccgcgtcgc ggtcgggcgc ggcccaggac ggcgacgcgt
5101 cgccgtcgcc taggttgcta gcggcggccg aagggcacgc gctcttgtag aagaagcagg
5161 ggtgtgcggg ccaggcatcg gcggcgattt cggggaacag cgccgcgagc gcggcaagcg
5221 cgccgcgacg gaagctgcgc atggctccgt gcaggtctcc gcgggggagg gggcgcttga
5281 ggcgaaagtc cacgtccagg acgatgttgg ttacggcgag gcgggcgttg aacagctcgt
5341 tgcggttcac gtagtactgg tcgcgcggcg cggccgggcc caggctccgg cggtccgagc
5401 ggccggcggc acaggccgcg cgctcagtga ggagcgcggt tagccgcgcg tctcgctcca
5461 caagcgcgtc ccggccgctc tctgcggcgg cggcagcggc cgccgcaacc tcgaccgcca
5521 cttcgtcggg gtctagggcg gcgacgctcg tgacggcggc ccagtcgtcg ccgtccgcga
5581 cggcaaatgc ctggtggccg cgcggtagct ccactcggta gacgggcgtg ggcgccgcgg
5641 tcccgcgcgc gccaaagagc ccgtccagcg gatgcgcgcc gtcgcgcgcg gcggcggccg
5701 ccagctcaag tagccgcttg gacaccccgc agcaggcggg cgtcgcatca ggggacgcac
5761 cgccgtccgg cgcgccaacg cgaagcgcgg cgtctagccc cgggcccggc accgcgcttg
5821 cgcttggcgc gccgggtgcg tgcagcaccc acccgaagcg agccgcctgg ccctcgaggt
5881 ggtccagcgc tgcgcgcagg gcggccgcgc cgtcgcagat tgtgcgcccg ggcccattag
5941 cggtcgccgc gagcaagcgc gcgtacgtac gcgcgcgcgc gtaagcctcg gctgttgcgg
6001 ggggcagccg aacaacggcg accgccacgt tctgttcgat gtagctttgg acgttaaact
6061 gcgcgcgcac gtgccgaaaa aaagcgtcaa cggcgcgctc gcggaggcgc gagacgcccg
6121 cgaggcgcgg cgcgagcgcc tcgccgccat cgggggggctc ggtggcggtg acggcgcgca
6181 ggtgctcggt gatctgccgg cgattaaagc cctcaaagta ggccaagtat acgtaggcca
6241 cgaactccgg gtcggccact ttaagactgc gacggtcgtg gtcgatgtac tcgcgcaggc
6301 agcggacctc ggcgaggtcg gcctcgatgc gcgcggccac gtacgcgggt gccccggcgg
6361 caaccgcgcc gcgggcgtag ccgctgcggc agcagaaggc ggcaagcgcc gcgaaggaaa
6421 ccaagtcggg gaaggcgagt cccgaggggt taggcggcgc ggcgacggcg tacgtggcca
6481 ggcagtcccg cacggcctgc aggtcgtagg tagcggcgtc gccggcgcgc tcagcctgga
6541 acacgtagaa gcgcgtggcc aacaccaagg ttttttcgcc gggcccaaac ttggagagga
6601 accagaaggg agtcgcaccg ctgttggagt aaagccgccg gtaggcggcg accgttttgt
6661 gctcgtggtg gatgtagagc gaggctaggc cgcggcggcc ggccgggcgc gcgcgcaggg
6721 ccgagcgcac tgtagtctgg ccctcaacat agcgggcgtc gtctgcggtg cggccggtgc
6781 gaggcgccag ctgctccgtg gccaccagca gcgcgtgatc atgtccgcgt gcagcgcaaa
6841 ggtgacgtcc tcggcgaggt gctcgagcag cacgcgcgcg ggtagggcct tgccgaggag
6901 cagtgcgtcg gcgagcgcgc gcgcgccctg cgcgctgttg aaggtgcaca cgaagacggg
6961 ccaggcgcgg ggtcgcggcg gcgcttccgc ccggcgggcc gcccagcaga taaaacgcga
7021 cgagcggccg cgcatccgcc agcgccagcg ccacgtcgtt tgggctttcg ccaccaaggc
7081 acgcggcgag ccgcccgggc cagttgtagg agaccacgta ggcgccacgg ccgggctcct
7141 cctggcccgt gagcagcatc agcgaaaacc cgatcgcgca gccgtcggtg gcgtacagga
7201 tttggagcgc gtcctcgagc gcggctgggc cgtccatggc gctgcagcgg ctggtcgggt
7261 ggctgtgcgg gcgcggcggg ggcacgcgag acgctccgca gtacgagccg ctggcgcggc
7321 gcctgagcgg accgacgcta tttcgcctgc aagaagcggt ggtagccgtc agcgcgctgc
7381 tgccggcgcc gctgacagtg gaggacgtgg cgcgctcggc agacggcacg cggcggcttg
7441 ccaaggcgca gtcgctagcg cggacctact acatctgcca gcggaacatc gagtgcctct
7501 caaagcacca ggccgcgtgt agtgacgcaa gcatcaccgc cgtcgtgacg aagcacatac
7561 aggatgctca gcgcatgcgc gacacctgcc tggccgcctt gcttcaaatg taccactcgg
7621 tgggcgctgt ggagggcacg acggacagca tggtggacca ggccatccgc atggcggccg
7681 aaagcaacat tgtaatggcc gacgttgcgg tgctggagcg cgccttgggc attcaggcgc
7741 agggcgcggg cgcggaggcg gcggccaggg caagcccgac ggccgttggt gccgaggctc
7801 gggccccgcc gcccctgccg cggcagccgg ccgcctcggc gccggtcgcc gtgtctccgg
7861 caccgccggt ggcgcctgca gaggcggccg ccacaaaacc acctagccgc gcggggcgcg
7921 cggcggccgc cgcttcttcc cccgccgttt tgcagcttgc ggcgtagccc ggtgcaataa
7981 aagcaaaata agtatacgca aaacacgtgt gtggtggagt cggtgtactt taatgtgctt
8041 tgttttacag cccggtggac ccaaagccgc gcggcccgcg cgcagagggg ggcaccgccg
8101 cggcgagatc ggcgacgcgg cgccagcgca ggcgcggggc cccaggggcg ggcggtgctg
8161 cgcgagggct agttgggaag ggctcgcggt cgttgaggcc ggacggaagc cactcgaggc
8221 gccgtgccag cagaagcagc tgcgccacgc gctggcctgc ggcagcaacg agcggttcct
8281 gcgtgacgtt tcgcaagaca aagcggcagg gctccccggg gggccaggct gtcggcagga
8341 cgatcagccc ccgaaggttg caggacgatc gaccaaacac gtagggcgcg gcagcgtggg
8401 cgtctgccgc gtaggctacg ggcagccgca cgtgtaaatt ttccccgggt gccaagacgg
8461 ccgtgtatgg catggcaata tcgtacccgg cgtcctcgtc gcgtttgggg gcgaacgtgg
8521 caaagaaggg cacttcgacg cccgcctctg tcccggcgtt tgcgtcgtcg tcgacggcga
8581 tgaggcgagg cagcgtggtg gttagccgcg cgagcgtcag ccgcagcgca agccccgccg
8641 ggggagcggc cgctgcggac tcgggcgccc agacgatggc gcgcaagatc cccgagtagc
8701 ccgagtcgac gatgccgacg gccacggctg gtgggcgggg catgtgtgtg tcacccgagc
8761 gcatttgcga cattataatg gcatatccgc cgggcgcggc cgccttcatg tttaaattaa
8821 tcagccggct ataaaggaga gatcccgacg gggctgtttc atctcgcttt gctgctggcg
8881 caattgggcc ccagagcgcc agcgagtcgg gctcacagca gctttccaac cgccaggggg
8941 ccgcctccgc gttgagctct acgacgagga tgccgcggtc gccgctcatc gttgcggttg
9001 tggccgccgc gctgtttgcc atcgtgcgcg gccgcgaccc cctgctagac gcgatgcggc
9061 gcgagggggc aatggacttt tggagcgcag gctgctacgc gcgcggggtg ccgctctcgg
9121 agccaccgca ggccctggtt gtttttttacg tggccctgac cgcggtaatg gtcgccgtgg
9181 ccctgtacgc gtacgggctt tgctttaggc tcatgggcgc cagcgggccc aataaaaagg
9241 agtcgcgggg gcggggctga ttgaccgcaa cgctgcggag taacttgtat ataaagctcg
9301 cggtcccggc gaccgctgcc tttttcgcac tcggcccgac ccgctttgag ctgcacgccc

```
 9361 gccggcccgc cgactcgctt gccatggccc ggttccacag gccctccgaa gacgaggacg
 9421 attacgagta cagcgacctt tgggtgcgag aaaacagcct ctatgactac gagtccggct
 9481 cggatgacca cgtatacgaa gagctgcgcg ccgcgacgag cggacccgag ccgagcgggc
 9541 ggcgcgctag cgtccgtgcg tgcgccagcg ctgcagccgt ccagcccgcc gcccgcggcc
 9601 gcgatcgagc cgcagccgcg gggacgaccg tagctgcgcc cgccgccgcg ccggcccgcc
 9661 gctcgagcag ccgggcgtcc tcgcgcccgc cgcgagctgc cgccgacccg cccgtcctcc
 9721 ggccagccac gcgcgggtcc tccggcggcg ccggggcagt cgccgtcggt ccacctcgac
 9781 ctcgcgcgcc ccccggtgct aatgctgttg cgtctggccg gccgctggcg ttcagcgcgg
 9841 ctccgaaaac gcccaaggcg ccctggtgtg gaccgacgca cgcctacaac cgaacgatct
 9901 tttgcgaggc cgtcgcgctc gtggccgccg agtacgcccg gcaggcggct gccagcgtct
 9961 gggactcgga ccccccaaag agcaacgagc gattggatcg catgttgaag tcggcggcaa
10021 ttcgcatcct cgtgtgcgag ggctccgggc ttctcgccgc cgcgaacgac atcttggccg
10081 cgcgggccca gcgccccgcc gcgcgcggga gcacaagcgg cggggaaagc cgccttcgcg
10141 gcgagcgggc ccggccgtag cgcgagcggg agggcttttt cgacgcgcgc ggcttaagca
10201 gcgcgctgct gtgctagtat gaaaataaac gcttgttaat taaacacacc aagccgagtt
10261 gcgttgtctt tgggatgagc gggcgcataa aaaccgcggg ccgcgcgctc gccagtcagt
10321 gcggcggtgc tgcggcggca accatggacc cgtacgacgc cattgaagcg ttcgatgact
10381 ccctgctcgg gtcgccgctc gcggcggggc cgctttatga cggcccgtcc cccgcgcggt
10441 tcgcgctgcc gcccccgcgc ccggctcccc tggccgcgtt gctggagcga atgcaggccg
10501 agctgggctt ccccgacggc cccgcgctgc tgcgggccat ggagcggtgg aacgaggact
10561 tattctcgtg tctgccgacc aacgcagacc tgtacgcaga cgccgcgctg ctctcggcag
10621 acgcagacgc ggtagtgggc gccatgtacc tagcggtgcc tggggacgcg gagcgcttgg
10681 acttgaacgc gcacgcgaac cagccgcttc ccgcaccgcc ggcctcggag gagggcctcc
10741 cggagtatgt ggccggcgta caggcgcatt ttctggcaga gctgcgcgcg cgggaagagc
10801 ggtacgcggg cctgtttttg ggctactgcc gcgcgctgct gcagcacctg cgcgcgacgg
10861 cggcgcgtgg ccgaggcgcg gcgggcgcgg gcgcccaggc agaccgcctg cggcagctgg
10921 tggcggcgcg gtactaccgc gaggcgagcc ggctggcgcg gctggccttt gcgcatatgt
10981 acgtggcgac ggcgcgcgaa gtctcttggc gcctgcactc ccagcagagc caggcgcagg
11041 gcgtgttcgt ttcgctgtac tatgcttggc cgcagcggcg gcagttcacc tgcctgttcc
11101 accccgtgct gttcaaccac ggcgtcgtgg cgctggagga cggcttcttg gacgcggcgg
11161 agctgcggcg gctaaactac cggcgtcggg agctggggct gccgctggtc cgcgcggggc
11221 tggtcgaggt tgaagtgggg cctctggtgg aggagccgcc gttttcggga agcttgccgc
11281 gggcgctggg cttcctgaat taccaagtac gcgcgaagat gggcgcgccc gccgaggccg
11341 gcgggcggct ggcgccggag cgggagcact cgtacgcgcg gccgcgcggc gcgatcaact
11401 acgggacgac tccagaggcc atgttgcggc ccccgtcgcc gagcgaagtg ctgccgtgcg
11461 accccgcgcc agcggctacc gtgcgcgtgg cgagccccgc cacacatctg gctcaggcgc
11521 cttcagccaa gggcgccgcc ccggccgagt ttgccgcctt ggctgggctt gcaaagcccg
11581 gtccggcccc gctcgcggcg gccccggccc aagccccgtt cgcagcggcc ttggccttag
11641 ccgagcccgc ggcagccctg gccccggccc cgcttgcggc ggccccagcc gagcccgcgg
11701 cggccgtcgc cgggccaagc ccggcaaacc cattcggcgg cacgtatgac gcgctgctgg
11761 gggaccgcct caaccagctg ctggacttct aagggcgggc gggcagtggc gctttcgacc
11821 cggcgcgtgg cgtttgcgag gcctccctct ggcgtaaggc ctctggcgcc gccctgcggg
11881 cggcgcgagc gtataaaagc cacttgggtc tacacgggat ttagttttcg cgcccgcggc
11941 tttctaggcg cccttagacg ccatggacgc cgctagggat gggcggcctg agcgccgccg
12001 cgccgtctcc ggaacgtacc gcacgcaccc gttccagcgc ccctctgccc ggcggagcgc
12061 tggacgccct gcgcgctgcg gacgccgagg ccgcggagcg ccgcgggtcc ggcgcccgcg
12121 gccgtacttc cagcggcccc cggacgagga caccagtgag gacgagaacg tgtatgatta
12181 catcgacggc gatagcagcg acagcgccga cgactacgat agcgattatt ttactgctaa
12241 ccgcggcccc aatcacggcg ccggcgatgc tatggacaca gacgcaccac ccgagcgcgc
12301 cccggaaggg ggtgccccgc aagactactt gacggcccac ctgcgcgcca tcgaggtcct
12361 gcccgagtca gcgccccacc ggagcctgct ggagcgcacg gcccggaccg tgtatgcgca
12421 gcagtttccc ccgcgcgatt tgagtgcggg ctccaaggcg ccggcacagc gcgcgcggcg
12481 gagcctccgc ggcttcccgc gtggcggcgg gggcggccaa gaacccgggc cagacgacga
12541 aggcgacgac gccgcagacc tgcgcgagga ccttgtgcca gacgaggcct acgcgcacct
12601 agagcgcgac gagcggctgt cggaagggcc cccgctcctc aacatggagg cggccgctgc
12661 ggctgcgggg gagaggagcg tggtggagga gctgtttacg tacgcccctg cccagcctca
12721 ggtagaggtg ccgctgccca ggattttgga gggccgggtg cggcccagcg ccttcttcgc
12781 gcagatgtcg ctggacgcgc tgtgccgcac gccgcccaac gatcagcgcg tggcgcgcga
12841 gcggcgcgct tgggagatgg ccggtacgcc gcatgggctc ctaataacca cgtggagcac
12901 ggtggacccg gaattctcga tcggcggcat gtacgtgggc gcccctgagg gcacccggcc
12961 ccggctagtg tggcggcgcg cgatgaagca ggccatggcg ctgcagtacc ggctgggggt
13021 gggggcctg tgccgagcag tagacggcgc agcatgccgc ccactgaggc gctgctcttt
13081 ttggcgtgac gcgctgctgc gcgagtgcgc aactgccatt ttttgtcgcg gccggggcgc
13141 gcgggcggcg ccgcgccgcc tgccgcggcc ggcggttggg ctgctggcag ccacgcagtt
13201 cacgccaccg gacgcgtccc cccacgcgac gctctttcgc ggctcaatgg gttccctgat
13261 ttactggcac gagctgcgcg tgatgctgac tgcggtgccg gccctgtgcg cgcgctacgc
13321 gggcgccggg ctgcagtcgg ccgagctgta cctgctggcg ctacggcact cagaggcgcc
13381 cggctacacg gcaaatgagc gctacgcgct ctcggcgtac ctgacgctgt ttgtagcgct
13441 cgcggagcgg ggcctgcgct ggctgtatct agcgggcgcg cacctgctcg ggccgcaccc
13501 cacagcggcg gccttccgcg aagtgcgcgc caagatcccg tacgagcggc tgccgctagg
13561 cagcgcgacg ctgcacgacg ccgaagtgga gacggtggac tcggccacct tccaagaggc
13621 cctggctttt agcgcgctgg cacatgttta cggggaggcc tacgtagcgg tgcgaaccgc
13681 gacgacgctg ctgatggccg agtacgcggt ccacgctgag cgccgggacg tgcggcagat
13741 gacagcggcc ttcctgggcg tggggctgat cgcgcagcgg ctgatgggca gcctgaacct
13801 gctgctgaac tgcgtagccg gcgcagcggt gtacgggggc cggcgtgtga cggtgcgcga
13861 gggcacgctc gcgcggtaca gcctgctagc ggacgcggca ctgccgctgg tgcgcccggt
```

13921 gttcctggtg gagttccggg aggcccgcga cggcgtcatg cgcgagctgc ggctgcggcc
13981 cgtggcgagc ccgcccctgg ccggcaagcg gcgggtcatg gagctgtacc tctcgctgga
14041 cagcatagag gcgctggtcg gccgcgagcc gctaggttcg cggccggtgc ttgggccgct
14101 cgtggacatc gcggaggcgc tggcggacca cccgcacctc gtcacgggcg atgggcgggg
14161 cccgcgcctg ggcggccgct agggcgacgg ccgcgcttac gcggcgctgg gtccgcccac
14221 atcagccacc acgcccgcgc gcccgccccg ccctcgtatg cctatatagc catcacgctt
14281 gaatgccaag cgccactttc ccgccgcggc gaaatggcgt ggccggccgc ctctcggggc
14341 ctcatcgagc ggcgggcaga gaaggggtgc ctgctgccga cgctcgcaga tgccacggcc
14401 gcggccgtgg tggccttgca ggaggcgacc gagcctctgt gcggggctcc gctgtttggc
14461 gccgagcgcg cggccgcgct gctcggcgtg cgctccaacg ccgtcccgga ggcgctggtt
14521 ctgtcggact cggcgaaaga cgccgacgac gagtaccggc tggagtatga ccgcgccgca
14581 gcgcgggtgc tggcgggcgc gcggctctct aaggacgccg tctggcgcgc ggtcatcggc
14641 tcgtactgga agtacctgaa ggcctcgagc ggcgctgacg tgaacatcga cggcgcggcc
14701 ggcggcgcgg cgatggagca ggcgcagctg acgaacgtga tgctctttgc gcccacatac
14761 gcgcgccggg cctcgcgctc gccgttcaag cacaagcagg acaacgcggc gtacaaaacc
14821 gcagcggcgg agctgcgcgg cgccctgcgc gcggtggaaa agtatatgta ttacatgcgg
14881 ccgggcgacc ccatggtcga aagccccgac acggaagccc gcctgcagga aattttggcg
14941 tacgccgcga cggcctaccg ctggctgctg tggttcatgg acgcgctcga tggcacggtg
15001 ctgcgcaagc ttggcaagcg cccctcggcc gcggtggggc cgcgcgagcc gcggccgccg
15061 ggcgagctgt gcgagcgcca tctgaccggc ggcccgggga tcgcctgcgg cagcggggcc
15121 gcgctcatgc tgacggccct gacggcggcg gtgctggcct tgctactgcg cgtcggggcc
15181 gcttggacgg aatcgtcatg gaagagcaat acgcagggcg tgacgggagc catcgtcgcc
15241 gcggtcgagc tggcgtcggc cgtacaccac cacctgcagt acctgctcaa catggccttt
15301 gtggggtacg cctgctggct gcgcgcgggc gtgcgcgacc cgtacatgat cgcggccatc
15361 cgcgcgcagt gccgcttcgc tcactttacg gggcagctga tgccgaccat gacttccgcc
15421 agctgggcgg ccctggagcg cggcacggcg agctggttta agctggcgct gctgaaaagc
15481 gtggcggcgc acggcgcgca gacgcgctac tactccaaca tcgtggagtc gatgcggctc
15541 ggcgggagcc gcgggctgct ggcgccggtg cgcgcgcggc cgtcgggccg cggccgccgc
15601 tgcccgcaga gtctggccgc gcgccccttg cccagcctgc cggccgcggc cgccgccccc
15661 ccgggctcgg gctcgggctc gggctcgggc tctgactctg actccgacct ggatctcggc
15721 tttgcccccg ccgtcggcgt ctatgcctcg atgcgcaacc tggagggcgc ctatgccgac
15781 gcgggcggcc cgctttcgcc ggcggcaagc gccgcgcggc gggaggcggc ggtgtacgaa
15841 aacgaaggcg agggcgaatt cgcgcctttg ccctcggcgt tcgccgaaga cggcagctcc
15901 gacagcgccg acgagctcgc tatcgacggc cccatgcctg ccccgccgcc ccgcggtggc
15961 cgcggcgccg acgagctcgc catcgacggt cccatgcctg ccccgccgcc ccgcggcggc
16021 cgcggcgccg acgagctcgc catcgacggc cccatgcctg ccccgccgcc ccgcggcggc
16081 cgcggcgcct ctgctgggcg cctccagtac gctgattcgc gcgccgtctc gagtgacgac
16141 gacgaggacg agggcaagga cgaggacgag aacaaggccg gggcgaccgc cccgttggcc
16201 gcggaccccg aatcggaact ggcccgcgcc atgcggcgtt gcagcctccg cgtcccggcc
16261 tcggccccgg ccccggcccc ggccccgtgc accgagcgcc cgggtaatcc aacccggtct
16321 tactcgcgct cgcgccctcg gctccgcgcc ctagacgacc ggcacggcct ggaggcgctg
16381 gcggctgccg gtgccgctca caccgcgcgc cacaaccgcg acgtgtggca gcgcttttcc
16441 cgcgtctgcg aggccggcga cgactacgaa aactacgacg aggcccgcgg cgcagagcgc
16501 ggacacctct cttgcgcctc ccgcgcgcgg cctgaggtgg agagggtaac gtcgctgtaa
16561 aggcgcccac cgcaaacgct gtaacacaca cacaataaaa agtttgtttt agtttattat
16621 gaaattgtac atgcgtggtc tttgggggggg ggcgcggcgg ctttgccgtc ggggccccgc
16681 gcctacaggc gcgcccgggc cttgcgccgc aggcacgagg ccgccaccag caggagcccc
16741 acggcgccga gaccgcaggc gacggccacg acgctgacga ggacggggct tccgattagg
16801 ccgggcgagg cgtcgtacgt ggcggtcgcg gagaactcgg gcagcggtgc cgggtagcca
16861 gtggcggtgc aggtgtagtc gacgggcccg tcggttgtag aaagcaggcg cacgccgcgc
16921 aggtttacca gcccgggccg ctcggcgcag acgccggtct gctcagtgcg cgacggggcg
16981 atgccgtcgc gcaccgtcca gcgcagggag acgcgcccct cggggacgca gcgcgcctcg
17041 cagacggcct cgccgccctc gaagtacacg cgcagctcgg gcgggcggta aacggccggc
17101 gtgccagccg cgtaaaagcg gcgctccatg ttagcgctct ggaaccagga gacgtcgcag
17161 cgcaggttgg gcgggtgggc ggttggcgtc gcgtcctcga gcgtaaggac ggacgtgcgc
17221 gaaaagagcc cggagtcgtc gaccgtaaag acgtcgcgcg cgtgccgagc ctccacgggg
17281 tagccgttgc ggaaccagtg caggcgcgtg gagcgcggcg ggtagtactc ggcggcgcgg
17341 cacacggccg cgtagccggc gccttctagc gctggctggg gttcgacgga aacagcgggc
17401 gcgcggtgcg tcgtgacggt cacgaccttg cgctgtgact tggtgcccat gtcgcggcgc
17461 caagtgtaca cgccctcggt ggcggccgtc agggagcgca cggtcagggg caagttgcgg
17521 gggtcggcgg gcgaagggaa aatatagttg tcgcccagct ccgcgctacg gtacgcgatc
17581 gagccgttct gggctacgaa cagcagcacg ggcggggccc gcggaaaggg gttgcgcacg
17641 gcctcgtcgt cgccgcgcgt ggagcggaac ctgcccacgc gctgaaacca gagctccagg
17701 cgcgcaccgc cagtggcgtt gtcggccacg ccgcagtgca cgtacagcgg ctcggcgtac
17761 gaggcggcca cggcctcgcg ctcgcagagc atccacttgc gctccttcgg cggggctttg
17821 ctcggccgcg gggggcgagg ccgcccccg ccgctaggtc gcccatcgcg gctcgcgttg
17881 ccagcgccgc cgggtcgccc gtcctcgggc ggggcgggcg gcggcgtgct gttggtaacg
17941 ggcgggtcgt gctcggacac ggacggcggc tccggcgtcc ccacgggcgt agtagcaccg
18001 ggcgtgctgt cctctggcgt agcgtcgggg ctgttgggcg tgggggcgt tgcgccggtg
18061 gtcccagcgg agctttccgt ctcggttggg gacggggagg gcggaggcga gggcgaggct
18121 tccgcctcct cggcgagccc ccgccgggca gacaggagcg cccaggcgaa aatagctgcg
18181 atcagccacg ctcgccccag cgggcccatg gcggacgcgc ggcgaggtct cgggctggcg
18241 gtctctcggc ggtcgtgcgc gcgggtggat ccaagatggc cgcgaccgcg gcgcggctac
18301 atttttaagg gcgtccgttt tgtgctttcg tggtccggga ttgagcacac gcgcggctgc
18361 aggcgcgtta ccgtcggcgg cagccgttca ttcgtcggcg cagacccagc aggccccgac
18421 gcagaagcac agcgcggcgt gcagggcctt ggccacgtgc gccgcggcca gccgtgcggt

18481 gccgcgcccg cagcgccgga cccacacgca ggccaccagc gtgcccgcgg ctgccgaggc
18541 cagcgctgcg ggcgcgccgc cgtccgcgcc gcagagcggc agcgctgcgc ccagagcgca
18601 gatgcccacg tgcgccatta gcgcgccgtc cgcggcgtcg gcgcgcgcgt agcgcaggca
18661 gaggtgctcg gcgagcgcga cgccgtgccc gcccgcgacg ctgagcagaa ccgcgccgcg
18721 cgtgcgccag cgcccaccgc cctcgagccc aagcgcgcgg cccggggccc agagcgccgc
18781 cgccgcggct aaggcggcgg ccgacagcgc gagctccgcg gcggcggcgc gcgccagcgc
18841 gcgcatgggc acggcgtcct cgcgcgcgcc gcacgggtca gcggggcacg ctgcctcgcc
18901 gagcggcgcc agagtccgca gcgccgcgta ccgccagatc ttgtagtggc aggtgtcttc
18961 cagcgccgcc gcggcgtccg tggcggcgac gaccagcgcg gccgcggcgc ccgcggccgc
19021 cagcgcctcg ggccgcgcgc cccagcgccc ggccgaaagg ccgagaagca gcccgcaggt
19081 catggtcagt agcgccgtgc gaaagtgcgc cccggtgccc gaggctgccg tcacaaagtg
19141 cgcgcagtgc accggcacac cgcagacgac gtaggcagcg gccgcgcccg ttgttacccc
19201 gcgcagcacg gcgggggcgg ggtctgtggc ccagacggcg agtgccgctg cgacagccag
19261 cgcctgcgcg agccggccaa gcggcgcgag ccggcggcgc agcgtctgtg cggcgggccg
19321 ccaacaaacg agcgcggccg cggccgtggc tgttaacgca agcgccgcgg ccgggtcttg
19381 cgcgcgcccg acggtggcca gggccgccgc catcaagccg gtgtgtgtgc ccatggccac
19441 cagcgcgccc gtggcggcaa gcgcacacgg gccgcagccg gctctcgccc ccgcgcagcc
19501 gctcacccgc acggacgcga acatggatgg tcccggttcc ccaaataacg caacgtggcc
19561 caggatcgtc ttttatcggc ctttattgtt tttcgcttaa ggagtttcgc ccccctcccc
19621 gccccgatcc gggcccgagc tcgggcccgg ggcgccggcg tcggcgcgcg gccgcttgcg
19681 ggcccggccg ccggaaactg cgaccgggtg cgcgccgtcg gtttgaatgc cggctccggc
19741 cccgcgacga ggttggccgg acgcggcggg ccgcttagcg ggaaggcggg gtgcgggctc
19801 ggcgcagtca tcagcatcgt cggcggaggc ggtggcggtg gcggggcggc agaaaaagaa
19861 cacagtcagc ccctccggcg ccgctgtgga cacgctcatc atggcggcgc tggcgggcgc
19921 gaggtagaag cgcacgaggg cgtcgccgcc gacctgccgc acctttgca gcagccgccg
19981 gaatcccgag ggggactcca actccagccg aaagtcaggc gccccgccag agcagcgcac
20041 ttccaatagg gcggccctgc ggccgccgcc ctgggcgcgg gcaaaaatgc gctcgctgcc
20101 tgcgctcggg gcgagcgcca gctggagctc tgccccggac tcgccgccct catggcgcgc
20161 ggcgaacgaa gctcggcccg atgcggactc ggcgctcagg caacgggcgc gccggtatgc
20221 gaataccacc gcctcgttgg gatctttggc aactgcctgc agctttgaga gctgcggccg
20281 cgagagcgag acggcgaggt cggcgccgcg cgtcggaagc atgattgagt actcgcctag
20341 ctcgtgcttg accaggctgg cctgcaatag ggcatcggcc tcccgaaagt aggtaacttg
20401 cgttagcacg ctcgcgggtg gctcaccggt gattagaaag gccacgttct gcactgtccg
20461 tgtcttgtcg gcgcggaagg cgtccagcag gccgcggcgg ctgtcgacgt tggcgaggaa
20521 gacggctcgc gcgtcgtcgc gggcgggggc ccactggaag gacgtgaact tctcggcggg
20581 gacggccacg tacacttgct cgtcgtagag gccgctgtgt accagcatgc cctcgcggct
20641 aaagaccaaa aaggcgtttc gcagcgaggc gccaaagggg ctcagcaggg cggagacgtc
20701 cgccagctgg cggccgataa gcgaggcgct cgcgattggg ttgccgttgc cgccgtcgga
20761 cagaccggcg gtgaggcggg cctcgccttc gtcggcgcgc agatgcgagg ggggctgcag
20821 catcgcggcg ggtgcttcgg cggcgctttc gctcgcctct tacgcgcgcg gtcgcaaagc
20881 gagtctgcgc tgcggcggcg ctctttatac tgggcggacg cccccgcagc ggcaaaacac
20941 acactcggcg gcctcagcgt atcaaacggc gacacgttta agtttcgacg cctataagcg
21001 ggcgcgcgca ctaggcctcc caatcggcac cgcgcgcggc tgtgcgggcg accctgcgca
21061 gagagagatg gggctcttca agctactgcg ttacgcgtac ggcaatcggc tggtaaagca
21121 cgacgccatc accacgccgc cgggcgtgat gaccccgatc gcggtcgacc tgtggaacgt
21181 gatgtatacg ctcctggagc gcttctgcgg cgacgcgccc ggcggcgtag gagacgccgc
21241 cgcgaccgcg cgctgcttcc tctcgctgct gcggatgctg ctcaagcgct cctactaccc
21301 gatctttgta gcggaccgcg gcatccacgg ggaccggcgc gccacgcggg gtgccaaggc
21361 cattgtggcg cagacgatgc gcgccgtcgg cggctcgggc cgcctcgggc ggctcgtcag
21421 cgacgattat acctcggagg acgaggtgct gggcgcgtac gagtaccccg tcccgcacgc
21481 ggacgcggca gccgacgacg acgaggaggc aacggcgaag gaatttgccg ggcgcgcctc
21541 ggcgggggcc gcgcgggcca acgcgcccaa gctggcacat cgcgtgtgcg tgagcctcat
21601 ccgctttttg ggctacgcgt acgtcgacgc cgctgagatg gaggcagacg acgtctgcgc
21661 aaacctcttc cacacaaaca ccgtggcgca catctacacg acggacacgg acatgatcct
21721 tatgggctgt gacctgattt tggacgcggc gccgttgttc cccccgacgc tacgctgccg
21781 cgacgtgctg gcgtcgctgg ggctcacgta cggccagttc ctcgcgacgt tcgtgcgctg
21841 ccacaccgac ttgcaccagc cgccaatgct gcgctcggtg cagcaggtgg tgcgggggct
21901 gcggcgcgct gccgaggccg agcccgcgac taccgagacg gagtctggct ccgagcgcga
21961 gccggagtcc gagctcggtc gtccgggcgc tgggccgcgg cgccggttgc cgcccgcggt
22021 cgacgacccg ctgaaaacta cgacgccggc gaccgtggaa gcgcacagcg tgcgcatgaa
22081 gtatacatct cggtaccctc cgattgcgca gacgtgcgcc gacgcgctgc ggctgctgcc
22141 ggcgtcccag acgcgcggcg gcgtgctgga gcgcaaattt gtaaagcacg tggtggacac
22201 gatcgcgccg cgaatgcgcg ggcgctgggc cgtgctgaag cgcgtgccca tcgcacagga
22261 cgcccccgac cctcggctcg tgtacgacac catcgtgagc gccgtaggca gcgccgccga
22321 ggccgacacg ctgatggggc tcttctggaa gcacatcccc actccacccc catttgccaa
22381 ggtgctggca gactactggg acgaggcccc cgcggggccg gggtcgcgac ggacaacccg
22441 ccaataaaaa cgcgcgcata cgcgagactg gctttcgttg acatggaaca ttttttattc
22501 gcggcgtggg ggtgagaagg aggaggaaag gcggggcgct ctggcagggc agcgggggtg
22561 ccctacaggt cgttgattac ggtgcctgtg tagttggtgc tgcggcgctc aaagaagttc
22621 gtgtgcttct cggcagtcat cagggccaaa ggaaaatcgg tcccaggagg cggggtgcca
22681 aacagaggag gcagctggat agcagcgagc aggcggtccg cgctgtactc gacgtacgca
22741 gaaatagcct ccacgtcaag tatatgactg ccgcgcggcg cgcaaccaaa taaactcgcg
22801 ctcaatttcc acgcttcgcg gaacagctcg tagatgcggg ccggcggcgg ccgctccccg
22861 ccgaggtagt tgtcgaagat gcagcacgac gcggccgtgt gcacggcttc gtcgcggctg
22921 atgaggtcgt tggtttggca cgtcacgacg aaaaggttgt gggtgcgcag gtaggcaatc
22981 gccgcaaacg aggaggagaa aaaaatgccc tcgattagaa tcatgagcac gtacttttcg

23041 gccaccgact ctgccgcggc cacgcgccgc tcgagccagt ccaccttgcg ccggaccgcc
23101 gggtcgccga gggcgccctc tacgtagccc gcgcgcgcca ccgcgtcgtt tctaaagagc
23161 agcagctgta tggcgctgta cacccgcgag tgcaccactt cgatggactc ctgctcgata
23221 tagtaatgca ggatgtcttt ttgggtgaac agctcggaca ggtccccgag gttgacgttc
23281 acgaggtcat cggcggccga gaggaacgcg aacagaaagc ggtaaaactc cagctcggcg
23341 ccgctgagcc gcgccacgtc cttggcgtcg tccgctaggg gaaactcggt ctccagccag
23401 cggtttgcga cgctgagcga ccgcaagtga tctaggtcgg ggcactcggt ctcgtaaaag
23461 tatttgtatt tacgcgtgag ggtcgccgcg tccgccgcct cggccatcgc gctcggcgcg
23521 cgtcgctaca ggtggcaccc agagcacacg aggtcgccgc ccgtgaagac gccgttgttg
23581 gtggccttgc ggatcttgca gtagtagagc cccgtcttaa ggcccttctt ataggcgtac
23641 actaggaggt tcatgatctg ggaggcgggc acctttccgt ccattggctc ggtcacgaag
23701 agcgacattg actggctctg gtccacgaac ggggcgcggt cggcgcagag gtcgatcagg
23761 cgctcttggt cgtactcgaa ggccgtcttg aacttggcca gcggatgccc gggcgcgagg
23821 tcgcccagcg cggcggccac cgaccactgc tcgcggtcca gcgcgcgcac ggccccgagc
23881 cggctggcct cgcgcgtaaa gtgctttcgc agcgcgcgca tcagcggcag gttcgggcgc
23941 agcagctcgc cgctcatcgt gaccttgctg aacatgttgg tgaagacggg cgagaagccc
24001 tcgctgccct ccgtcacctg cgacgaggac acggtcggca taagggcgac aaactgcgcg
24061 ttgtacagcc cgtgccgcgc gaccttctcg cgcagccggg cccaggcccg cggcagcgag
24121 aggaccacgc cctcgtagcc gtcgaacggc atgagcccgc gcgcgaactt gctgcgcgca
24181 aagtcctcga acggcgcgca gccgtactcg cacagcgtgg cgctggtggc catgacggcc
24241 aggagcaggc gctcggcgat ctccacgttc agccgccgcg cggcgggcga gagcatgtcc
24301 atgccgagct ccaagaggag cgtgtgcagg ccctggaagc cgatgcccag cgagcggtgg
24361 cgcgccacgc cgcgcgcggc cttttcggta gggtactgtc cgcctagcat catagcgttg
24421 acaaaaatgg cggccgtggc ggccgccgtg gacagagcgg caaagtcaaa ggcgagcgcg
24481 ccgccctcac cctcgcgcac gcagcgcggc aggttgacgc tggccaagtt gcacacgccg
24541 tgggcgtcgg ggctcgcgcg ctgcacgatt tccgtgcaga ggttggagcc cgttagcgcg
24601 tccccggccg tgtccatgtg gtaatggcgg ttacacgcgt ccttgaacat gacgaagggg
24661 ctccccgtca tgacgatgct tcggacgatg aggaaagcta ggtcctgcac gggcacggtc
24721 tcgacgccta gcccctcgcg ctccagtcgc tcgtactcgg ccgtaaaggc cgggccgtgc
24781 agccggctga ggtgcgacgc gcggtcgtcg aagagcgtcc acacaacgcc ctcgcggcct
24841 tcgaggtggg cgaggtagcg gtcaaagagc aggtccggca cccagaggca gctgaacagg
24901 ttgtcgcagc gcgtcgactc gtcccgggcg agcaggccgc gcatgtttag cacggcccgc
24961 acgtcgcagt gccagggctc gaggtacacg cagatgcccg tcgggcgctc gctgtcgctg
25021 ttgatggcca tggccatcga gtccagcagc ttcagcgccc ccatgatgcc acgcttgcag
25081 tcgcgcgaga ccgcccggtc gaagctctgg aaggagattc cgatcccacc gcggttgagc
25141 aagattcgcg cgacctccgt ggtgatcgcc tccacggcct ccgtactgct ggacacctgc
25201 ggattgagca ggtagcagct ggccagcgag ccccgcgcgc ggccggcaaa gagcatgatc
25261 ggcgtcgcgg ggacaacgag ctgccggtac agcgcggtca ggtaggcgtt gaacaccgcg
25321 caccacgtgg cgccctcgcc gacgagggcg cgcccaaagg ccggctcccg catcgtccac
25381 gtggcggcgg tcgcggcgat ccgcacgaag aactggccca tagactcgat cgccccgccc
25441 tcgagcttgg ccaggtacat ctcttcgtac ttcagcgccg actgcaggcc gagcgcgcgc
25501 agggtggcgt actcggtaag ctcgaagtat cggagcgaga cctccacgaa ggcgcggttg
25561 gcgcgcaccg gctccgcgac ctcggacacg agcgcgagct cggccgatgt aagccagtcg
25621 tccagaggca cgctccgagc acgcacgcgc aagtgcacga gttgcccgca ctttacgtac
25681 acgcgttcgt cggcccgcga ctgcgctctc atgcgatcca cgacctcgcc gacgtaagcc
25741 gccactgcgg cccgagaagg acgagaagcg gcggcgggcg gcggcggcac ggcaccgcag
25801 cccagctgcg cccattccgc gtgctcggcc tcgagctgct ccgccgcgtc ggccgggcag
25861 gctgtctgca tgaacgcgtc gctcgccatc ttgctcgccc ccctcgcttg cagcccgccc
25921 ctgccgaccc gctggctttt tgtctttcgc ccgccgaccc gccggcgctt ggtctgcccg
25981 atcgcacccg ccccgacgcc ttgggaacaa gcgcgcggcc ggctctggct ccccggagat
26041 aaaaaccgag cgtatggcgg cagcaaaagg tgcgggccag gtgctcgctc ggcaggcaac
26101 ctgggcccgg cagcagagat atttaacggc ggtttgaggg gcgtggcggc ccttccctgt
26161 tgatttatgg catcgcacac aacggtgttt gcggaacaca ttttatttaa aacgacagcg
26221 ccccccttgtg tcagtaaaag cactccaccc agtccccggt tccccacacc aagccctcga
26281 tcttgacgac gggcacgtcg caagactggt agcgctcgct gcggcaagtg actcgcggcg
26341 agtcgtgggg cagcgtcccc aggcgcgcga aggcggcgta catgcagctc tcccgggtgg
26401 gccgcccggc agcgtccggc gcccagcgcg gcaggaacgc cgtcgcgtcg cagtcgccca
26461 gccgcgagac ggggcagcgg taggccgcgc ggctgttcgc cagcgcgggg agcggaaact
26521 cgtccgcggc cccggccact tctgcagcgt cgcccgccgt cccccggagc acgttttcgg
26581 cgcgcgtgcg gtgcagcaag tagctcagcc cgctggcgaa tgtggtttcg ttaagcttgc
26641 tgacggccac gtgggcgcga aagccctcgt gctccaagcg ctgcgtgtac acgaagacca
26701 ggtacacaaa tttgacgccg gcgggctcca gccgcagctc ggcgtccacg tccaggaacg
26761 cgcaggcggg cacgtgggcc gtagagcgcg ggtgcgcggc ctggtcagtg cgcgcgccct
26821 cctgcgcgcc gcagacgacg gccgtgacgc tggccagctt gtcttgcgtg gtccacgaga
26881 gcagtccgcc caggcacccg agtgcctgat gcgggaacgc gcggcagcgg atcatggcct
26941 gcaggcaggc gtagaagcgg tctagccgca atgccatgcg gcggtcgccg gagttggaaa
27001 tgaggtgcgc gcgcagcgcg tctgcggcgg cgcggttgcc gtactcggcg gcgcaggcgg
27061 ctgccagaaa ggaaaaggat acaagagagg cccgcagccc cccgggcggc accgcgccca
27121 cgctggaggc gtcgccgagg tcgcgccaag cctcttcgac gtcgcgaaac tgccgtccgg
27181 ggggcgcagc cgcggcggcc agcccaataa tgtcggcggg gtgcttcagc gttaggacgg
27241 gcgcgccggg gcgctcgagc tgcgggtcgc aaaagtccgt cagggtaacc tgccgcgaga
27301 gccggatgtg aggctgcccg ccgggcgaga ggacggcggt gccggcgggc gtgtccacgg
27361 caatctgccg gggcgtgacg atttgaatcc ccgacatgtt ctggatggtt accgttgcgt
27421 cagacacgtg cagcatcccg ccggcccaag ggttgtagcc ccggggtgcc cgcccgcgag
27481 cgccgccaac cgcaggcgcc gtcactgact gcacgccggc ttcggcggca gaggcctcgg
27541 ccgccgccgc ggcggcggcg gggacgcccg agaacggcgg cgcggcggct gggagccgca

```
27601 tccgcaagtg gttgccgatt tgaatgtaac tcgagctccc gttaggcgcg gccatcgttc
27661 ctcgtccgct cggcactcgc gctcgggtcg ggtgttatag ggtggcggat tcgagctgcc
27721 tttatagcgc cggcgcacgc ggcgggggca agggcgtcag cggcggaagc cgcggcggcg
27781 gttgcggcgg ggggctgtgc ggggcgtaca ataaactgcg cggcgggtgc gggctctggc
27841 cattcgcgcc ccggcgcacg cgcggctgac atgagcggag accccgtgcg ggccctgtgg
27901 gccgcgctcg agcggttgga tggcgaggtc gccggcccgg ccgcgcttgc ggaggccagg
27961 gcggccgtct cggagttcct cctcgcgtcc gggcccagct cgctagactt cgtggcgccg
28021 cgctgggccg cgctgcagcg cgcggcgtgc cgcgcttacg agcgcctgca cacgccagac
28081 gcggcgctgc tggcggaaaa cctgcccggt ctggtgctgt ggcgcctgcc cggggccgcg
28141 cgcgacaccg ccgatttcat ggccggcgtt cgggacctgg ccaacagcat gatcgccgag
28201 gcgccgttgg gttacctggc ggccgcgcgc ctgcgcgcca cggcggcgtt cggcccggtg
28261 aacatgcagc gcgtggtggt ggagtgggcc tcgctctttt tggagatcta cgcacgcgag
28321 gacgcggcgt gcgtgggtgt gttaggcccc gaccctgcgt gccgctcgcc ggcgggcagc
28381 gcggccgtca tccgcccgct gctgcagagc cgcttccgcc tgctgtatga catgcccttt
28441 tttcaggcgg ggcttagcgc cctggcgcac gccgccaact ggaaagtgcc tatggccgcc
28501 gtggcacgac gcgccgcgga cgccgcggcg ccgccgctag cgcgcgcgct ttttgccgtg
28561 gcgcttgtcg acgagtactt tcccgagcca gacgacgagg acacggcgcc ggggctggct
28621 gaggcgtttg cggaaattgc tgacttggtg ccgcccgagg cgctagtgcc cgcgggtgag
28681 gctaacgctt ttgcgcgctc gtcgcacgac gtgcgcgtat cggcggcgct ggcctaccgg
28741 gacccctttg tgcgcggcgc ggccgcgggc agcgtcgccg cgcgcgtgcg tgccgacgcg
28801 ggccttctcg ccgacgacac gttgctcggc cgggacgccg tcgccgttca cgcaggcgcg
28861 gtggtgcggc tgctagaacg cgcggccgcg cgcgcgacgc cggcggcgct ggggcgagtt
28921 gcagagcacg cggccgccgt ttgggacgcc gtgcaggcga gcgccacgcc agaccaagcc
28981 gtggagacgc tggccgcggc ggggtttacg ccgggaacgt gcgccatgct agagcgcgcc
29041 gtgctggcgc agctatcgcg cccagagccg cgcgcgccgg cagacgtgct gcaggcggtg
29101 ggctgcgtgg cggtggcggg cggcgtgctg tttaaactct ttgacgcgta cgggcccagt
29161 gcggactacc tcgcgcacta cacggccact atcgcaaacc tgcacccgta ctacgcggac
29221 gtgctgccgt tgctggggct gcccgacggc gggctggagc agacgatccg ccactgcatg
29281 gccccgcggc cgcgcacgga ctacgtggcg gcgattcgcg cggcgctggc ggcagaggcc
29341 gcggccgcgg acaagcgagc cgcgagcgcg agtgcgcggg cggccgttga aaacagcggc
29401 gaccgcgcgg cggccggagc tgccgcgcgc gaggccctcc taacctggtt tgacctgcgc
29461 gccagcgagc gctggggcgt ggcgccgccc gcggccgaag cgccgcccgc ggccgaggcg
29521 gcacgctctc cggccgcggg cggcgcttcg gccgcagagc tcgcccgcgc ggcgcgggcg
29581 ctcgagttcc cccgcacgga cgccgtgccg gctgccgtct tgcgagaccc ggcctttgcg
29641 ccccacttcg ccgccgccgt gctgtcggac gtgctggtgg ctgcggacgc gctgcccttc
29701 agcgcaaacg gcgtggcgca gctgatggcg ctgatcgctt gggcgcgaga ctgcggcgcg
29761 ggagcggtgg ccaacgtaga cggctaccgg acaaaactgt cggccctggc ggccgggctc
29821 tggccgtttg tggacgcgag cgccccggcg cccacgacga cgcaggtccg caacgcggag
29881 gctgtgctgg gcgagctgca cacggtagct acgaccgcgg cggagtgcct gccgcccgaa
29941 gtgcgcccgc ctgtgcccgc gcgcccgcgg gtgggcggtt gtgtcttctt agcgagcatg
30001 tacctgcacg ccgccttcgc gcggctgcag ggctatgtcg ccgagacgga agcgctggcc
30061 gcgtctatgg ccgcggccgt gggcgacgtt gccggcgcgg tggcgcggct gggagtgctg
30121 ttcgactgcc actttgcgtc ggtgccgggg cagcagatgc tggcgatata cgcgacgcgc
30181 ggcgcgccgt gcgccctggg tgcgtggcgc tcggcggacc tggccgacgc ggtgcgcggc
30241 gcgcgcgccg aagccgcgcg cgcccgggcc gaggtgcgcg tgtcgctggc ggcgttgcag
30301 cgcgccgcgg cgcagacgac acaagcgctg caggagtgtg aagctgcgga cgcccgcccc
30361 cccggcggcg ggctggacga cgagcaccgc gcgttgctgg cgggccactc ggcgctggtg
30421 cgggcgcaga cggcgctggc gctggccgcc ggcaagctcg tggcgggcgc ggaggcgccg
30481 gggctgcacg aggtgggccg ctttctgcag cgctgggacg cgatcggcgc ggccctcggg
30541 cgcgcgctag acgacagtgc cggcgagcgc gacgtcgccg agctcgtcgc gcggctccgc
30601 ggcgtctggg acgaggtcca ggaggaccgc cgcgtagcgg ccccggggcc gccgcgcagc
30661 gccgcaaacg cggcggccgc cgaagaggcg gtgctggcgc tgttggaggg ctacccggag
30721 gttcggggag acgagggcag cccggcgctc ctggacgccc gcgcggacgt ggccgactgg
30781 gcgggcgtag accgcggccc gctgcagcgc cgcgcgtctg cgggcgcgga cgccgccgcg
30841 tctgccgccg cggcaaacac ggcggcgggg ccgtggctta cgacggaaga cctgctcgcc
30901 gaagtcgatg gcgtttgcgc cagtcgcccg gccgcagccc ggtgaggcgc gcgccggcgg
30961 tgcggcggga ggccttcgca taaacggcgc tgcgcgcgcg gtgcccccta gtaccctgt
31021 ggagcagcga agcggcacca tgtccggcgt tgccggcgcg cgcgcgccgg caacgccggc
31081 cgacgtcgcg gtcgccgctg tgggttttcg caaccagtac gacgcggcgc tggggccggg
31141 cagcgcggtg gcatgccttc ggtcctcgct gtcgtttctg cggctggcct tcgcgggcgg
31201 cgtcgacgcc gcgctgggcg ccgacgccat cgacggtgct ctcgctgagg gcgcggcgtg
31261 ggcgcgcgaa agcggggcgc gcccggaaat gtgctcgatc gtgcacctgc caaaccgcat
31321 caccgaccag gcgggcgcgg ggagcgggct ctgctgcgtg ttttcgcgcg tgtatgggga
31381 gtgcggcttc tacacgccgc cggcggagcg cgccctgagc acccaagtcc cagcgcgcga
31441 attc
```

L3 ANSWER 132 OF 199 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): HSMULHOM GenBank (R)
GenBank ACC. NO. (GBN): L10283
GenBank VERSION (VER): L10283.1 GI:388703
CAS REGISTRY NO. (RN): 151210-86-5
SEQUENCE LENGTH (SQL): 8433
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Viruses
DATE (DATE): 29 Oct 1993

DEFINITION (DEF): Gallid herpesvirus type 1 homologous sequence (UL50, UL49.5, UL49, UL48, UL47, UL46, and UL45) genes, complete cds.
SOURCE: Gallid herpesvirus type 1 (strain GA) DNA.
ORGANISM (ORGN): Gallid herpesvirus 1
Viruses; dsDNA viruses, no RNA stage; Herpesviridae; Alphaherpesvirinae; Infectious laryngotracheitis-like viruses
NUCLEIC ACID COUNT (NA): 2454 a 1751 c 1825 g 2403 t
REFERENCE: 1 (bases 1 to 8433)
AUTHOR (AU): Yanagida,N.; Yoshida,S.; Nazerian,K.; Lee,L.F.
TITLE (TI): Nucleotide and predicted amino acid sequences of Marek's disease virus homologues of herpes simplex virus major tegument proteins
JOURNAL (SO): J. Gen. Virol., 74 (Pt 9), 1837-1845 (***1993***)
OTHER SOURCE (OS): CA 120:3013

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..8433	/organism="Gallid herpesvirus 1" /strain="GA" /db-xref="taxon:10386"
gene	complement(<3..305)	/gene="UL50"
CDS	complement(<3..305)	/gene="UL50" /function="possible UTPase" /note="UL50h; MDV homologue of UL50 of HSV-1; putative" /codon-start=1 /protein-id="AAA03146.1" /db-xref="GI:388704" /translation="MNVHESHPRRDRDLENITLE ALTVPWRLQFRVDEALYAVNPNGW TCYIEERDQRCLRVTNNCVISLLKSDLKRKYQTC TLNIGIRVAVPQNYVVILAKLTD"
gene	285..572	/gene="UL49.5"
CDS	285..572	/gene="UL49.5" /note="hydrophobic protein; UL49.5h; MDV homologue of UL49.5 of HSV-1" /codon-start=1 /protein-id="AAA03147.1" /db-xref="GI:388705" /translation="MGLMDIHNAVCSLVIGVAIL IATSQATFVDWGSSITSMGDFWES TCSAVGVSIAFSSGFSVLFYMGLVAVISALLAGS YHACFRLFTADMFKEEW"
CAAT-signal	628..634	
gene	718..1467	/gene="UL49"
CDS	718..1467	/gene="UL49" /note="UL49h; MDV homologue of UL49 of HSV-1 (VP22)" /codon-start=1 /protein-id="AAA03148.1" /db-xref="GI:388706" /translation="MGDSERRKSERRRSLGYPSA YDDVSIPARRPSTRTQRNLNQDDL SKHGPFTDHPTQKHKSAKAVSEDVSSTTRGGFTN KPRTKPGVRAVQSNKFAFSTAPSS ASSTWRSNTVAFNQRMFCGAVATVAQYHAYQGAL ALWRQDPPRTNEELDAFLSRAVIK ITIQEGPNLMGEAETCARKLLEESGLSQGNENVK SKSERTTKSERTRRGGEIEIKSPD PGSHRTHNPRTPATSRRHHSSARGYRSSDSE"
gene	1575..2858	/gene="UL48"
CDS	1575..2858	/gene="UL48" /note="UL48h; MDV homologue of UL48 of HSV-1 (VP16)" /codon-start=1 /protein-id="AAA03149.1" /db-xref="GI:388707" /translation="MEANMSFENDYYSPIQLFAE IEAYANTMDKSPDLDILRTIEEFD ETLLSEIEVRTQSIPSPLVAPSVTKMSLPSPSPA PPNSLYTRLLHELDFVEGPSILAR LEKINVDLFSCFPHNKHLYEHAKILSVSPSEVLE

```
                                     ELSKNTWTYTALNLNEHGEMALPM
                                     PPTTKADLPSYVDDIQNFYLGELEAREKSYATMF
                                     YGYCRALAEYIRQSAIKDLRDARV
                                     EDKNIGACSKARQYIAERYYREAARFAKLLYVHL
                                     YLSTTRDVSQRLEASQMGRQNIFV
                                     YLKCEWLQERHFHCLFQPVIFNHGVVIVEGRVLT
                                     APELRAQNYIRSEFGLPLIRCKLV
                                     EEPDMPLISPPPFSGDAPRASVYLLQCIRSKLEV
                                     YSLSHPPNPQLHVHKEHVHVQKLE
                                     SPPNYGTTVEALLMDSSDRNSISPGDPVATTIST
                                     L"
polyA-signal     2941..2946          /note="terminator for UL49.5h,
                                     UL49h, and UL48h (2.5 kb
                                     transcript)"
terminator       2970..2976
gene             3097..5523          /gene="UL47"
CDS              3097..5523          /gene="UL47"
                                     /note="UL47h; MDV homologue of
                                     UL47 of HSV-1 (VP13/14)"
                                     /codon-start=1
                                     /protein-id="AAA03150.1"
                                     /db-xref="GI:388708"
                                     /translation="MQMPSMHRYGHPGQNQRREN
                                     QSIRNYLSTRSGSRNRISRSPHNM
                                     ASVYTRAPAIAYDDDTYDTLEESEDNGFVKTIPN
                                     EEQFDNSRGRDRTRSGRSNGHSFL
                                     GYLRDTFTERQPSGRRGSDTSRDMINASLKSRAR
                                     SRRRSSSRRRHRNASMHMHFRGGS
                                     RRSATGSQNLINHDRHRRISQSSLGSSREGEYNH
                                     ASRSSRVRRRHRRSSRRRGPRAGG
                                     HGDSFTSITPSGSAEHPISDIDQKRLRKNSDTSS
                                     RGTRESPIDDSFGEDNYRLVSRNR
                                     ATSIYTTPSALYTRTESLKTYKRTTGDSKGTSPA
                                     LASFLEHKTLSADVINHIPLLRML
                                     ESVPRSEAIREDELLYMSAKTFKYVSHWYSNSRP
                                     DYANGKMYTSPPPENALAWKRTAK
                                     QAHALILHLGRDSLRSSVMSLRELNQSNAVLFLL
                                     NSCLKIAICIHKNKMHKYGNVKIL
                                     STMPHVRKGDAQIFENSTIHTMRDPMASAARASY
                                     GSLAYWPELRCALGSENKRIVRYA
                                     IVAMLQAEIYLLTRISSQRVSMNKSELRILSSCI
                                     TMECVAACIAVQFLYTSLWQILYS
                                     SKINREYIWLKTASERSKKLPMASTDLLYAEGAC
                                     LGRLESSLYGTEGTPLGRTLVEAY
                                     LATRSAFTELIYEFQSNSDLFLEKQNVKLGEKLT
                                     AAVIAATVVLQRLLGHLNIIIAQM
                                     VIGSVYHKKDVDVWSETFKMYQYLSYVCKSLYRP
                                     VTIDEYINDRDDTMEYLTLEFARG
                                     DPPTGMASVIYEDEKSEELESLKLVPPPINYDIL
                                     GNLVPLRNAIEDASDVIFEKRAVE
                                     TARREPQRAN"
gene             5665..7371          /gene="UL46"
CDS              5665..7371          /gene="UL46"
                                     /note="UL46h; MDV homologue of
                                     UL46 of HSV-1'"
                                     /codon-start=1
                                     /protein-id="AAA03151.1"
                                     /db-xref="GI:388709"
                                     /translation="MKRLSSSEQSLELFDRDSPQ
                                     EYSCILPNELTVSASALRALEDSL
                                     IEKLPSGLTLGIRESVLCETLSNKVPESVIVHLA
                                     LGDVRGEYISLYSANVKRRLKRAA
                                     LTPAVVKDYYTDSYQRYVCKRRRIPCVDLPGTRE
                                     PARSTVALLFYPAIQRNPLTQKPF
                                     RLQKDNKMFVKCWAEIWDALNFIQKYVYYMRPDE
                                     ITTPSLDTSARLELLFGYVKTLYM
                                     WAMWLMDLLDTRIVSNKFGTRVPISIDNIFSNLT
                                     EVMGSLSSDKWMSTALLCRSIEHL
                                     LSSLIHISSLWTCCQWRETKHGEMLRPIVSIVAL
                                     VSLLHHHCQYIINITFNGYARWLE
                                     GGLGNPMLRSAIRQQKRFEHYLGGLFPSIRPTAW
                                     GELEFSIRAWFELALAKSMVIHGS
                                     LLKKSIVSNNVLEPLCKPRHTQIGERHDTRFTRS
                                     TSMPSSSGHIHSTLQNNQQAIVPE
                                     CSSGQLSSIATALWSADELQNDYVEMKGGVLCPA
                                     PQPADSITPNSSQTNNGTASDGSP
```

```
                                        TRVTDASLDPTEVESSTTVAETPPVTVAVESVYV
                                        CRETARNKSPSSKVERILRRLRVA TD"
polyA-signal    7465..7470              /note="terminator for UL49.5h,
                                        UL49h, UL48h, UL47h, and UL46h
                                        (7.8, 4.6, and 2.0 kb
                                        transcpirts)"
polyA-signal    complement(7491..7496)  /note="terminator for UL45h"
terminator      7500..7507
gene            complement(7504..8139)  /gene="UL45"
CDS             complement(7504..8139)  /gene="UL45"
                                        /note="UL45h; MDV homologue of
                                        UL45 of HSV-1"
                                        /codon-start=1
                                        /protein-id="AAA03152.1"
                                        /db-xref="GI:388710"
                                        /translation="MMSPTPEDDRDLVVVRGRLR
                                        MMDNGAEHDRERRSYTAWPHLCCG
                                        CTIGIILTMFVIATTLLLASLFAFSYMSLESGTC
                                        PKEWIGLGYSCMRVAGNNATELEA
                                        LDMCAQHNSKLVDFTNAKTLVEAIVPFGSTNASF
                                        GNIFRLRDSRSTCILPTIGGPISV
                                        DCPRTCSVVCQRPRPLSTAASIIRDARIYLRLER
                                        RDYYEVYSSILSNAIMK"

SEQUENCE (SEQ):
     1 ggatccgtta actttgccaa aatgaccacg taattctgag gaacggcaac tcgtattccg
    61 atattcaatg tacacgtttg atatttgcgc tttaaatccg atttcagtaa cgagatcaca
   121 caattgttgg taacgcgaag acaacgctga tcacgctctt ctatataaca ggtccaaccg
   181 tttgggttta ctgcatataa cgcttcatcg acacggaatt gcagacgcca gggaactgtt
   241 agtgcttcca acgttatatt ctccaaatca cgatctcgac gaggatggga ctcatggaca
   301 ttcataatgc agtctgtagt ttagttatcg gcgttgctat tttgattgcc acttcgcaag
   361 cgacgtttgt cgattgggga agttcaatca caagtatggg agatttttgg gagtctacgt
   421 gttctgcagt aggcgtgtca atagcttttt catctgggtt ttctgtgctg ttttatatgg
   481 gtctggtggc ggtaatctcc gccctcttag cgggttcgta tcacgcatgc tttcgactat
   541 tcaccgcaga tatgtttaaa gaggagtggt aaattatgtg ggcgtggaca aatctcttat
   601 ctcttcataa gagatttgtt gactttgaac caatattcat atgttggaga cgccacacgg
   661 tacaatagaa ggtgcacttg ttcatatctt actgtttaat attatatctt agttatcatg
   721 ggggattctg aaaggcggaa atcggaacgg cgtcgttccc ttggatatcc ctctgcatat
   781 gatgacgtct cgattcctgc tcgcagacca tcaacacgta ctcagcgaaa tttaaaccag
   841 gatgatttgt caaaacatgg accatttacc gaccatccaa cacaaaaaca taaatcggcg
   901 aaagccgtat cggaagacgt ttcgtctacc acccggggtg gctttacaaa caaaccccgt
   961 accaagcccg gggtcagagc tgtacaaagt aataaattcg ctttcagtac ggctccttca
  1021 tcagcatcta gcacttggag atcaaataca gtggcattta atcagcgtat gttttgcgga
  1081 gcggttgcaa ctgtggctca atatcacgca taccaaggcg cgctcgccct ttggcgtcaa
  1141 gatcctccgc gaacaaatga agaattagat gcatttcttt ccagagctgt cattaaaatt
  1201 accattcaag agggtccaaa tttgatgggg gaagccgaaa cctgtgcccg caaactattg
  1261 gaagagtctg gattatccca ggggaacgag aacgtaaagt ccaaatctga acgtacaacc
  1321 aaatctgaac gtacaagacg cggcggtgaa attgaaatca aatcgccaga tccgggatct
  1381 catcgtacac ataaccctcg cactcccgca acttcgcgtc gccatcattc atccgcccgc
  1441 ggatatcgta gcagtgatag cgaataatgt aacataggaa cagccctact actgcaagta
  1501 agtcgtcttt tatagacatc cgaattaaaa actagtacat atatatctta tctactcatt
  1561 attgtatagt gtgaatggag gcaaatatga gttttgaaaa cgattactac agtcctatcc
  1621 aattattcgc tgaaattgag gcgtatgcga atactatgga taagtccccg gatcttgata
  1681 tcctacgaac aattgaagaa tttgatgaaa cgcttctctc tgaaattgaa gtcagaaccc
  1741 aatctattcc atcgcctctg gttgctccgt ctgttactaa aatgtcactt ccatccccat
  1801 ctccagctcc tcccaattct ctctacacta gactgttgca tgagttggat tttgtcgaag
  1861 gcccgtctat attagcacgt ctggaaaaaa taaatgtaga tctattctca tgtttccctc
  1921 ataataaaca cttatatgaa catgcaaaaa ttttatctgt atctccttcg gaagtattgg
  1981 aagagttgtc gaagaataca tggacgtata cggctttaaa tttaaatgaa catggagaga
  2041 tggccctgcc catgcctccc acaacaaagg ccgatttacc ttcttatgta gacgacatac
  2101 aaaacttcta tttgggagaa ttagaagcaa gggagaaatc atatgctact atgttttatg
  2161 gatactgtcg tgctctggca gagtatatta gacagtcggc gattaaagat cttcgggacg
  2221 ctcgagtcga agataaaaat attggtgcgt gtagtaaagc acgacaatac atcgccgaaa
  2281 ggtattatcg agaagcggca aggtttgcga agctcttata tgtgcactta tacctttcta
  2341 ccacgcggga tgtatcacag cgactcgaag catctcaaat gggacgacaa aatatatttg
  2401 tatatttgaa atgcgaatgg ttacaagaaa gacactttca ttgtttattt caacctgtaa
  2461 tttttaacca tggcgtagtt attgtcgaag ggcgtgtttt gactgctcct gaactccggg
  2521 ctcagaatta tatacgttcc gagttcggtc ttcctctaat acgatgtaaa ttagtagaag
  2581 agcctgacat gccgttgatc tcgcccccac cgttttcagg tgatgctcct cgggcatcag
  2641 tatatttatt gcagtgtatt agatcaaagt tggaagtata ttctctatca cacccccta
  2701 acccgcaatt gcatgtgcat aaggaacatg tacatgttca aaagctagaa tcaccgccaa
  2761 actatggaac tactgtcgaa gcattgttga tggactcttc agacagaaat tcaatttccc
  2821 ctggtgatcc tgttgccact accatcagta ctttataagg aggtatttgt ctattagtat
  2881 gatggtgagt tggcagaacg aaactatact taaatgatat tatacgtaaa tgtgacgttt
  2941 aataaacgaa tttgtcgtat tcgctttgtc tttgtttctc acgtcccatc aatgatgtaa
  3001 tattattgat gcaattacac ttccgccgtt agatcaatac attataaaac ggcgtagttt
```

3061 tgataacagt atgctggtag cacattccac cgaagaatgc aaatgccttc tatgcatcgg
3121 tatggacatc ctggtcaaaa tcaacgacgg gaaaaccaat caatcagaaa ttacttgtcg
3181 actagaagtg gatcacgcaa tcgtatatcg cgaagtccgc ataatatggc gagtgtgtat
3241 acaagagcac cggcgattgc ctatgatgac gatacatacg atacgctaga ggagagcgag
3301 gataatgggt ttgtaaaaac cattcctaat gaggaacaat ttgacaattc acgggggcgg
3361 gaccgtacac gatctggcag aagcaatggg catagttttc taggttatct ccgagatact
3421 ttcactgaga ggcaaccttc gggtcgtcgc ggtagtgata catctcgtga tatgattaat
3481 gcatcattaa aatcgagagc gaggtctaga agacgctcgt catctagacg acgccatcgt
3541 aatgccagca tgcatatgca ttttcgtggg ggttccagac gatctgcaac gggttctcaa
3601 aatttgataa atcacgatag acatagaaga atatcccaat ctagtctagg atcgtctaga
3661 gaaggagaat ataatcatgc atcacgatca agccgtgtta gaaggcgcca ccgtaggtca
3721 tcacgaaggc gaggacctag ggccggtggt cacggagatt cttttacatc cattactccc
3781 agtggaagtg cagaacatcc aatatccgat atcgatcaaa aacggttacg aaaaaactca
3841 gatacatcgt ctcggggcac tcgtgaatcc cccatagatg atagttttgg agaagacaat
3901 taccgattag tttctcgcaa tagggccact tcaatttata caaccccctc tgctttatat
3961 actagaacag agtcgctaaa aacctataag cgtaccactg gtgatagtaa aggtacgagt
4021 ccggctttgg cctcctttct cgagcataaa acacttagcg cagatgtcat caaccacatt
4081 ccattattgc gaatgttaga atctgtgccc agatccgagg ctatacgtga agatgaatta
4141 ttgtatatgt ctgcaaaaac tttcaaatat gtgtcacatt ggtattccaa cagccggcca
4201 gattatgcca atgggaagat gtatacttcc cccccgcctg agaatgctct cgcttggaaa
4261 cggaccgcga aacaggccca tgctcttatt ctccatttag gcagagattc cttaagaagt
4321 tctgtaatgt cattgcgtga gttgaatcaa agcaatgcag ttttattttt acttaattcc
4381 tgtttaaaaa tagcaatttg tatacataaa aataaaatgc ataaatatgg aaatgtaaaa
4441 atattatcca caatgccaca cgttcggaaa ggtgatgctc aaatattcga aaatagtact
4501 atacatacaa tgcgagaccc tatggcttcg gctgcacgag cttcctatgg atcgcttgcg
4561 tattggccag agcttcgctg tgcattaggg tctgagaaca aacgaattgt acgatatgcc
4621 attgtggcta tgttgcaagc agaaatatat ctacttacaa ggatctcttc ccaaagagtg
4681 tcaatgaata agagtgaact tagaatttta tcctcgtgca ttacgatgga atgtgtggca
4741 gcatgtatag ctgtgcaatt tctatacact tccttatggc aaatacttta cagttctaaa
4801 atcaatcgtg aatacatatg gctgaaaact gccagcgaga gaagtaaaaa gttaccaatg
4861 gcaagtacgg atctccttta tgcagagggg gcctgccttg ggaggttaga gtcatctctg
4921 tatggtacag agggtacacc tctagggaga acacttgtag aagcgtatct tgccacaaga
4981 tctgcattta cggagttaat atatgagttt caatcaaaca gtgatttatt tctagagaag
5041 cagaatgtca agctgggaga aaaattaacc gctgccgtga ttgctgcaac tgttgtctta
5101 cagcgtttgc tcggccattt aaatatcatt atcgcgcaga tggttattgg atctgtatat
5161 cacaaaaaag acgtggatgt ttggtcagag acattcaaga tgtatcaata tctatcgtat
5221 gtctgtaaaa gtttatatag accagtgacc attgatgaat acataaatga ccgtgatgat
5281 actatggagt atttaacact tgaatttgca cgaggcgatc cacctactgg catggcatca
5341 gtgatttatg aagatgaaaa aagtgaagaa ctagaatctt tgaaacttgt acccccgccg
5401 attaattatg acattctagg taatttagtt cctttacgga atgcgataga agatgcgagt
5461 gatgtgatat tcgagaaaag agccgtcgaa accgcccgcc gtgagccaca acgggcgaat
5521 tgacgtaggg aagagggcgg gacttttact ccggatgtag aataatggca tttaagagtg
5581 gtacatgttt aaaaccggga ctcttgcagc atcctgtact atatttcagt tttctctgta
5641 gtgtgtccat ccatatgggt tataatgaag cggctcagct cttctgaaca gtcgttggaa
5701 ctgtttgacc gagattcgcc acaagaatat tcatgtatat tacccaacga attaactgta
5761 tctgcgtctg cattaagagc tcttgaggac agccttatag agaagttgcc atccgggttg
5821 acattgggta taagggaatc ggtattgtgt gaaactcttt ccaataaggt tccagaatct
5881 gttattgttc atcttgcgtt gggagatgtt agaggagagt atatatccct atacagcgca
5941 aatgtgaaac gcagattgaa acgggcggcg ttgacacctg cggtggtaaa agactactac
6001 acagactcgt atcagcgcta tgtctgtaag cggcggcgta taccttgtgt tgatctcccg
6061 ggaactcgtg aacctgccag atccaccgtt gcgttgctat tttatccagc tatacaacga
6121 aatcccttaa cacaaaaacc atttcggctt caaaaagata acaaaatgtt cgtcaaatgc
6181 tgggcggaaa tatgggatgc gttaaatttt attcagaagt atgtgtatta tatgagacct
6241 gacgaaataa caacacctag tctcgatact tccgctcgac tggagttgtt atttggttat
6301 gtgaagacac tgtacatgtg ggcaatgtgg ttaatggact tgctagatac gcgaattgtt
6361 tctaacaaat tcggcacccg cgtacctatc agcattgata atatattttc aaatcttact
6421 gaggttatgg gttcgttatc gtcagataag tggatgagca ctgcattgct ctgtcgctcc
6481 atagaacacc ttttgtcttc acttatccat attagttctc tgtggacatg ttgtcaatgg
6541 cgcgaaacca aacatggaga aatgttgcgt cctatagtta gcattgtcgc gttggtttct
6601 ctcttgcacc atcactgtca atatattatc aatattactt ttaatggata tgcaagatgg
6661 ttggaggggg gtttgggtaa tcctatgtta agatcggcaa ttcgacaaca aaaacggttt
6721 gaacattatt tgggaggact tttcccatcc attcgcccca cggcatgggg agaacttgaa
6781 tttagcatca gagcatggtt tgaacttgca ttagccaagt caatggtaat tcacggctct
6841 ttactcaaaa agtccattgt gagcaataat gtccttgaac ctttatgtaa accaaggcat
6901 actcaaattg gagaaaggca tgatacgagg tttacacgat ctaccagcat gccgtcttct
6961 tcgggacata tacacagtac attacagaat aatcaacaag cgattgttcc tgagtgttct
7021 tcgggacaac tatcttcaat cgctaccgct ttgtggtcag cggacgaact ccaaaacgat
7081 tacgtggaaa tgaaaggtgg agttttatgt ccagccccac agccagctga ctcgatcact
7141 ccaaattcca gtcaaacaaa taatgggaca gcttcagacg gttctccaac gagagtgacc
7201 gatgcgtccc tcgatccaac cgaagttgaa tcatcaacta cagtagctga gacaccgcct
7261 gttacagttg ccgtcgaatc ggtatatgta tgcagagaaa ccgcacgaaa caaatctcca
7321 tcatccaaag tggaacgaat attgcgtagg ttgagggtgg ctaccgattg atactatgtt
7381 caaacatata tgtttttatc tttagcgtaa cgatttgtcc caaacatgta tacccttca
7441 cctttcatgc tcgattatta aagaaataaa gaaccgcttt aagaatagtg tttatttttg
7501 tgtttatttc ataattgcgt tcgagagaat ggaactgtaa acttcgtagt aatcgcgtcg
7561 ttctaaacga agatagatac gagcatctct gattatagaa gccgcggtac ttaatggtcg

```
  7621 ggggcgttgg catacaacgc tgcatgtcct tggacaatcg accgatatag gacctccaat
  7681 ggtgggtagt atacaggtag atctactgtc ccgtagtcta aatatatttc caaaggaagc
  7741 attcgtggag ccgaatggga caattgcttc aaccaatgtt tttgcgttag taaaatctac
  7801 gagtttactg ttatgctggg cacacatatc taatgcctcg agttctgtag cattgtttcc
  7861 agccacgcgc atgcaactgt accctaatcc aatccattcc ttagggcatg ttcccgactc
  7921 tagagacatg tacgagaatg caaacaatga tgctaataat aacgttgtcg cgatgacgaa
  7981 catagttaag ataattccga tggtacatcc acaacacaaa tggggccatg cggtgtatga
  8041 tcgccgttct cgatcatgtt cggcaccgtt atccatcatt cggagacgtc cacgtactac
  8101 cactaaatcg cgatcgtcct cgggtgtagg cgacatcatt cttatacgat catgtctatg
  8161 gagtacattc gtggttatat ttctgagtaa ctatatacga tcatatttag cgattgtacg
  8221 gtatgcatgt tcgtattcga tttgtaaaat tgttatcgac gtatttgtcg gtgggggcgc
  8281 gatccgtgca actcttttgt cataggttgg gaaactttcg atacttattt tttccatatg
  8341 acccgtaagt ctaatgcact atatcgaaag gtactgatag agtgtggctg gatgcaatga
  8401 caaaactaat attcatagaa acgatatgaa ttc
```

L3 ANSWER 133 OF 199 GENBANK.RTM. COPYRIGHT 2004 on STN

```
LOCUS (LOC):              ADECP     GenBank (R)
GenBank ACC. NO. (GBN): M81775 M81776 M81777
GenBank VERSION (VER):  M81775.1  GI:209738
CAS REGISTRY NO. (RN):  140600-01-7
SEQUENCE LENGTH (SQL):  1096
MOLECULE TYPE (CI):       ss; RNA; linear
DIVISION CODE (CI):       Viruses
DATE (DATE):              27 Apr 1993
DEFINITION (DEF):         Andean potato mottle virus coat protein (  ***VP22***
                          ) mRNA, 3' end.
SOURCE:                   Andean potato mottle virus cDNA to genomic RNA.
 ORGANISM (ORGN):         Andean potato mottle virus
                          Viruses; ssRNA positive-strand viruses, no DNA stage;
                          Comoviridae; Comovirus
NUCLEIC ACID COUNT (NA): 304 a   161 c   240 g   391 t
REFERENCE:                1  (bases 1 to 1096)
   AUTHOR (AU):           Shindo,N.; Krengiel,R.; Brioso,P.S.; Vicente,A.C.;
                          Weyne,M.; de Oliveira,D.E.; Timmerman,B.
   TITLE (TI):            Complete nucleotide sequence of the 22 kDa coat protein
                          of Andean potato mottle virus
   JOURNAL (SO):          Plant Mol. Biol., 19 (3), 505-507 (  ***1992***  )
   OTHER SOURCE (OS):     CA 118:249964
```

FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..1096	/organism="Andean potato mottle virus" /db-xref="taxon:12259"
gene	1..594	/gene="VP22"
CDS	1..594	/partial /gene="VP22" /codon-start=1 /product="coat protein" /protein-id="AAA42420.1" /db-xref="GI:209739" /translation="FCSPCINVWSEFCALDIPVV DTTKVNFAQYSLDLVNPTVSANAS GRNWRFVLIPSPMVYLLQTSDWKRGKLHFKLKIL GKSNVKRSEWSSTSRIDVRRAPGT EYLNAITVFTAEPHADEINFEIEICGPNNGFEMW NADFGNQLSWMANVVIGNPDQAGI HQWYVRPGENFEVAGNRMVQPLALSGEDGTGMLP ILK"

SEQUENCE (SEQ):

```
     1 ttttgtagtc catgtataaa tgtttggagt gagttttgtg cattagatat tcctgttgtg
    61 gacacaacta aggttaattt tgcccaatat tctctggatc ttgtgaatcc aacagtttct
   121 gcaaatgcct ctgggcgtaa ttggaggttt gttcttatac cttctcccat ggtgtattta
   181 cttcaaactt cagactggaa aagaggaaag ttgcatttta agcttaaaat actggggaaa
   241 tccaatgtta aacgatctga atggagtagc acaagcagga tagatgtgag aagagcacct
   301 ggtacagagt atttaaatgc tatcactgtt ttcactgctg agccacatgc agatgagata
   361 aattttgaaa tagaaatttg tgggccaaac aacggatttg agatgtggaa tgctgatttt
   421 ggaaaccaat tgtcttggat ggcaaatgtt gttattggaa atcctgatca agcgggtata
   481 catcaatggt atgttaggcc aggagaaaat tttgaggttg caggaaatag gatggttcaa
   541 cctctagcgc tttctgggga ggatggtact ggtatgcttc caatactaaa gtagccaata
   601 aatttggatt tgtgcgtgtt ccttctgaga aacgctctgg tgtgcattca ccacctagga
   661 gctaggactc tgggttttaa tgcaaattgt tttaattttg ttatttaaat ggtttgcttt
   721 aatttaagta gtcgtaatcg tttatctgga attttaacaa gtttttacgt tactgagctt
```

```
   781 ctgcccttgt aagaacactt gtgtaaattt gtagtttata aactctagtt tgtatttctg
   841 gatttgtgcg tgttccttct gagaaacgct ctggtgtgca ttcaccacct aggaggtagg
   901 actctgggtt tcaatgcaaa ctgtttttaa ttttgttact taaatagttt gctttagttc
   961 aagtaattat gatcgtttat ttggaatttc ataagttctt gcgtttctga gcttctgccc
  1021 ttgtaagaac acttgtgtaa atttgtagtt tacaaacttt ggtttgcatt tgtgttttaa
  1081 aaaaaaaaaa aaaaaa
```

L3 ANSWER 134 OF 199 LIFESCI COPYRIGHT 2004 CSA on STN
AN 2000:9036 LIFESCI
TI Protein therapy - delivery guaranteed
AU Bayley, H.
CS Department of medical biochemistry and genetics at the Texas A&M Health Science Center, College Station, TX 77843-1114, USA; E-mail: bayley@tamu.edu
SO Nature Biotechnology [Nat. Biotechnol.], (***19991100***) vol. 17, no. 11, pp. 1066-1067.
ISSN: 1087-0156.
DT Journal
TC General Review
FS W3
LA English

L3 ANSWER 135 OF 199 LIFESCI COPYRIGHT 2004 CSA on STN
AN 1998:92608 LIFESCI
TI Herpes simplex virus type 1 tegument protein ***VP22*** induces the stabilization and hyperacetylation of microtubules
AU Elliott, G.; O'Hare, P.
CS Marie Curie Research Institute, The Chart, Oxted, Surrey RH8 OTL, United Kingdom.
SO J. Virol., (***19980800***) vol. 72, no. 8, pp. 6406-6413.
ISSN: 0022-538X.
DT Journal
FS V
LA English
SL English

L3 ANSWER 136 OF 199 MEDLINE on STN
AN 2000008734 MEDLINE
DN PubMed ID: 10543389
TI Can ***VP22*** resurrect gene therapy?.
CM Comment on: J Mol Med. 1999 Aug;77(8):609-13. PubMed ID: 10543392
AU Luft F C
CS Franz-Volhard-Klinik, Humboldt University of Berlin, Berlin-Buch, Germany.. luft@fvk-berlin.de
SO Journal of molecular medicine (Berlin, Germany), ***(1999 Aug)*** 77 (8) 575-6.
Journal code: 9504370. ISSN: 0946-2716.
CY GERMANY: Germany, Federal Republic of
DT Commentary
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199911
ED Entered STN: 20000111
Last Updated on STN: 20000111
Entered Medline: 19991118

L3 ANSWER 137 OF 199 MEDLINE on STN
AN 97414190 MEDLINE
DN PubMed ID: 9269047
TI Study of immunogenicity and virulence of bovine herpesvirus 1 mutants deficient in the UL49 homolog, UL49.5 homolog and dUTPase genes in cattle.
AU Liang X; Chow B; Babiuk L A
CS Veterinary Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada.
SO Vaccine, ***(1997 Jul)*** 15 (10) 1057-64.
Journal code: 8406899. ISSN: 0264-410X.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199710
ED Entered STN: 19971105
Last Updated on STN: 20020926
Entered Medline: 19971020

L3 ANSWER 138 OF 199 MEDLINE on STN
AN 95264482 MEDLINE
DN PubMed ID: 7745736
TI Characterization of bovine herpesvirus 1 UL49 homolog gene and product: bovine herpesvirus 1 UL49 homolog is dispensable for virus growth.
AU Liang X; Chow B; Li Y; Raggo C; Yoo D; Attah-Poku S; Babiuk L A
CS Veterinary Infectious Diseases Organization, University of Saskatchewan, Saskatoon, Canada.
SO Journal of virology, ***(1995 Jun)*** 69 (6) 3863-7.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-U21137
EM 199506
ED Entered STN: 19950621
Last Updated on STN: 19950621
Entered Medline: 19950613

L3 ANSWER 139 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1646911 PHARMAML
TI Cantab making"significant progress"
SO Marketletter May 20, 1999
DT Newsletter
WC 221

L3 ANSWER 140 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1644751 PHARMAML
TI Cantab On Track To Being A Fully Integrated Company
SO Marketletter December 3, 1998
DT Newsletter
WC 1651

L3 ANSWER 141 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1644315 PHARMAML
TI UK Biotech Firms Back In Vogue With Investors?
SO Marketletter November 5, 1998
DT Newsletter
WC 1448

L3 ANSWER 142 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1641854 PHARMAML
TI Cantab Reports Solid Progress During 1st Qtr
SO Marketletter May 28, 1998
DT Newsletter
WC 237

L3 ANSWER 143 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1641682 PHARMAML
TI Stock Commentary Europe
SO Marketletter May 14, 1998
DT Newsletter
WC 337

L3 ANSWER 144 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1641505 PHARMAML
TI Phogen Signs First Commercial Deal
SO Marketletter April 30, 1998
DT Newsletter
WC 59

L3 ANSWER 145 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1636166 PHARMAML
TI Cantab And Marie Curie Cancer Care Form New Biotech Company; Cantab Shares
SO Marketletter March 10, 1997
DT Newsletter
WC 55

L3 ANSWER 146 OF 199 PHARMAML COPYRIGHT 2004 MARKETLETTER on STN
AN 1635838 PHARMAML
TI New Discovery At Marie Curie Research Institute
SO Marketletter February 10, 1997
DT Newsletter
WC 57

L3 ANSWER 147 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1999:19715 PHIN
DN S00644158
DED 17 Nov 1999
TI Cantab ahead of budget at nine months
SO Scrip (***1999***) No. 2490 p15
DT Newsletter
FS FULL

L3 ANSWER 148 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1999:9623 PHIN
DN S00623580
DED 26 May 1999
TI Phogen joint venture to receive more funding
SO Scrip (***1999***) No. 2440 p14
DT Newsletter
FS FULL

L3 ANSWER 149 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1999:2652 PHIN
DN S00609030
DED 22 Jan 1999
TI New gene therapy techniques
SO Scrip (***1999***) No. 2405 p22
DT Newsletter
FS FULL

L3 ANSWER 150 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:15871 PHIN
DN B00592838
DED 1 Jul 1998
TI ReqMed Co.: Japanese Entrepreneurial Spirit Takes a First Step
SO Bioventure-View (***1998***) No. 1307 p18
DT Newsletter
FS FULL

L3 ANSWER 151 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:11262 PHIN
DN B00583792
DED 1 Jun 1998
TI Research and Clinical Progress: Phogen Ltd
SO Bioventure-View (***1998***) No. 1406 p30
DT Newsletter
FS FULL

L3 ANSWER 152 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:9688 PHIN
DN S00580586
DED 15 May 1998
TI Cantab's ***VP22*** shows early promise
SO Scrip (***1998***) No. 2335 p29
DT Newsletter
FS FULL

L3 ANSWER 153 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:13839 PHIN
DN B00546118
DED 1 Jul 1997
TI Biotech's Transatlantic Challenge BVV's Eurotour Continues
SO Bioventure-View (***1997***) No. 1207 p4
DT Newsletter
FS FULL

L3 ANSWER 154 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:8845 PHIN
DN B00535906
DED 1 Apr 1997

TI Agreements - Cantab Pharmaceuticals
SO Bioventure-View (***1997***) No. 1204 p18
DT Newsletter
FS BRIEF

L3 ANSWER 155 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:8623 PHIN
DN S00536364
DED 9 May 1997
TI PHARMAPROJECTS - New Formulations for week ending 2 May 1997
SO Scrip-Online-plus (***1997***)
DT Newsletter
FS FULL

L3 ANSWER 156 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:5606 PHIN
DN S00528886
DED 11 Mar 1997
TI Cantab Pharmaceuticals teams up with UK cancer charity
SO Scrip (***1997***) No. 2213 p10
DT Newsletter
FS FULL

L3 ANSWER 157 OF 199 PHIN COPYRIGHT 2004 PJB on STN

AN 97:3906 PHIN
DN S00526786
DED 25 Feb 1997
TI Gene therapy update
SO Scrip (***1997***) No. 2209 p23
DT Newsletter
FS FULL

L3 ANSWER 158 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:732888 PROMT
TITLE: Cantab Reports Third Quarter Financial Results Ahead of Budget.
SOURCE: PR Newswire, (***10 Nov 1999***) pp. 1097.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1841
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 159 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:399865 PROMT
TITLE: Enhancement of Mucosal Immune Responses to HIV Gp160.
SOURCE: Vaccine Weekly, (***14 Jun 1999***) .
ISSN: 1074-2921.
PUBLISHER: Charles W. Henderson
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 417
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 160 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:340020 PROMT
TITLE: Cantab making"significant progress".
SOURCE: Marketletter, (***24 May 1999***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 228
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 161 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:331352 PROMT
TITLE: Phogen Receives Extended Funding to Continue Drug Delivery Program.

SOURCE: PR Newswire, (***20 May 1999***) pp. 4072.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 936
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 162 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:331351 PROMT
TITLE: Cantab Pharmaceuticals Reports First Quarter Financial Results and Significant Progress in Key Development Programs.
SOURCE: PR Newswire, (***20 May 1999***) pp. 4071.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1541
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 163 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:141589 PROMT
TITLE: Cantab Reports 1998 Fourth Quarter and Year End Financial Results and Corporate Review of Progress.
SOURCE: PR Newswire, (***9 Mar 1999***) pp. 1400.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1986
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 164 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:633293 PROMT
TITLE: Cantab On Track To Being A Fully Integrated Company.
SOURCE: Marketletter, (***7 Dec 1998***) pp. NA.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 1655
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 165 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:591203 PROMT
TITLE: Cantab Reports Third Quarter Financial Results - Company makes progress in key clinical programs -.
SOURCE: PR Newswire, (***12 Nov 1998***) pp. 1402.
LANGUAGE: English
WORD COUNT: 1591
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 166 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:577595 PROMT
TITLE: UK Biotech Firms Back In Vogue With Investors?
SOURCE: Marketletter, (***9 Nov 1998***) pp. NA.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 1444
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 167 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:497629 PROMT
TITLE: Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Herpes Lesions.
SOURCE: Vaccine Weekly, (***21 Sep 1998***) pp. NA.
ISSN: 1074-2921.
LANGUAGE: English
WORD COUNT: 289
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 168 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:451675 PROMT
TITLE: Joined for strength
SOURCE: Med Ad News, (***Aug 1998***) pp. 26.
ISSN: 0745-0907.
LANGUAGE: English
WORD COUNT: 3198
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 169 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:382725 PROMT
TITLE: New Faces, New Names
SOURCE: BioPharm, (***Jul 1998***) pp. 10.
ISSN: 1040-8304.
LANGUAGE: English
WORD COUNT: 154
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 170 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:295529 PROMT
TITLE: Delivering p53 with Herpesvirus Protein
SOURCE: Applied Genetics News, (***1 Jun 1998***) pp. N/A.
ISSN: 0271-7107.
LANGUAGE: English
WORD COUNT: 334
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 171 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:264243 PROMT
TITLE: drug delivery system, ***VP22*** herpesvirus protein
Phogen preclinical data
Preclinical results of Phogen's treatment reported
SOURCE: R & D Focus Drug News, (***25 May 1998***) pp. N/A.
ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 196
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 172 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:262791 PROMT
TITLE: Cantab Reports Solid Progress During 1st Qtr
SOURCE: Marketletter, (***1 Jun 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 248
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 173 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:237169 PROMT
TITLE: Stock Commentary Europe
SOURCE: Marketletter, (***18 May 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 337
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 174 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:237110 PROMT
TITLE: Phogen Signs First Commercial Deal
SOURCE: Marketletter, (***4 May 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 59
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 175 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:208184 PROMT
TITLE: Phogen and Invitrogen Collaborate to Market ***VP22***
Reagents
SOURCE: PR Newswire, (***27 Apr 1998***) pp. 0427NYM008.

LANGUAGE: English
WORD COUNT: 806
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 176 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:175690 PROMT
TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :Cantab-Reports Year-End Results - A Year Of Solid Progress
SOURCE: BioAccess, (***1 Apr 1998***) pp. N/A.
ISSN: 1356-3432.
LANGUAGE: English
WORD COUNT: 681
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 177 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1998:109999 PROMT
TITLE: Cantab Pharmaceuticals Reports Year-End Results; Company Turns in a Year of Solid Progress Across All Business Areas
SOURCE: PR Newswire, (***2 Mar 1998***) pp. 0302NYM022.
LANGUAGE: English
WORD COUNT: 1474
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 178 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:496714 PROMT
TITLE: Biotech's Transatlantic Challenge (PART 1)
SOURCE: BioVenture View, (***1 Aug 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 2338
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 179 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:355215 PROMT
TITLE: Biotech's Transatlantic Challenge --BVV's Eurotour Continues-Part 1
SOURCE: BioVenture View, (***1 Jul 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 4781
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 180 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:198204 PROMT
TITLE: Phogen JV expores potential of herpesvirus drug delivery. This biotech co formed to develop new drug delivery means using ***VP22*** herpesvirus protein tech
SOURCE: Genetic Engineering News, (***15 Mar 1997***) pp. 4.
ISSN: 0270-6377.
LANGUAGE: English

L3 ANSWER 181 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:190488 PROMT
TITLE: Corporate Agreements:Cantab Pharmaceuticals plc
SOURCE: BioVenture View, (***1 Apr 1997***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 153
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 182 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:166243 PROMT
TITLE: Cantab Pharmaceuticals Reports Fourth Quarter Results
SOURCE: PR Newswire, (***19 Mar 1997***) pp. 0319NYW026.
LANGUAGE: English
WORD COUNT: 1474
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 183 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:158009 PROMT
TITLE: Cantab joins forces with MCCC to form biotech company
SOURCE: Pharmaceutical Business News, (***12 Mar 1997***) pp. N/A.
ISSN: 0956-0661.
LANGUAGE: English
WORD COUNT: 511
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 184 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:147009 PROMT
TITLE: Industry News (Joint Venture) New Company To Develop Drug Delivery Technology Against Disease
SOURCE: Disease Weekly Plus, (***10 Mar 1997***) pp. N/A.
LANGUAGE: English
WORD COUNT: 617
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 185 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:135685 PROMT
TITLE: Industry News (Joint Venture) New Company To Develop Drug Delivery Technology Against Disease
SOURCE: Cancer Weekly Plus, (***10 Mar 1997***) pp. N/A.
LANGUAGE: English
WORD COUNT: 617
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 186 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:122260 PROMT
TITLE: Cantab Pharmaceuticals and Marie Curie Cancer Care Form New Biotechnology Company to Develop Drug Delivery Technology
SOURCE: PR Newswire, (***27 Feb 1997***) pp. 0227NYTH010.
LANGUAGE: English
WORD COUNT: 989
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 187 OF 199 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 97:75700 PROMT
TITLE: New Discovery At Marie Curie Research Institute
SOURCE: Marketletter, (***10 Feb 1997***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 56
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 188 OF 199 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:763858 SCISEARCH
GA The Genuine Article (R) Number: 226QX
TI Preliminary structural characterization of ***VP22*** , a protein expressing novel intercellular trafficking activity
AU Kueltzo L (Reprint); OHare P; Middaugh C R
CS UNIV KANSAS, DEPT PHARMACEUT CHEM, LAWRENCE, KS 66047; MARIE CURIE RES INST, SURREY RH8 0TL, ENGLAND
CYA USA; ENGLAND
SO FASEB JOURNAL, (***23 APR 1999***) Vol. 13, No. 7, Supp. [S], pp. A1393-A1393.
Publisher: FEDERATION AMER SOC EXP BIOL, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998.
ISSN: 0892-6638.
DT Conference; Journal
FS LIFE
LA English
REC Reference Count: 0

L3 ANSWER 189 OF 199 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1999:137239 SCISEARCH
GA The Genuine Article (R) Number: 165CH
TI European drug news - In vivo potential for ***VP22*** in gene therapy shown

AU Fox S
SO GENETIC ENGINEERING NEWS, (***1 FEB 1999***) Vol. 19, No. 3, pp. 20-&.
    Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY
    10538.
    ISSN: 0270-6377.
DT Article; Journal
LA English
REC Reference Count: 0

L3 ANSWER 190 OF 199 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
    on STN
AN 1998:312179 SCISEARCH
GA The Genuine Article (R) Number: ZH354
TI C-type lectin-like receptors in peptide-specific HLA class I-restricted
    cytotoxic T lymphocytes: differential expression and modulation of
    effector functions in clones sharing identical TCR structure and epitope
    specificity
AU Noppen C (Reprint); Schaefer C; Zajac P; Schutz A; Kocher T; Kloth J;
    Heberer M; Colonna M; DeLibero G; Spagnoli G C
CS UNIV BASEL, DEPT SURG, DIV RES, HEBELSTR 20, CH-4031 BASEL, SWITZERLAND
    (Reprint); BASEL INST IMMUNOL, BASEL, SWITZERLAND; UNIV BASEL, DEPT RES,
    BASEL, SWITZERLAND
CYA SWITZERLAND
SO EUROPEAN JOURNAL OF IMMUNOLOGY, (***APR 1998***) Vol. 28, No. 4, pp.
    1134-1142.
    Publisher: VCH PUBLISHERS INC, 303 NW 12TH AVE, DEERFIELD BEACH, FL
    33442-1788.
    ISSN: 0014-2980.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 29
    ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 191 OF 199 USPATFULL on STN
AN 2004:129601 USPATFULL
TI Nucleic acid transfer phage
IN Akuta, Teruo, Kumamoto, JAPAN
    Yokoi, Haruhiko, Tokyo, JAPAN
    Okuyama, Hajime, Hyogo, JAPAN
    Takeda, Katsuo, late of Tokyo, JAPAN deceased
    Eiko Takeda, United States legal representative
    Hasegawa, Mamoru, Ibaraki, JAPAN
    Nakanishi, Mahito, Osaka, JAPAN
PA DNAVEC Research, Inc., JAPAN (non-U.S. corporation)
PI US 6740524 B1 20040525
    WO 9966061 19991223 <--
AI US 2001-720003 20010904 (9)
    WO 1999-JP3272 19990618
PRAI JP 1998-189845 19980618
DT Utility
FS GRANTED
LN.CNT 887
INCL INCLM: 435/456.000
    INCLS: 530/350.000; 435/320.100; 435/252.300; 435/252.330; 435/235.100;
    435/069.700; 435/975.000; 536/023.400
NCL NCLM: 435/456.000
    NCLS: 435/069.700; 435/235.100; 435/252.300; 435/252.330; 435/320.100;
    435/975.000; 530/350.000; 536/023.400
IC [7]
    ICM: C12N015-86
    ICS: C12N015-62; C12N001-21; C12N005-10; C07K019-00
EXF 530/350; 435/235.1; 435/320.1; 435/252.33; 435/456; 435/69.7; 435/975;
    536/23.4; 424/93.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 192 OF 199 USPATFULL on STN
AN 2003:228405 USPATFULL
TI Promoter for telomerase reverse transcriptase
IN Morin, Gregg B., Davis, CA, United States
    Andrews, William H., Richmond, CA, United States
PA Geron Corporation, Menlo Park, CA, United States (U.S. corporation)
PI US 6610839 B1 20030826
    WO 9814593 19980409 <--
AI US 1999-402181 19990929 (9)
    WO 1997-US17885 19971001

RLI Continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997
Continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997, now abandoned Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 10430
INCL INCLM: 536/024.100
INCLS: 435/194.000; 435/320.100
NCL NCLM: 536/024.100
NCLS: 435/194.000; 435/320.100
IC [7]
ICM: C07H021-04
ICS: C12N009-12; C12N015-00
EXF 435/194; 435/320.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 193 OF 199 USPATFULL on STN
AN 1998:59111 USPATFULL
TI Programming which can make threshold voltages of programmed memory cells have a narrow distribution in a nonvolatile semiconductor memory
IN Takeshima, Toshio, Tokyo, Japan
Sugawara, Hiroshi, Tokyo, Japan
PA NEC Corporation, Tokyo, Japan (non-U.S. corporation)
PI US 5757699 19980526 <--
AI US 1997-862965 19970603 (8)
PRAI JP 1996-140497 19960603
DT Utility
FS Granted
LN.CNT 817
INCL INCLM: 365/185.240
INCLS: 365/185.220; 365/185.190; 365/185.030
NCL NCLM: 365/185.240
NCLS: 365/185.030; 365/185.190; 365/185.220
IC [6]
ICM: G11C007-00
EXF 365/185.24; 365/185.21; 365/185.19; 365/185.03

L3 ANSWER 194 OF 199 USPATFULL on STN
AN 97:25432 USPATFULL
TI Display apparatus
IN Kawaguchi, Takafumi, Yamatotakada, Japan
Tomiyoshi, Akira, Nara, Japan
Takeda, Makoto, Nara, Japan
PA Sharp Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)
PI US 5614922 19970325 <--
AI US 1995-414717 19950331 (8)
PRAI JP 1994-66145 19940404
DT Utility
FS Granted
LN.CNT 1311
INCL INCLM: 345/089.000
INCLS: 345/094.000; 345/100.000
NCL NCLM: 345/089.000
NCLS: 345/094.000; 345/100.000
IC [6]
ICM: G09G003-36
EXF 345/87; 345/89; 345/94; 345/99; 345/100; 345/150; 345/208; 345/211; 359/55; 359/56

L3 ANSWER 195 OF 199 USPATFULL on STN
AN 94:29081 USPATFULL
TI Semiconductor IC device having sense amplifier circuit
IN Kawahara, Takayuki, Kokubunji, Japan
Akiba, Takesada, Kokubunji, Japan
Kitsukawa, Goro, Tokyo, Japan
Kawajiri, Yoshiki, Akishima, Japan
Itoh, Kiyoo, Higashikurume, Japan
Sakata, Takeshi, Kunitachi, Japan
PA Hitachi, Ltd., Tokyo, Japan (non-U.S. corporation)
Hitachi Device Engineering Co., Ltd., Mobara, Japan (non-U.S. corporation)
PI US 5300839 19940405 <--
AI US 1992-865852 19920409 (7)
PRAI JP 1991-82228 19910415
JP 1992-11727 19920127

DT Utility
FS Granted
LN.CNT 1031
INCL INCLM: 307/530.000
INCLS: 365/203.000
NCL NCLM: 327/052.000
NCLS: 365/203.000; 365/208.000
IC [5]
ICM: G11C007-06
EXF 307/247.1; 307/350; 307/530; 365/189.06; 365/203; 365/205; 365/208

L3 ANSWER 196 OF 199 USPATFULL on STN
AN 91:55132 USPATFULL
TI Image forming apparatus with AC bias voltages for preventing developer mixture
IN Tajima, Hatsuo, Matsudo, Japan
Kobayashi, Yoshiaki, Tokyo, Japan
PA Canon Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)
PI US 5030996 19910709 <--
AI US 1990-574893 19900830 (7)
PRAI JP 1989-223196 19890831
DT Utility
FS Granted
LN.CNT 758
INCL INCLM: 355/246.000
INCLS: 118/645.000; 355/326.000
NCL NCLM: 399/232.000
NCLS: 399/270.000
IC [5]
ICM: G03G021-00
EXF 355/246; 355/214; 355/326; 355/327; 355/328; 355/261; 355/265; 355/266; 118/645; 118/647; 118/651; 118/653; 346/157

L3 ANSWER 197 OF 199 USPATFULL on STN
AN 79:17060 USPATFULL
TI Two-color electrostatic printing apparatus
IN Yamauchi, Mineo, Musashino, Japan
Sumi, Akira, Musashino, Japan
PA Yokogawa Electric Works, Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 4148043 19790403 <--
AI US 1977-782095 19770328 (5)
PRAI JP 1976-35640 19760331
DT Utility
FS Granted
LN.CNT 853
INCL INCLM: 346/157.000
INCLS: 346/154.000
NCL NCLM: 347/115.000
NCLS: 347/142.000
IC [2]
ICM: G03G015-02
EXF 346/157; 346/153; 346/154; 355/14

L3 ANSWER 198 OF 199 USPATFULL on STN
AN 77:17043 USPATFULL
TI Process for polymerizing tetrafluoroethylene in aqueous dispersion
IN Holmes, David Alan, Vienna, WV, United States
PA E. I. Du Pont de Nemours and Company, Wilmington, DE, United States (U.S. corporation)
PI US 4016345 19770405 <--
AI US 1976-670075 19760324 (5)
RLI Continuation-in-part of Ser. No. US 1972-317804, filed on 22 Dec 1972, now abandoned
DT Utility
FS Granted
LN.CNT 590
INCL INCLM: 526/206.000
INCLS: 526/255.000
NCL NCLM: 526/206.000
NCLS: 526/255.000
IC [2]
ICM: C08F014-26
EXF 526/229; 526/255; 526/206
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 199 OF 199 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

AN 1991-067287 [10] WPIDS
DNN N1991-052055
TI Colour image forming appts. - has image bearing element toner developer and developing bias voltage applying device.
DC P84 S06
IN KOBAYASHI, Y; TAJIMA, H
PA (CANO) CANON KK
CYC 5
PI EP 415753 A 19910306 (199110)* <--
R: DE FR GB IT
US 5030996 A 19910709 (199130) <--
EP 415753 B1 19931201 (199348) EN 18 G03G015-01 <--
R: DE FR GB IT
DE 69004896 E 19940113 (199403) G03G015-01 <--
ADT EP 415753 A EP 1990-309486 19900830; US 5030996 A US 1990-574893 19900830; EP 415753 B1 EP 1990-309486 19900830; DE 69004896 E DE 1990-604896 19900830, EP 1990-309486 19900830
FDT DE 69004896 E Based on EP 415753
PRAI JP 1989-223196 19890831
IC G03G015-01; G03G021-00
STN INTERNATIONAL LOGOFF AT 14:44:17 ON 22 SEP 2004

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 70 of 70 returned.

☐ 1. Document ID: US 20040157771 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 70 File: PGPB Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040157771 A1

TITLE: Rank-ligand-induced sodium/proton antiporter polypeptides

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge	WA	US	
Tometsko, Mark E.	Seattle	WA	US	
Dougall, William C.	Seattle	WA	US	
Mosley, Bruce A.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20040142892 A1

L2: Entry 2 of 70 File: PGPB Jul 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040142892
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040142892 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: 514/44; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for expressing a product of interest in a cell that involve a secretable RNA Polymerase.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 3. Document ID: US 20040132088 A1

L2: Entry 3 of 70 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 4. Document ID: US 20040132033 A1

L2: Entry 4 of 70 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132033
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132033 A1

TITLE: Human heparanase gene regulatory sequences

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolffe, Elizabeth J.	Orinda	CA	US	
Wolffe, Alan P.	Orinda	CA	US	
Qi, Hong	Cottonwood	CA	US	

US-CL-CURRENT: 435/6; 435/200, 435/320.1, 435/325, 435/69.1, 536/21, 536/23.2

ABSTRACT:

Nucleotide sequences comprising regulatory regions of the human heparanase gene are provided. Also provided are methods and compositions for regulating heparanase expression, as well as methods and compositions for using heparanase sequences to regulate a heterologous target gene.

☐ 5. Document ID: US 20040115770 A1

L2: Entry 5 of 70 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma

membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 6. Document ID: US 20040063907 A1

L2: Entry 6 of 70 File: PGPB Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 7. Document ID: US 20040058881 A1

L2: Entry 7 of 70 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058881
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058881 A1

TITLE: Ii-key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert E.	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

☐ 8. Document ID: US 20040038338 A1

L2: Entry 8 of 70 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038338
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038338 A1

TITLE: Influence of LRP cytoplasmic domain on Abeta production

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koo, Edward H.	La Jolla	CA	US	
Pietrzik, Claus	Nierstein		DE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid .beta.-protein (A.beta.). Methods for preventing or treating diseases wherein

amyloid .beta.-protein (A.beta.) is a major constituent of amyloid plaques or amyloidosis by interfering with production of A.beta. are described, as is a high throughput assay for screening compounds that inhibit A.beta. production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.

☐ 9. Document ID: US 20040034199 A1

L2: Entry 9 of 70 File: PGPB Feb 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040034199
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040034199 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: February 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A	Bainbridge Island		GB	
Cosman, David J.	Bainbridge Island		GB	

US-CL-CURRENT: 530/358; 435/199, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 10. Document ID: US 20040002455 A1

L2: Entry 10 of 70 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	

Morse, Clarence C.	Asbury	NJ	US
Guo, Yong	Freshmeadows	NJ	US
Cheng, Su	Bridgewater		US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

☐ 11. Document ID: US 20030235575 A1

L2: Entry 11 of 70 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235575
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030235575 A1

TITLE: Identification of oligoadenylate synthetase-like genes

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Matzuk, Martin M.	Pearland	TX	US	
Bai, Yuchen	Newtown	PA	US	
Yan, Wei	Houston	TX	US	

US-CL-CURRENT: 424/94.61; 435/199, 435/320.1, 435/325, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to compositions and methods for modulating conception in animals. More particularly, the composition modulates mRNA degradation during gametogenesis and early development. Yet further, the present invention relates to pharmaceutical compositions and methods for modulating diseases of the reproductive organs, such as hyperproliferative diseases.

☐ 12. Document ID: US 20030229019 A1

L2: Entry 12 of 70 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229019
PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030229019 A1

TITLE: Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Burke, James R.	Chapel Hill	NC	US	
Strittmatter, Warren J.	Durham	NC	US	
Nagai, Yoshitaka	Osaka		JP	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 435/7.1, 514/44, 530/324, 536/23.1

ABSTRACT:

Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

☐ 13. Document ID: US 20030224444 A1

L2: Entry 13 of 70 File: PGPB Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224444
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224444 A1

TITLE: Antibodies to native conformations of membrane proteins

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sabbadini, Roger A.	Lakeside	CA	US	
Berkley, Neil	San Diego	CA	US	
Surber, Mark W.	Coronado	CA	US	

US-CL-CURRENT: 435/7.1; 435/326, 435/69.1, 530/387.1

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

☐ 14. Document ID: US 20030219859 A1

L2: Entry 14 of 70 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

☐ 15. Document ID: US 20030204069 A1

L2: Entry 15 of 70 File: PGPB Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030204069
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030204069 A1

TITLE: Segments of the human gene for telomerase reverse transcriptase

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morin, Gregg B.	Toronto	NV	CA	
Andrews, William H.	Reno		US	

US-CL-CURRENT: 536/23.2; 435/199, 435/320.1, 435/325, 435/456, 435/6, 435/69.1

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse

transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

---

☐ 16. Document ID: US 20030198626 A1

L2: Entry 16 of 70 File: PGPB Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030198626
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030198626 A1

TITLE: Inhibition of Ii expression in mammalian cells

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Xu, Minzhen	Northborough	MA	US	
Humphreys, Robert	Acton	MA	US	

US-CL-CURRENT: 424/93.21; 435/320.1, 435/366, 435/456, 435/69.1, 536/23.5

ABSTRACT:

The present invention is directed toward composition and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. More specifically, disclosed are compositions and methods which relate to MHC Class II molecule presentation of antigenic epitopes which, under normal circumstances, would not be presented in association with MHC Class II molecules. The invention relates to presentation in cells which normally express MHC Class II molecules, as well as cells which can be induced to express MHC Class II molecules.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

---

☐ 17. Document ID: US 20030194727 A1

L2: Entry 17 of 70 File: PGPB Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194727
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194727 A1

TITLE: Phenotypic screen of chimeric proteins

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Kim, Jin-Soo	Yuseong-gu	KR
Park, Kyung-Soon	Yuseong-gu	KR
Lee, Dong-Ki	Yuseong-gu	KR
Seol, Wongi	Yuseong-gu	KR
Lee, Horim	Chungcheongnam-do	KR
Lee, Seong-Il	Yuseong-gu	KR
Yang, Hyo-Young	Yuseong-gu	KR
Lee, Yangsoon	Yuseong-gu	KR
Jang, Young-Soon	Yuseong-gu	KR

US-CL-CURRENT: 435/6; 435/219, 435/252.3, 435/254.2, 435/320.1, 435/325, 435/69.1, 435/7.2

ABSTRACT:

In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

☐ 18. Document ID: US 20030175920 A1

L2: Entry 18 of 70 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175920
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175920 A1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonny, Christophe	Morges		CH	

US-CL-CURRENT: 435/184; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).

☐ 19. Document ID: US 20030171318 A1

L2: Entry 19 of 70 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171318
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030171318 A1

TITLE: Composition and method for treating viral infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: 514/44; 424/186.1, 435/6, 435/69.1, 514/12

ABSTRACT:

Methods for inhibiting virus propagation and treating virus infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 20. Document ID: US 20030170871 A1

L2: Entry 20 of 70 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170871
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170871 A1

TITLE: Alphavirus-based vectors for persistent infection

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dubensky, Thomas W. JR.	Piedmont	CA	US	
Polo, John M.	Hayward	CA	US	
Perri, Silvia	Castro Valley	CA	US	
Belli, Barbara	San Diego	CA	US	

US-CL-CURRENT: 435/235.1; 424/93.21, 435/325, 435/456, 435/69.1, 536/23.72

ABSTRACT:

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein 2 gene which, when operably incorporated into an alphavirus replicon particle, eukaryotic layered vector initiation system, alphavirus vector construct or

RNA vector replicon, provides a noncytopathic phenotype or confers the ability to establish persistent replication. Also disclosed are RNA vector replicons, alphavirus vector constructs, alphavirus replicon particles and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules, as well as methods of using such replicons, constructs, particles and eukaryotic layered vector initiation systems for expression of recombinant proteins.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

---

☐ 21. Document ID: US 20030166141 A1

L2: Entry 21 of 70 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166141
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166141 A1

TITLE: Regulation of endogenous gene expression in cells using zinc finger proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Case, Casey C.	San Mateo	CA	US	
Cox, George N. III	Louisville	CO	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Liu, Qiang	Foster City	CA	US	
Rebar, Edward J.	El Cerrito	CA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/366, 435/456, 702/19

ABSTRACT:

The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw Desc

---

☐ 22. Document ID: US 20030166099 A1

L2: Entry 22 of 70 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166099
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166099 A1

TITLE: Minicells comprising membrane proteins

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Sabbadini, Roger A.	Lakeside	CA	US
Surber, Mark W.	Coronado	CA	US
Berkley, Neil	San Diego	CA	US
Segall, Anca M.	San Diego	CA	US
Klepper, Robert	San Diego	CA	US

US-CL-CURRENT: 435/69.1; 435/325

ABSTRACT:

The invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 23. Document ID: US 20030165945 A1

L2: Entry 23 of 70 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 24. Document ID: US 20030152945 A1

L2: Entry 24 of 70 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152945 A1

TITLE: Cell cycle progression proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Deak, Peter	Cambridge		GB	
Glover, David Moore	Sandy		GB	
Midgley, Carol	Milton Keynes		GB	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Polynucleotides encoding a number of Drosophila gene products are provided. Polynucleotide probes derived from these nucleotide sequences, polypeptides encoded by the polynucleotides and antibodies that bind to the polypeptides are also provided.

☐ 25. Document ID: US 20030148265 A1

L2: Entry 25 of 70 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148265
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148265 A1

TITLE: Anti-viral conjugate comprising a factor allowing the translocation of a protein across a cell membrane and comprising a single-chain antibody fragment directed against a viral protein

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brooks, Timothy John Gilby	Wiltshire		GB	
Duggan, Jacqueline Marie	Wiltshire		GB	

US-CL-CURRENT: 435/5; 424/159.1, 435/235.1, 435/252.3, 435/320.1, 435/69.1, 530/388.3

ABSTRACT:

A protein conjugate comprising conjugate comprising a first region comprising a factor that permits translocation of a protein across a cell membrane; and a second region comprising a single-chain antibody fragment which has affinity for a viral protein, in particular a viral protein which is necessary for replication of a virus such as a flavivirus.

☐ 26. Document ID: US 20030143681 A1

L2: Entry 26 of 70 File: PGPB Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143681
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143681 A1

TITLE: Human ataxin-1-like polypeptide IMX97018

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Anderson, Dirk M.	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/199, 435/254.2, 435/320.1, 435/325, 435/6, 536/23.2

ABSTRACT:

This invention relates to IMX97018, a new members of the human ataxin-1-like polypeptide family, methods of making such polypeptides, and to methods of using them to diagnose and treat neurological conditions and to identify compounds that alter IMX97018 polypeptide activities.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 27. Document ID: US 20030119771 A1

L2: Entry 27 of 70 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	
Tomme, Peter Herwig Maria	Gent		BE	
Klaassen, Hubertus Johannes Matheus	Herent		BE	

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as

the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

☐ 28. Document ID: US 20030118611 A1

L2: Entry 28 of 70 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118611
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118611 A1

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Corey, Lawrence	Seattle	WA	US	

US-CL-CURRENT: 424/231.1; 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1, 435/69.1, 435/69.7, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

☐ 29. Document ID: US 20030108886 A1

L2: Entry 29 of 70 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108886
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108886 A1

TITLE: Autogene nucleic acids encoding a secretable RNA polymerase

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finn, John	Vancouver		CA	
MacLachlan, Ian	Vancouver		CA	

US-CL-CURRENT: 435/6; 435/199, 435/252.3, 435/320.1, 435/69.1, 514/44, 536/23.2

ABSTRACT:

This invention provides methods, nucleic acids, compounds, and compositions for expressing a product of interest in a cell that involve a secretable RNA Polymerase.

☐ 30. Document ID: US 20030108880 A1

L2: Entry 30 of 70 File: PGPB Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030108880
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030108880 A1

TITLE: Modified zinc finger binding proteins

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Disclosed herein are compositions and method comprising non-canonical (e.g., non-C2H2) zinc finger proteins.

☐ 31. Document ID: US 20030104526 A1

L2: Entry 31 of 70 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104526
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030104526 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/320.1, 435/325, 435/6, 536/23.2

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

☐ 32. Document ID: US 20030103992 A1

L2: Entry 32 of 70 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030103992
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030103992 A1

TITLE: Clasp membrane proteins

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 424/185.1; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to cell surface molecules, designated cadherin-like asymmetry proteins ("CLASPs"). In particular, it relates to CLASP polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function.

☐ 33. Document ID: US 20030100093 A1

L2: Entry 33 of 70 File: PGPB May 29, 2003

PGPUB-DOCUMENT-NUMBER: 20030100093
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030100093 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	Pl. Croix-Blanche	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	
Andrews, William H.	Richmond		US	

US-CL-CURRENT: 435/199; 435/320.1, 435/325, 435/368, 435/69.1, 536/23.2

ABSTRACT:

The present invention is directed to cells comprising a recombinant polynucleotide sequence that encodes a telomerase reverse transcriptase protein, variant, or fragment having telomerase catalytic activity when complexed with a telomerase RNA.

☐ 34. Document ID: US 20030096344 A1

L2: Entry 34 of 70 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096344
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096344 A1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cech, Thomas R.	Boulder	CO	US	
Lingner, Joachim	PI. Croix-Blanche 25	CO	CH	
Nakamura, Toru	Boulder	CA	US	
Chapman, Karen B.	Sausalito	CA	US	
Morin, Gregg B.	Davis	CA	US	
Harley, Calvin B.	Palo Alto	CA	US	

Andrews, William H. Richmond US

US-CL-CURRENT: 435/69.1; 424/146.1, 435/199, 435/320.1, 435/325

ABSTRACT:

The present invention is directed to pharmaceutical compositions comprising a telomerase reverse transcriptase polypeptide or a polypeptide homologous to a telomerase reverse transcriptase. The present invention is also directed to pharmaceutical compositions comprising a polynucleotide encoding either of the aforesaid polypeptides. The present invention is further directed to methods for eliciting an immune response to telomerase reverse transcriptase in a subject.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 35. Document ID: US 20030087411 A1

L2: Entry 35 of 70 File: PGPB May 8, 2003

PGPUB-DOCUMENT-NUMBER: 20030087411
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030087411 A1

TITLE: Death associated kinase containing ankyr in repeats (DAKAR) and methods of use

PUBLICATION-DATE: May 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Holland, Pamela M.	Seattle	WA	US	
Peschon, Jacques J.	Seattle	WA	US	
Virca, George D.	Bellevue	WA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

This invention relates to DAKAR, a new member of the serine/threonine kinase family, methods of making such polypeptides, and to methods of using them to treat conditions associated with apoptosis and epithelial proliferation and differentiation, as well as methods to identify compounds that alter DAKAR-associated cellular activities.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 36. Document ID: US 20030077827 A1

L2: Entry 36 of 70 File: PGPB Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077827
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030077827 A1

TITLE: Surface transfection and expression procedure

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uhler, Michael D.	Ann Arbor	MI	US	

US-CL-CURRENT: 435/455; 435/325, 435/6, 435/69.1

ABSTRACT:

The present invention relates to a method of transfecting cells comprising applying cells directly onto nucleic acids which are immobilized in transfection complexes on a surface and which transfect the cells. Preferably, the nucleic acids are immobilized in an array. In another aspect of the present invention, the method further includes expression of the nucleic acids in the transfected cells. In yet another aspect of the present invention, the method further comprises detecting the expression of the nucleic acids in the transfected cells.

☐ 37. Document ID: US 20030068675 A1

L2: Entry 37 of 70 File: PGPB Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068675
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030068675 A1

TITLE: Position dependent recognition of GNN nucleotide triplets by zinc fingers

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Liu, Qiang	Foster City	CA	US	

US-CL-CURRENT: 435/69.1; 435/226, 435/6, 702/19

ABSTRACT:

The specificity of binding of a zinc finger to a triplet or quadruplet nucleotide target subsite depends upon the location of the zinc finger in a multifinger protein and, hence, upon the location of its target subsite within a larger target sequence. The present disclosure provides zinc finger amino acid sequences for recognition of triplet target subsites having the nucleotide G in the 5'-most position of the subsite, that have been optimized with respect to the location of the subsite within the target site. Accordingly, the disclosure provides finger position-specific amino acid sequences for the recognition of GNN target subsites. This allows the construction of multi-finger zinc finger proteins with improved affinity and specificity for their target sequences, as well as enhanced biological activity.

☐ 38. Document ID: US 20030049602 A1

L2: Entry 38 of 70 File: PGPB Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049602
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030049602 A1

TITLE: Inhibitors of microbial gene expression replication and pathogenesis

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schaffer, Priscilla A.	Boston	MA	US	
Schang, Luis M.	Edmonton	PA	CA	
Jordan, Robert	Erdenheim		US	

US-CL-CURRENT: 435/5; 424/229.1, 435/345, 435/69.1, 435/91.1

ABSTRACT:

The invention relates to the identification of cdk inhibitors as inhibitors of microbial gene expression, replication and reactivation. Compositions and assays for the identification and use of such inhibitors are provided as are methods of use of the inhibitors

☐ 39. Document ID: US 20030044404 A1

L2: Entry 39 of 70 File: PGPB Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044404
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044404 A1

TITLE: Regulation of angiogenesis with zinc finger proteins

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rebar, Edward	El Cerrito	CA	US	
Jamieson, Andrew	San Francisco	CA	US	
Liu, Qiang	Foster City	CA	US	
Liu, Pei-Qi	Richmond	CA	US	
Wolffe, Alan	Orinda	CA	US	
Eisenberg, Stephen P.	Boulder	CO	US	
Jarvis, Eric	Boulder	CO	US	

US-CL-CURRENT: 424/94.63; 435/226, 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by using various zinc finger proteins that bind to particular target sites in one or more VEGF genes. Nucleic acids encoding the zinc finger proteins are also disclosed. Methods for modulating the expression of one or more VEGF genes with the zinc finger proteins and nucleic acids are also disclosed. Such methods can also be utilized in a variety of therapeutic applications that involve the regulation of endothelial cell growth. Pharmaceutical compositions including the zinc finger proteins or nucleic acids encoding them are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 40. Document ID: US 20030040038 A1

L2: Entry 40 of 70 File: PGPB Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030040038
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030040038 A1

TITLE: INDUCIBLE REGULATORY SYSTEM AND USE THEREOF

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DOWDY, STEVEN F.	CLAYTON	MO	US	
JESSEE, JOEL A.	MOUNT AIRY	MD	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455

ABSTRACT:

The present invention provides an inducible regulatory system in which transcription of a target nucleotide sequence in a host cell is activated by the introduction of a fusion protein having a transcription activator region and a protein transduction domain for entry of the fusion protein into the cell.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

---

☐ 41. Document ID: US 20030036163 A1

L2: Entry 41 of 70 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

☐ 42. Document ID: US 20030008324 A1

L2: Entry 42 of 70 File: PGPB Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030008324 A1

TITLE: Caspase-7-interacting protein and use thereof

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.1; 435/226, 435/320.1, 435/325, 435/69.1, 435/69.7

ABSTRACT:

Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 43. Document ID: US 20020177152 A1

L2: Entry 43 of 70 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177152
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177152 A1

TITLE: COX 1-interacting proteins and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/189, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising COX1 and one or more proteins selected from the group consisting of THR S14 and Opa1. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with COX1 and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

☐ 44. Document ID: US 20020173026 A1

L2: Entry 44 of 70 File: PGPB Nov 21, 2002

PGPUB-DOCUMENT-NUMBER: 20020173026
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020173026 A1

TITLE: Survivin-interacting proteins and use thereof

PUBLICATION-DATE: November 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Cimbora, Daniel	Salt Lake City	UT	US	

US-CL-CURRENT: 435/199; 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of HDLC1, beta-actin, DNA helicase II, COPP, OSTP, SLC8A1, A2-CAT. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or

preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 45. Document ID: US 20020169283 A1

L2: Entry 45 of 70 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 46. Document ID: US 20020168683 A1

L2: Entry 46 of 70 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	

Cosman, David J.	Bainbridge Island	WA	US

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 47. Document ID: US 20020155432 A1

L2: Entry 47 of 70 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155432
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155432 A1

TITLE: Genetically engineered herpes virus for the treatment of cardiovascular disease

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schwartz, Lewis B.	Hinsdale	IL	US	
Weichselbaum, Ralph R.	Chicago	IL	US	
Roizman, Bernard	Chicago	IL	US	

US-CL-CURRENT: 435/5; 424/199.1, 424/205.1, 424/229.1, 435/320.1, 435/69.1

ABSTRACT:

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 48. Document ID: US 20020146788 A1

L2: Entry 48 of 70 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146788
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020146788 A1

TITLE: Artificial endonuclease

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Franklin, Sonya	Iowa City	IA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/6, 435/69.1

ABSTRACT:

The present invention provides artificial endonucleases and methods to prepare and use those endonucleases.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 49. Document ID: US 20020106676 A1

L2: Entry 49 of 70 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106676
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106676 A1

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 435/6; 435/226, 435/320.1, 435/368, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 50. Document ID: US 20020102267 A1

L2: Entry 50 of 70 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102267
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020102267 A1

TITLE: CLASP-5 transmembrane protein

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-5 ("CLASP-5"). In particular, it relates to CLASP-5 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-5 function.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 51. Document ID: US 20020086382 A1

L2: Entry 51 of 70 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086382
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086382 A1

TITLE: Clasp-3 transmembrane protein

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-3 ("CLASP-3"). In particular, it relates to CLASP-3 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-3

function.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 52. Document ID: US 20020086361 A1

L2: Entry 52 of 70 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086361
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086361 A1

TITLE: Modulators of antiestrogen pharmacology

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Montano, Monica	Shaker Heights	OH	US	
Sutton, Amelia	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/456, 435/458, 530/350, 536/23.5

ABSTRACT:

A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibiodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 53. Document ID: US 20020061296 A1

L2: Entry 53 of 70 File: PGPB May 23, 2002

PGPUB-DOCUMENT-NUMBER: 20020061296
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020061296 A1

TITLE: Delivery method for the tumor specific apoptosis inducing activity of apoptin

PUBLICATION-DATE: May 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Noteborn, Mathieu H.M.	Leiderdrop		NL	
Voorhoeve, Pieter M.	Amesterdam		NL	

Zhang, Ying-Hui	Leiden	NL
Leliveld, Sirik R.	Leiden	NL

US-CL-CURRENT: 424/93.21; 424/94.63, 435/226, 435/320.1, 435/325, 435/69.1

ABSTRACT:

The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example novel therapeutic proteinaceous compounds that can contain apoptin alone or jointly with other proteinaceous protein or protein fragments, especially in those cases when cells are derailed such as cancer-, auto-immune-derived cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 54. Document ID: US 20020039765 A1

L2: Entry 54 of 70 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 55. Document ID: US 20020001805 A1

L2: Entry 55 of 70 File: PGPB Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

☐ 56. Document ID: US 6780986 B1

L2: Entry 56 of 70 File: USPT Aug 24, 2004

US-PAT-NO: 6780986
DOCUMENT-IDENTIFIER: US 6780986 B1

TITLE: RIP60 nucleic acid and polypeptide sequences and uses therefor

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Heintz; Nicholas H.	Jericho	VT		
Houchens; Christopher R.	Baltimore	MD		

US-CL-CURRENT: 536/23.5; 435/455, 435/69.1, 435/71.1, 435/91.4, 536/23.1

ABSTRACT:

The invention relates to nucleic acids and encoded polypeptides from the human zinc finger protein RIP60. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, fragments of the foregoing including functional fragments and variants. Kits containing the foregoing molecules additionally are provided.

7 Claims, 6 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 57. Document ID: US 6777185 B2

L2: Entry 57 of 70 File: USPT Aug 17, 2004

US-PAT-NO: 6777185
DOCUMENT-IDENTIFIER: US 6777185 B2

TITLE: Functional genomics using zinc finger proteins

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Case; Casey C.	San Mateo	CA		
Zhang; Lei	Davis	CA		
Urnov; Fyodor	Richmond	CA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/23.1, 536/23.4

ABSTRACT:

The present invention provides methods of regulating gene expression using recombinant zinc finger proteins, for functional genomics and target validation applications.

53 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 58. Document ID: US 6723512 B2

L2: Entry 58 of 70 File: USPT Apr 20, 2004

US-PAT-NO: 6723512
DOCUMENT-IDENTIFIER: US 6723512 B2

TITLE: METHODS USING GENETIC PACKAGE DISPLAY FOR DETECTING AND IDENTIFYING PROTEIN-PROTEIN INTERACTIONS THAT FACILITATE INTERNALIZATION AND TRANSGENE EXPRESSION AND CELLS OR TISSUES COMPETENT FOR THE SAME AND METHODS FOR EVOLVING GENE DELIVERY VECTORS

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Larocca; David	Encinitas	CA		

Kassner; Paul	San Mateo	CA
Baird; Andrew	San Diego	CA

US-CL-CURRENT: 435/6; 435/320.1, 435/5, 435/69.1, 435/DIG.14, 435/DIG.15, 435/DIG.2, 435/DIG.35, 435/DIG.4, 536/23.1

ABSTRACT:

A genetic package display system and methodology for probing protein-protein interactions that lead to cell transduction, selecting and/or identifying internalizing ligands, target cells and tissues which internalize known or putative ligands, and cell transduction facilitating peptides is provided. A ligand displaying genetic package that carries a selectable marker (e.g., reporter, selection, etc.) and presents a ligand on its surface is utilized to identify internalizing ligands, tranduction facilitating peptides, and/or a variety of cells and tissue types for the ability to be successfully transduced by the ligand displaying genetic package. Also provided are methods for evolving a ligand displaying package to facilitate gene delivery or delivery of any desired agent (e.g., pharmaceutical, polypeptide, peptide, etc.) into a cell and/or targeting cellular compartments such as the nucleus, endosome, chloroplast, mitochondria, etc.

33 Claims, 21 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 59. Document ID: US 6703487 B2

L2: Entry 59 of 70 File: USPT Mar 9, 2004

US-PAT-NO: 6703487
DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324, 530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 60. Document ID: US 6660259 B2

L2: Entry 60 of 70 File: USPT Dec 9, 2003

US-PAT-NO: 6660259
DOCUMENT-IDENTIFIER: US 6660259 B2

TITLE: Herpes simplex virus for treating unwanted hyperproliferative cell growth

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Laquerre; Sylvie	Walnut Creek	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/91.41

ABSTRACT:

The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.

15 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 61. Document ID: US 6653102 B2

L2: Entry 61 of 70 File: USPT Nov 25, 2003

US-PAT-NO: 6653102
DOCUMENT-IDENTIFIER: US 6653102 B2

TITLE: Nucleic acid encoding a phosphatase 2C that interacts with Fe 65

DATE-ISSUED: November 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Roch; Jean-Marc	Salt Lake City	UT		
Bartel; Paul L.	Salt Lake City	UT		
Heichman; Karen	Salt Lake City	UT		
Mauck; Kimberly	Sandy	UT		
Dufford; Max	Salt Lake City	UT		

US-CL-CURRENT: 435/69.1; 435/183, 435/252.3, 435/254.11, 435/254.2, 435/320.1, 435/325, 536/23.5

ABSTRACT:

The present invention relates to the discovery of protein--protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 4

☐ 62. Document ID: US 6649158 B1

L2: Entry 62 of 70 File: USPT Nov 18, 2003

US-PAT-NO: 6649158
DOCUMENT-IDENTIFIER: US 6649158 B1

TITLE: Methods and compositions to induce antitumor response

DATE-ISSUED: November 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFace; Drake M.	San Diego	CA		

US-CL-CURRENT: 424/93.2; 435/320.1, 435/325, 435/69.1, 435/83

ABSTRACT:

The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention invention is induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells. The present invention provides a method to induce an antitumor immune response through the use of such compositions.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 63. Document ID: US 6635244 B2

L2: Entry 63 of 70 File: USPT Oct 21, 2003

US-PAT-NO: 6635244
DOCUMENT-IDENTIFIER: US 6635244 B2

TITLE: Adenovirus E1B-55K single amino acid mutants and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shen; Yuqiao	Richmond	CA		
Nye; Julie	Berkeley	CA		
Hermiston; Terry	Corte Madera	CA		

US-CL-CURRENT: 424/93.2; 424/93.1, 424/93.6, 435/235.1, 435/320.1, 435/455, 435/456, 435/69.1, 435/91.4, 435/91.41, 536/23.1

ABSTRACT:

Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.

7 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 64. Document ID: US 6485977 B1

L2: Entry 64 of 70 File: USPT Nov 26, 2002

US-PAT-NO: 6485977
DOCUMENT-IDENTIFIER: US 6485977 B1

TITLE: Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collmer; Alan	Ithaca	NY		
Beer; Steven V.	Ithaca	NY		

US-CL-CURRENT: 435/455; 435/320.1, 435/325, 435/456, 435/69.1, 435/69.7, 536/23.1, 536/23.4, 536/24.1

ABSTRACT:

The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.

11 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 65. Document ID: US 6475789 B1

L2: Entry 65 of 70 File: USPT Nov 5, 2002

US-PAT-NO: 6475789
DOCUMENT-IDENTIFIER: US 6475789 B1

TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods

DATE-ISSUED: November 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cech; Thomas R.	Boulder	CO		
Lingner; Joachim	Epalinges			CH
Nakamura; Toru	Boulder	CO		
Chapman; Karen B.	Sausalito	CA		
Morin; Gregg B.	Palo Alto	CA		
Harley; Calvin B.	Palo Alto	CA		
Andrews; William H.	Richmond	CA		

US-CL-CURRENT: 435/366; 424/94.1, 435/320.1, 435/69.1, 536/23.2

ABSTRACT:

The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

8 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 34

☐ 66. Document ID: US 6472176 B2

L2: Entry 66 of 70 File: USPT Oct 29, 2002

US-PAT-NO: 6472176
DOCUMENT-IDENTIFIER: US 6472176 B2

TITLE: Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof

DATE-ISSUED: October 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kovesdi; Imre	Rockville	MD		
Bruder; Joseph T.	Ijamsville	MD		

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 435/69.7, 435/69.8, 536/23.1, 536/23.2, 536/23.4, 536/23.5, 536/23.7, 536/24.1

ABSTRACT:

The invention pertains to a polynucleotide encoding a chimeric protein comprising an endoplasmic reticulum localization signal peptide, a transport moiety, and a moiety of interest, wherein the endoplasmic reticulum localization signal peptide, the transport moiety, and the moiety of interest are operably linked with each other, a vector comprising the polynucleotide, a cell comprising such a vector, and a method of expressing a protein comprising the transport moiety and the moiety of interest.

25 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 67. Document ID: US 6451579 B1

L2: Entry 67 of 70 File: USPT Sep 17, 2002

US-PAT-NO: 6451579
DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 68. Document ID: US 6413518 B1

L2: Entry 68 of 70 File: USPT Jul 2, 2002

US-PAT-NO: 6413518
DOCUMENT-IDENTIFIER: US 6413518 B1
**** See image for Certificate of Correction ****

TITLE: Immunologically significant herpes simplex virus antigens and methods for identifying and using same

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koelle; David M.	Seattle	WA		
Chen; Hongbo	Shoreline	WA		
Corey; Lawrence	Mercer Island	WA		
Hosken; Nancy Ann	Seattle	WA		
McGowan; Patrick	Seattle	WA		
Fling; Steven P.	Bainbridge Island	WA		
Posavad; Christine M.	Seattle	WA		

US-CL-CURRENT: 424/186.1; 424/184.1, 424/192.1, 424/231.1, 435/69.1, 435/69.3, 435/91.1, 435/91.4, 536/23.5

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

12 Claims, 56 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 23

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 69. Document ID: US 6350572 B1

L2: Entry 69 of 70 File: USPT Feb 26, 2002

US-PAT-NO: 6350572
DOCUMENT-IDENTIFIER: US 6350572 B1

TITLE: Interaction between cyclin D1 and steroid receptor coactivators and users thereof in assays

DATE-ISSUED: February 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernards; Rene	Alcoude			NL
Zwijsen; Renate	Utrecht			NL

US-CL-CURRENT: 435/4; 435/41, 435/69.1, 435/69.4, 435/69.7, 435/7.1, 435/7.2, 435/7.21, 435/7.23, 435/7.8, 435/70.1, 435/70.3

ABSTRACT:

The present invention relates to the finding that cyclin D1 interacts in a ligand-independent fashion with coactivators of the SRC-1 family. The direct interaction of cyclin D1 enhances estrogen receptor (ER) mediated transcription and provides a novel target for the development of assays for substances which modulate the cell cycle. The invention provides assay methods for the prevention of growth of tumours, for assays for compounds useful in the prevention of tumours and compounds obtainable by such assays.

5 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 70. Document ID: US 6313269 B1

L2: Entry 70 of 70 File: USPT Nov 6, 2001

US-PAT-NO: 6313269
DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atheroschlerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Terms	Documents
L1 AND VP22	70

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 79 of 79 returned.

☐ 1. Document ID: US 20040157771 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 79 File: PGPB Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040157771 A1

TITLE: Rank-ligand-induced sodium/proton antiporter polypeptides

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge	WA	US	
Tometsko, Mark E.	Seattle	WA	US	
Dougall, William C.	Seattle	WA	US	
Mosley, Bruce A.	Seattle	WA	US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 2. Document ID: US 20040151739 A1

L4: Entry 2 of 79 File: PGPB Aug 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040151739
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040151739 A1

TITLE: Use of a composition for the stimulation of nerve growth, the inhibition of scar tissue formation, the reduction of secondary damage and/or the accumulation of macrophages

PUBLICATION-DATE: August 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Monnier, Philippe P.	Tubingen		DE	
Mueller, Bernhard K.	Tubingen		DE	
Schwab, Jan	Tubingen		DE	

US-CL-CURRENT: 424/239.1; 514/12, 530/350

ABSTRACT:

The invention relates to the use of a composition, comprising a fusion protein and at least one transporter for the in-vivo inhibition of scar tissue formation, the in-vivo reduction of secondary damage and/or the in-vivo accumulation of macrophages. The fusion protein contains at least one binding domain for the transporter and at least one modulation domain for the covalent modification of small GTP-binding proteins. The transporter permits the uptake of the fusion protein in a target cell.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 3. Document ID: US 20040132969 A1

L4: Entry 3 of 79 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132969
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132969 A1

TITLE: Antibodies, peptides, analogs and uses thereof

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Melvin, William Thomas	Aberdeen		GB	
Thompson, William Douglas	Inverurie		GB	
Stirk, Christina Maureen	Stonghaven		GB	

US-CL-CURRENT: 530/350

ABSTRACT:

Fibrin degradation products stimulate cell proliferation and angiogenesis. The present invention provides peptides, analogs and antibodies which are useful in the modulation of fibrin fragment E activities such as modulation of cell proliferation.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 4. Document ID: US 20040132088 A1

L4: Entry 4 of 79 File: PGPB Jul 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040132088
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040132088 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: July 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

☐ 5. Document ID: US 20040115770 A1

L4: Entry 5 of 79 File: PGPB Jun 17, 2004

PGPUB-DOCUMENT-NUMBER: 20040115770
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040115770 A1

TITLE: Polypeptides for increasing mutant CFTR channel activity

PUBLICATION-DATE: June 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Robbins, Paul D.	Mt. Lebanon	PA	US	
Frizzell, Raymond	Pittsburgh	PA	US	
Mi, Zhibao	Pittsburgh	PA	US	
Sun, Fei	Warrendale	PA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/455, 530/350

ABSTRACT:

The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or

recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, .DELTA.F508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous .DELTA.F508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, .DELTA.F508 CFTR.

☐ 6. Document ID: US 20040072270 A1

L4: Entry 6 of 79 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072270
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072270 A1

TITLE: Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Fernandez-Salas, Ester	Fullerton	CA	US	
Steward, Lance E.	Irvine	CA	US	
Aoki, Kei Roger	Coto de Caza	CA	US	

US-CL-CURRENT: 435/7.32; 435/23, 530/350

ABSTRACT:

The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity.

☐ 7. Document ID: US 20040063907 A1

L4: Entry 7 of 79 File: PGPB Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063907
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040063907 A1

TITLE: Gene differentially expressed in breast and bladder cancer and encoded polypeptides

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zauderer, Maurice	Pittsford	NY	US	
Evans, Elizabeth E.	Rochester	NY	US	
Borrello, Melinda A.	Pittsford	NY	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity.

☐ 8. Document ID: US 20040058881 A1

L4: Entry 8 of 79 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058881
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058881 A1

TITLE: Ii-key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert E.	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 514/44; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Disclosed is a nucleic acid molecule comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid molecule comprises a second expressible nucleic acid sequence encoding an antigen presentation enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, the MHC Class II-presented epitope being contained in the protein of interest of step a); and iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less.

☐ 9. Document ID: US 20040038338 A1

L4: Entry 9 of 79 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038338
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038338 A1

TITLE: Influence of LRP cytoplasmic domain on Abeta production

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koo, Edward H.	La Jolla	CA	US	
Pietrzik, Claus	Nierstein		DE	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

A truncated dominant negative mammalian LDL receptor related protein (LRP) cytoplasmic tail mutant (LRP-CT) molecule and DNA sequences for its construction is described in this disclosure as is a method for disrupting generation of amyloid .beta.-protein (A.beta.). Methods for preventing or treating diseases wherein amyloid .beta.-protein (A.beta.) is a major constituent of amyloid plaques or amyloidosis by interfering with production of A.beta. are described, as is a high throughput assay for screening compounds that inhibit A.beta. production. Also described is a method for inhibiting LRP or APP:Fe65 interaction in vivo, and kit suitable for providing the required reactants for screening assays.

☐ 10. Document ID: US 20040038303 A1

L4: Entry 10 of 79 File: PGPB Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038303
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038303 A1

TITLE: Biologic modulations with nanoparticles

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Unger, Gretchen M.	Chaska	MN	US	

US-CL-CURRENT: 435/7.1; 530/350, 530/387.1, 530/396, 536/123

ABSTRACT:

Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth.

☐ 11. Document ID: US 20040002455 A1

L4: Entry 11 of 79 File: PGPB Jan 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040002455
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040002455 A1

TITLE: Targeted immunogens

PUBLICATION-DATE: January 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Uger, Robert Adam	Richmond Hill	CA	US	
Salha, Danielle	Toronto	NY	CA	
Barber, Brian	White Plains	NJ	US	
Morse, Clarence C.	Asbury	NJ	US	
Guo, Yong	Freshmeadows	NJ	US	
Cheng, Su	Bridgewater		US	

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides reagents and methods for producing and utilizing

targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity of the host.

☐ 12. Document ID: US 20030235594 A1

L4: Entry 12 of 79 File: PGPB Dec 25, 2003

PGPUB-DOCUMENT-NUMBER: 20030235594
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030235594 A1

TITLE: Ii-Key/antigenic epitope hybrid peptide vaccines

PUBLICATION-DATE: December 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Humphreys, Robert	Acton	MA	US	
Xu, Minzhen	Northborough	MA	US	

US-CL-CURRENT: 424/192.1; 435/320.1, 435/325, 435/69.3, 530/350, 536/23.5

ABSTRACT:

Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: _____) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: i) immunologically neutral chemical structures, ii) a MHC Class I epitope or a portion thereof, and/or iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

☐ 13. Document ID: US 20030229202 A1

L4: Entry 13 of 79 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030229202
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030229202 A1

TITLE: Membrane penetrating peptides and uses thereof

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guo, Yong	Fresh Meadows	NY	US	
Morse, Clarence C.	Asbury	NJ	US	
Yao, Zhengbin	Sugar Land	TX	US	
Keesler, George A.	Hillsborough	NJ	US	

US-CL-CURRENT: 530/350; 435/455

ABSTRACT:

The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.

☐ 14. Document ID: US 20030228634 A1

L4: Entry 14 of 79 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030228634
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030228634 A1

TITLE: Expression vectors encoding epitopes of target-associated antigens and methods for their design

PUBLICATION-DATE: December 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Simard, John J.L.	Vancouver	CA	CA	
Diamond, David C.	West Hills	CA	US	
Qiu, Zhiyong	Los Angeles	CA	US	
Lei, Xiang-Dong	West Hills		US	

US-CL-CURRENT: 435/7.2; 435/320.1, 530/350

ABSTRACT:

The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the

proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette. The housekeeping epitope(s) can be derived from a target-associated antigen, and the housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

☐ 15. Document ID: US 20030220480 A1

L4: Entry 15 of 79 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220480
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220480 A1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bonny, Christophe	Morges		CH	

US-CL-CURRENT: 530/350

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

☐ 16. Document ID: US 20030220474 A1

L4: Entry 16 of 79 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220474
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220474 A1

TITLE: Conjugate of biodegradable aliphatic polyester with Tat49-57 peptide or peptide chain containing Tat49-57 peptide and nanoparticle manufactured using the same

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Park, Ju Young	Yongin-si		KR	
Nam, Yoon Sung	Yongin-si		KR	

Han, Sang Hoon	Suwon-si	KR
Chang, Ih Seop	Yongin-si	KR

US-CL-CURRENT: 530/350; 436/518, 436/531

ABSTRACT:

Conjugates of a biodegradable aliphatic polyester-based polymer with Tat.sub.49-57 peptide or a peptide chain containing the Tat.sub.49-57 peptide, and nanoparticles manufactured using the same. Intracellular permeability of the Tat.sub.49-57 peptide can be enhanced by exposing Tat peptide moieties to the surface of the nanoparticles.

☐ 17. Document ID: US 20030220264 A1

L4: Entry 17 of 79 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030220264
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030220264 A1

TITLE: Reversible modification of membrane interaction

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rozema, David B.	Madison	WI	US	
Wakefield, Darren	Madison	WI	US	
Wolff, Jon A.	Madison	WI	US	
Ekena, Kirk	Madison	WI	US	
Hagstrom, James E.	Middleton	WI	US	

US-CL-CURRENT: 514/12; 530/350, 530/406

ABSTRACT:

An process for the reversible modification of membrane interaction of a compound is described. Modification of membrane interaction can be used to facilitate delivery of molecules to cells in vitro and in vivo. The described modifiers, which are used to reversibly inactivate the membrane active compounds, can also be utilized as cross-linkers or to reverse the charge of a molecule.

☐ 18. Document ID: US 20030219859 A1

L4: Entry 18 of 79 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219859

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219859 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 514/12, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

☐ 19. Document ID: US 20030219378 A1

L4: Entry 19 of 79 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219378
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219378 A1

TITLE: Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Piwnica-Worms, David	Ladue	MO	US	

US-CL-CURRENT: 424/1.69; 424/188.1, 424/9.34, 424/9.6, 530/350

ABSTRACT:

Methods and compositions for medical imaging, evaluating intracellular processes and components, radiotherapy of intracellular targets, and drug delivery by the use of novel cell membrane-permeant peptide conjugate coordination and covalent complexes having target cell specificity are provided. Kits for conjugating radionuclides and other metals to peptide coordination complexes are also provided.

☐ 20. Document ID: US 20030190324 A1

L4: Entry 20 of 79 File: PGPB Oct 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030190324
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030190324 A1

TITLE: Immunologically significant herpes simplex virus antigens and methods for using same

PUBLICATION-DATE: October 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Hosken, Nancy A.	Seattle	WA	US	
Posavad, Christine M.	Seattle	WA	US	
Chen, Hongbo	Shoreline	WA	US	
McGowan, Patrick	Seattle	WA	US	

US-CL-CURRENT: 424/186.1; 435/235.1, 435/320.1, 435/325, 435/5, 435/69.3, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

☐ 21. Document ID: US 20030175807 A1

L4: Entry 21 of 79 File: PGPB Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030175807
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030175807 A1

TITLE: Chimeric GFP-aequorin as bioluminescent Ca+at the single cell level

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baubet, Valerie	Kansas City	MO	US	
Le Mouellic, Herve	Paris		FR	

Brulet, Philippe Paris FR

US-CL-CURRENT: 435/7.1; 530/350, 536/23.2

ABSTRACT:

A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 22. Document ID: US 20030170826 A1

L4: Entry 22 of 79 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170826
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030170826 A1

TITLE: Peptides for facilitating composite receptor expression and translocation of macromolecules

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rabinovich, Peter	Madison	CT	US	
Bray-Ward, Patricia	Madison	CT	US	
Ward, David C.	Madison	CT	US	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/7.5, 530/350, 536/23.5

ABSTRACT:

The invention relates to compositions and methods for expressing a composite receptor on the cell surface. The composite receptor can be integrated into a cell membrane via a fusion peptide which includes a cell penetrating domain linked to a transmembrane domain. In a preferred embodiment, the composite receptor further comprises a ligand binding domain. In yet another embodiment the invention relates to compositions and methods for translocating a nucleic acid or other molecule across the cell membrane into the cell. In a preferred embodiment, the nucleic acid or other molecule is linked to a fusion peptide comprising an adapter domain which is linked to a cell penetrating domain.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 23. Document ID: US 20030166160 A1

L4: Entry 23 of 79 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166160

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030166160 A1

TITLE: Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hawley, Stephen B.	San Diego	CA	US	
Chapin, Steven	San Diego	CA	US	
Sheridan, Philip L.	San Diego	CA	US	
Houston, L. L.	Del Mar	CA	US	
Glynn, Jacqueline M.	San Diego	CA	US	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

ABSTRACT:

Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and/or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from the properties of monomers, complexes and compounds having only one targeting element directed to a paracellular and/or transcytotic ligand. The complexes and compounds of the invention undergo endocytosis, transcytosis and exocytosis; following endocytosis, the complexes or compounds may be transported into the cytosol or an organelle of a cell. In polarized cells, transcytosis can proceed in a "forward" or "reverse" direction. Reverse transcytosis is used for the non-invasive delivery of biologically active agents from the lumen of, e.g., the gastrointestinal tract or the airways of lungs, to the circulatory system. The complexes and compounds are incorporated in various compositions and medical devices suitable for medicinal or veterinary use.

☐ 24. Document ID: US 20030165945 A1

L4: Entry 24 of 79 File: PGPB Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030165945
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030165945 A1

TITLE: Human Pellino polypeptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	
Cosman, David J.	Bainbridge Island	WA	US	
Li, Xiaoxia	Solon	OH	US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

☐ 25. Document ID: US 20030119771 A1

L4: Entry 25 of 79 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119771
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119771 A1

TITLE: Modulators of bone homeostasis identified in a high-throughput screen

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rompaey, Luc Van	Keerbergen		BE	
Van Es, Helmuth Hendrikus Gerardus	Haarlem		NL	
Tomme, Peter Herwig Maria	Gent		BE	
Klaassen, Hubertus Johannes Matheus	Herent		BE	

US-CL-CURRENT: 514/44; 435/226, 435/320.1, 435/366, 435/6, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis.

In particular, the present invention relates to polynucleotides and the encoded polypeptides that are identified in a high-throughput screen designed to detect modulation of bone alkaline phosphatase activity. Moreover, the present invention relates to vectors, host cells, antibodies and diagnostic methods for detecting diseases involving the discovered polynucleotides, and therapeutic methods for treating such diseases. The invention further relates to methods and means for drug compound screens designed to develop new therapeutic strategies.

☐ 26. Document ID: US 20030118611 A1

L4: Entry 26 of 79 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118611
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118611 A1

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Koelle, David M.	Seattle	WA	US	
Corey, Lawrence	Seattle	WA	US	

US-CL-CURRENT: 424/231.1; 424/186.1, 424/192.1, 424/199.1, 435/235.1, 435/320.1, 435/69.1, 435/69.7, 530/350, 536/23.72

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

☐ 27. Document ID: US 20030118600 A1

L4: Entry 27 of 79 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118600
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118600 A1

TITLE: Transfer compounds, production and use thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gerdes, Johannes	Feldhorst		DE	
Scholzen, Thomas	Neritz		DE	
Wohlenberg, Claudia	Hamburg		DE	

US-CL-CURRENT: 424/185.1; 435/320.1, 435/325, 435/69.3, 514/44, 530/350, 536/23.2

ABSTRACT:

The invention relates to the use of a carboxy-terminal fragment of the Ki-67 protein or of an active part, fragment or homologue thereof as a compound that can be used

for intracellular transfer and for the introduction in and the release by the cells. The invention further relates to transfer compounds that contain the above-mentioned Ki-67 protein and to the vectors encoding the same. The invention also relates to corresponding pharmaceutical compositions and to the use of the transfer protein as an excipient or active agent in the treatment of diseases.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 28. Document ID: US 20030105277 A1

L4: Entry 28 of 79 File: PGPB Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030105277
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030105277 A1

TITLE: Compositions and therapeutic methods for viral infection

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morham, Scott	Salt Lake City	UT	US	
Zavitz, Kenton	Salt Lake City	UT	US	
Hobden, Adrian	Salt Lake City	UT	US	

US-CL-CURRENT: 530/300; 424/186.1, 530/350

ABSTRACT:

Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a compound capable of inhibiting viral budding from the infected host cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 29. Document ID: US 20030066095 A1

L4: Entry 29 of 79 File: PGPB Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030066095
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030066095 A1

TITLE: Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Baubet, Valerie	Paris		FR	

LeMouellic, Herve	Paris	FR
Brulet, Philippe	Paris	FR

US-CL-CURRENT: 800/3; 424/9.6, 435/4, 530/350, 536/23.5

ABSTRACT:

A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des

☐ 30. Document ID: US 20030055219 A1

L4: Entry 30 of 79 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055219
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030055219 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/7.1, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw. Des

☐ 31. Document ID: US 20030054409 A1

L4: Entry 31 of 79 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054409
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054409 A1

TITLE: Novel complex-forming proteins

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jerome, Valerie	Coelbe		DE	
Sedlacek, Hans-Harald	Marburg		DE	
Mueller, Rolf	Marburg		DE	

US-CL-CURRENT: 435/7.1; 435/183, 435/320.1, 435/325, 435/69.5, 435/69.7, 530/350, 530/351

ABSTRACT:

The invention relates to a complex of specifically complex-forming proteins which are not naturally occurring, comprising the following components: a) at least one ligand specific for a target structure, b) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component c) and the component b) being connected covalently to the component a), c) at least one protein comprising a mutated dimerization domain, the mutated dimerization domain having been derived by mutation of a naturally occurring dimerization domain, it being possible for this mutated dimerization domain to interact specifically with component b) and the component c) is linked covalently to the component d), and d) at least one effector. In addition, the invention relates to the use and preparation of these complexes, and to nucleic acid constructs coding for the proteins mentioned and use thereof.

☐ 32. Document ID: US 20030054000 A1

L4: Entry 32 of 79 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030054000
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030054000 A1

TITLE: Anti-pathogen system and methods of use thereof

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dowdy, Steven F.	Clayton	MO	US	

US-CL-CURRENT: 424/94.63; 435/226, 530/327, 530/350, 536/23.4, 536/24.33

ABSTRACT:

The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 33. Document ID: US 20030044427 A1

L4: Entry 33 of 79 File: PGPB Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030044427
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030044427 A1

TITLE: Compositions and methods for treating Papillomavirus-infected cells

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howley, Peter M.	Wellesley	MA	US	
Benson, John	Brookline	MA	US	
Kasukawa, Hiroaki	Princeton	NJ	US	

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 34. Document ID: US 20030036163 A1

L4: Entry 34 of 79 File: PGPB Feb 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030036163
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030036163 A1

TITLE: Novel PN9826 nucleic acids and use thereof

PUBLICATION-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wettstein, Daniel Albert	Salt Lake City	UT	US	
Mauck, Kimberly A.	Sandy	UT	US	

US-CL-CURRENT: 435/69.1; 435/183, 435/320.1, 435/325, 530/350, 536/23.2

ABSTRACT:

Novel PN9826 protein and nucleic acids encoding PN9826 are provided. PN9826-containing protein complexes formed by PN9826 and a PN9826-interacting protein (e.g., LTBP1) are also provided. LTBP1 and PN9826 may be involved in common biological processes such as angiogenesis, metastasis, and cell growth and adhesion. Thus, the protein complexes as well as PN9826 can be used in screening assays to select modulators of PN9826 and the protein complexes formed by PN9826 and LTBP1. The identified modulators can be useful in modulating the functions and activities of PN9826 and protein complexes containing PN9826.

☐ 35. Document ID: US 20030032592 A1

L4: Entry 35 of 79 File: PGPB Feb 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030032592
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030032592 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: February 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 435/7.1, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 36. Document ID: US 20030017174 A1

L4: Entry 36 of 79 File: PGPB Jan 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030017174
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030017174 A1

TITLE: HERPES SIMPLEX VIRUS VP22 VACCINES AND METHODS OF USE

PUBLICATION-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BURKE, RAE LYNN	SAN FRANCISCO	CA	US	
TIGGES, MICHAEL A.	OAKLAND	CA	US	

US-CL-CURRENT: 424/231.1; 424/204.1, 530/300, 530/350, 530/826

ABSTRACT:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

☐ 37. Document ID: US 20020177692 A1

L4: Entry 37 of 79 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020177692
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020177692 A1

TITLE: BCL-XL-interacting protein and use thereof

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bartel, Paul	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350; 435/184, 435/287.2, 435/320.1, 435/325, 435/69.7

ABSTRACT:

Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the

protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 38. Document ID: US 20020169283 A1

L4: Entry 38 of 79 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169283
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020169283 A1

TITLE: Clasp-7 transmembrane protein

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan David	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-7 ("CLASP-7"). In particular, it relates to CLASP-7 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-7 function.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 39. Document ID: US 20020168683 A1

L4: Entry 39 of 79 File: PGPB Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020168683
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020168683 A1

TITLE: Human pellino polypeptides

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bird, Timothy A.	Bainbridge Island	WA	US	

Cosman, David J. Bainbridge Island WA US

US-CL-CURRENT: 435/7.1; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 40. Document ID: US 20020165352 A1

L4: Entry 40 of 79 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020165352
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020165352 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 530/350

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitis (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 41. Document ID: US 20020164666 A1

L4: Entry 41 of 79 File: PGPB Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164666

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020164666 A1

TITLE: Protein-protein interactions

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Cimbora, Daniel M.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	

US-CL-CURRENT: 435/7.23; 435/183, 530/350, 530/388.1

ABSTRACT:

The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 42. Document ID: US 20020147306 A1

L4: Entry 42 of 79 File: PGPB Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147306
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020147306 A1

TITLE: Peptides that modulate the interaction of B class ephrins and PDZ domains

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lin, Danny	Scarborough		CA	
Pawson, Anthony	Toronto		CA	
Gish, Gerald	East York		CA	

US-CL-CURRENT: 530/350; 530/324

ABSTRACT:

The invention relates to complexes comprising a B class ephrin and a PDZ domain containing protein; peptides that interfere with the interaction of a B class ephrin

with a PDZ domain binding site, and a PDZ domain containing protein; and, uses of the peptides and complexes. Methods for modulating the interaction of a B class ephrin and a PDZ domain containing protein, and methods for evaluating compounds for their ability to modulate the interaction are also described.

☐ 43. Document ID: US 20020115607 A1

L4: Entry 43 of 79 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115607
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115607 A1

TITLE: Protein-protein interactions in neurodegenerative diseases

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roch, Jean-Marc	Salt Lake City	UT	US	
Bartel, Paul L.	Salt Lake City	UT	US	
Heichman, Karen	Salt Lake City	UT	US	

US-CL-CURRENT: 514/12; 424/146.1, 435/194, 435/226, 530/350

ABSTRACT:

The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

☐ 44. Document ID: US 20020106378 A1

L4: Entry 44 of 79 File: PGPB Aug 8, 2002

PGPUB-DOCUMENT-NUMBER: 20020106378
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020106378 A1

TITLE: Materials and methods for intracellular transport and their uses

PUBLICATION-DATE: August 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Oxted		GB	
Elliott, Gillian Daphne	Oxted		GB	

US-CL-CURRENT: 424/186.1; 530/350

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

☐ 45. Document ID: US 20020086361 A1

L4: Entry 45 of 79 File: PGPB Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086361
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086361 A1

TITLE: Modulators of antiestrogen pharmacology

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Montano, Monica	Shaker Heights	OH	US	
Sutton, Amelia	Cleveland Heights	OH	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/456, 435/458, 530/350, 536/23.5

ABSTRACT:

A protein, designated ERCoA3 is provided. The ERCoA3 protein interacts with the estrogen receptor and the progesterone receptor and causes activation of these receptors is provided. Also provided are polynucleotides which encode ERCoA3 or block translation of the mRNA which encodes ERCoA3. Antibiodies that bind to one or more epitopes in the human ERCoA3 protein are provided. The present invention also relates to methods of inhibiting or reducing tamoxifen or estrogen induced proliferation of cancer cells, particularly breast cancer cells, endometrial cancer cells and uterine cancer cells. The method comprises reducing the activity or levels of ERCoA3 in such.

☐ 46. Document ID: US 20020068302 A1

L4: Entry 46 of 79 File: PGPB Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020068302
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020068302 A1

TITLE: Clasp-4 transmembrane protein

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lu, Peter S.	Mountain View	CA	US	
Garman, Jonathan D.	San Jose	CA	US	
Candia, Albert F. III	Menlo Park	CA	US	

US-CL-CURRENT: 435/7.1; 530/350, 536/23.1

ABSTRACT:

The present invention relates to a cell surface molecule, designated cadherin-like asymmetry protein-4 ("CLASP-4"). In particular, it relates to CLASP-4 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP-4 function.

☐ 47. Document ID: US 20020039765 A1

L4: Entry 47 of 79 File: PGPB Apr 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020039765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020039765 A1

TITLE: Transport proteins and their uses

PUBLICATION-DATE: April 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
O'Hare, Peter Francis Joseph	Surrey		GB	
Elliott, Gillian Daphne	Surrey		GB	

US-CL-CURRENT: 435/69.7; 435/320.1, 435/325, 435/471, 435/472, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and

homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting oat high efficiency is required.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 48. Document ID: US 20020032154 A1

L4: Entry 48 of 79 File: PGPB Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020032154
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020032154 A1

TITLE: Interferon-suppressing placental lactogen peptides

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Peyman, John A.	New Haven	CT	US	

US-CL-CURRENT: 514/12; 435/184, 530/350

ABSTRACT:

Interferon-Suppressing Placental Lactogen Peptides (ISPLP) are disclosed which block actions of the human cytokine interferon-gamma. In addition, methods are disclosed for the treatment with ISPLP of certain disorders associated with increased expression of interferon-gamma-stimulated major histocompatibility complex antigens, such as autoimmune diseases, inflammatory diseases, and transplant rejection.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

☐ 49. Document ID: US 20020001805 A1

L4: Entry 49 of 79 File: PGPB Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001805
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020001805 A1

TITLE: Immunogenic ovarian cancer genes

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Roden, Richard Bruce	Washington	DC	US	
Naora, Honami	Baltimore	MD	US	

US-CL-CURRENT: 435/6; 435/325, 435/69.1, 435/7.23, 530/350, 536/23.5

ABSTRACT:

The present invention is based on the discovery of autoantibodies in cancer patients specific for a number of antigens that are normally intracellular, including homeobox protein HOXA7, homeobox protein HOXB7, ADP-ribosylation factor 1 (Arf-1), ATP-dependent iron transporter ABC-7, and a novel protein encoded by a EcoRI/XhoI fragment of bacteriophage .lambda. clone 44B.1 deposited under ATCC accession No. [N]. The presence of these autoantibodies can be correlated with neoplastic processes in patients, and therefore detection of autoantibodies (or detection of expression of the antigens by other means) can be used as a component of a cancer screening program. The present invention provides such screening assays. In addition, the studies leading to the identification of the predictive autoantigens have also succeeded in identifying a hitherto unknown antigen that is disclosed herein.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 50. Document ID: US 20010044417 A1

L4: Entry 50 of 79 File: PGPB Nov 22, 2001

PGPUB-DOCUMENT-NUMBER: 20010044417
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010044417 A1

TITLE: Compound containing a labile disulfide bond

PUBLICATION-DATE: November 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wolff, Jon A.	Madison	WI	US	
Monahan, Sean D.	Madison	WI	US	
Budker, Vladimir G.	Middleton	WI	US	
Slattum, Paul M.	Madison	WI	US	
Rozema, David B.	Madison	WI	US	

US-CL-CURRENT: 514/44; 514/2, 530/350, 536/23.1

ABSTRACT:

A labile disulfide-containing compound under physiological conditions containing a labile disulfide bond and a transduction signal.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 51. Document ID: US 6787326 B1

L4: Entry 51 of 79 File: USPT Sep 7, 2004

US-PAT-NO: 6787326
DOCUMENT-IDENTIFIER: US 6787326 B1

TITLE: Interaction between the VHL tumor suppressor and hypoxia inducible factor, and

assay methods relating thereto

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ratcliffe; Peter John	Oxford			GB
Maxwell; Patrick Henry	Oxford			GB
Pugh; Christopher William	Oxford			GB

US-CL-CURRENT: 435/14; 435/6, 435/7.1, 435/8, 530/350

ABSTRACT:

The invention relates to the finding that the VHL tumour suppressor protein regulates hypoxia inducible factor .alpha. subunits, by targeting HIF .alpha. for destruction in normoxic, but not hypoxic cells. The invention provides assays for modulators of this interaction, and peptides based upon HIF .alpha. subunit sequence which may modulate this interaction.

16 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 52. Document ID: US 6780970 B2

L4: Entry 52 of 79 File: USPT Aug 24, 2004

US-PAT-NO: 6780970
DOCUMENT-IDENTIFIER: US 6780970 B2

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

DATE-ISSUED: August 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonny; Christophe	Morges			CH

US-CL-CURRENT: 530/324; 530/300, 530/325, 530/326, 530/332

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

13 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 53. Document ID: US 6773920 B1

L4: Entry 53 of 79 File: USPT Aug 10, 2004

US-PAT-NO: 6773920
DOCUMENT-IDENTIFIER: US 6773920 B1

TITLE: Delivery of functional protein sequences by translocating polypeptides

DATE-ISSUED: August 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dalby; Brian	Carlsbad	CA		
Bennett; Robert P.	Encinitas	CA		

US-CL-CURRENT: 435/462; 435/455, 435/468, 435/471, 530/300, 530/350

ABSTRACT:

The invention provides methods for modulating a cellular process by contacting a cell in culture with a cell process-modifying molecule attached to a translocating polypeptide. For example, in one embodiment, a cell in culture is transfected with a target gene by contacting the cell in culture with a polynucleotide (that contains the target gene) attached to a translocating polypeptide. In another embodiment, expression of a target gene product in a cell in culture that contains a target gene under control of one or more regulatory elements is modulated by contacting the cell in culture with one or more regulatory agents attached to a translocating polypeptide. The one or more regulatory agents are translocated into the cell in culture and interact therein with the one or more regulatory elements to modulate expression of the target gene product by the cell.

37 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 54. Document ID: US 6740524 B1

L4: Entry 54 of 79 File: USPT May 25, 2004

US-PAT-NO: 6740524
DOCUMENT-IDENTIFIER: US 6740524 B1

TITLE: Nucleic acid transfer phage

DATE-ISSUED: May 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Akuta; Teruo	Kumamoto			JP
Yokoi; Haruhiko	Tokyo			JP
Okuyama; Hajime	Hyogo			JP

Takeda; Katsuo	late of Tokyo	JP
Hasegawa; Mamoru	Ibaraki	JP
Nakanishi; Mahito	Osaka	JP

US-CL-CURRENT: 435/456; 435/235.1, 435/252.3, 435/252.33, 435/320.1, 435/69.7, 435/975, 530/350, 536/23.4

ABSTRACT:

The present invention provides a novel phage expressing in its head a bi-functional protein that has nuclear translocation and cell adhesion activities. The phage is used to package a foreign substance such as a gene. As a bi-functional protein, TAT protein of HIV can be used. The phage is useful in gene therapy.

18 Claims, 8 Drawing figures
Exemplary Claim Number: 1,15
Number of Drawing Sheets: 8

☐ 55. Document ID: US 6734167 B2

L4: Entry 55 of 79 File: USPT May 11, 2004

US-PAT-NO: 6734167
DOCUMENT-IDENTIFIER: US 6734167 B2

TITLE: Uses of transport proteins

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Surry			GB
Normand; Nadia Michelle	Boulogne-Billancourt			FR
Brewis; Neil Douglas	Surry			GB
Phelan; Anne	Kent			GB

US-CL-CURRENT: 514/12; 424/204.1, 424/231.1, 530/350, 536/23.1, 536/23.5

ABSTRACT:

This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 56. Document ID: US 6703487 B2

L4: Entry 56 of 79 File: USPT Mar 9, 2004

US-PAT-NO: 6703487
DOCUMENT-IDENTIFIER: US 6703487 B2

TITLE: Human pellino polypeptides

DATE-ISSUED: March 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bird; Timothy A.	Seattle	WA		
Cosman; David J.	Seattle	WA		

US-CL-CURRENT: 530/350; 435/252.3, 435/254.11, 435/254.2, 435/325, 435/69.1, 530/324, 530/351, 536/23.5

ABSTRACT:

There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 57. Document ID: US 6683048 B1

L4: Entry 57 of 79 File: USPT Jan 27, 2004

US-PAT-NO: 6683048
DOCUMENT-IDENTIFIER: US 6683048 B1

TITLE: Compounds and methods for stimulating gene expression and cellular differentiation

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blaschuk; Orest W.	Westmount			CA
Gour; Barbara J.	Montreal			CA

US-CL-CURRENT: 514/2; 514/11, 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/9, 530/300, 530/326, 530/328, 530/329 , 530/330

ABSTRACT:

Modulating agents for inhibiting an interaction between .alpha.-catenin and .beta.-catenin are provided. The modulating agents comprise one or more of: (a) a .beta.-catenin HAV motif; (b) a peptide analogue or mimetic of a .beta.-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a .beta.-catenin HAV motif. Methods for using such modulating agents for inhibiting

cadherin-mediated cell adhesion in a variety of contexts are also provided.

16 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 58. Document ID: US 6677116 B1

L4: Entry 58 of 79 File: USPT Jan 13, 2004

US-PAT-NO: 6677116
DOCUMENT-IDENTIFIER: US 6677116 B1

TITLE: Methods for treating cancer by modulating .beta.-catenin mediated gene expression

DATE-ISSUED: January 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blaschuk; Orest W.	Westmount			CA
Byers; Stephen	Washington	DC		
Gour; Barbara J.	Kemptville			CA

US-CL-CURRENT: 435/6; 514/14, 514/2, 514/9, 530/300, 536/22.1

ABSTRACT:

Modulating agents for inhibiting .beta.-catenin mediated gene expression are provided. The modulating agents comprise one or more of: (1) the peptide sequence LXXLL (SEQ ID NO:1); or (2) a peptide analogue or peptidomimetic thereof. Methods for using such modulating agents for modulating .beta.-catenin mediated gene expression and cellular differentiation in a variety of contexts (e.g., for modulating hair growth or treating cancer or Alzheimer's disease) are provided.

13 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 59. Document ID: US 6673354 B2

L4: Entry 59 of 79 File: USPT Jan 6, 2004

US-PAT-NO: 6673354
DOCUMENT-IDENTIFIER: US 6673354 B2

TITLE: Compositions and methods for treating papillomavirus-infected cells

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howley; Peter M.	Wellesley	MA		
Benson; John	Brookline	MA		
Kasukawa; Hiroaki	Princeton	NJ		

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

17 Claims, 14 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 60. Document ID: US 6669951 B2

L4: Entry 60 of 79 File: USPT Dec 30, 2003

US-PAT-NO: 6669951
DOCUMENT-IDENTIFIER: US 6669951 B2

TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothbard; Jonathan B.	Cupertino	CA		
Wender; Paul A.	Menlo Park	CA		
McGrane; P. Leo	Mountain View	CA		
Sista; Lalitha V. S.	Sunnyvale	CA		
Kirschberg; Thorsten A.	Mountain View	CA		

US-CL-CURRENT: 424/436; 514/11, 514/16, 514/169, 514/2, 514/634, 514/636, 530/300, 530/329, 564/236, 564/243

ABSTRACT:

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that

has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

88 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 34

☐ 61. Document ID: US 6664040 B2

L4: Entry 61 of 79 File: USPT Dec 16, 2003

US-PAT-NO: 6664040
DOCUMENT-IDENTIFIER: US 6664040 B2

TITLE: Compositions and methods for delivery of a molecule into a cell

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sherman; Michael P.	San Francisco	CA		
Greene; Warner C.	San Francisco	CA		
de Noronha; Carlos M.C.	San Francisco	CA		
Schubert; Ulrich	Bethesda	MA		
Henklein; Peter	Berlin			GB

US-CL-CURRENT: 435/5; 435/29, 435/325, 435/41, 530/300, 530/350, 530/395

ABSTRACT:

Provided is a composition comprising a Vpr polypeptide conjugated to a therapeutic molecule. Preferably, the Vpr comprises synthetic Vpr. The therapeutic molecule can comprise any molecule capable of being conjugated to Vpr or a fragment thereof, including a polypeptide, a polynucleotide, and/or a toxin. The invention additionally provides a method for delivering a molecule into a cell. The method comprises contacting the cell with a conjugate comprising a Vpr polypeptide conjugated to the molecule. The invention further provides a method for modulating the expression of a transgene in a cell, a method for killing a target cell population in a subject, a method for increasing the sensitivity of cells to radiation therapy, and a method for inhibiting cell proliferation.

14 Claims, 83 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 29

☐ 62. Document ID: US 6635258 B2

L4: Entry 62 of 79 File: USPT Oct 21, 2003

US-PAT-NO: 6635258
DOCUMENT-IDENTIFIER: US 6635258 B2

TITLE: Herpes simplex virus VP22 vaccines and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke; Rae Lyn	San Francisco	CA		
Tigges; Michael A.	Oakland	CA		

US-CL-CURRENT: 424/231.1; 424/185.1, 424/204.1, 424/229.1, 530/350

ABSTRACT:

Vaccines containing herpes simplex virus (HSV) VP22 polypeptides capable of eliciting a cellular immune response and methods for treating and preventing HSV infections using the vaccines are disclosed. The vaccines can include additional HSV polypeptides, such as HSV glycoproteins. Also disclosed are methods of DNA immunization.

24 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 63. Document ID: US 6632616 B2

L4: Entry 63 of 79 File: USPT Oct 14, 2003

US-PAT-NO: 6632616
DOCUMENT-IDENTIFIER: US 6632616 B2
**** See image for Certificate of Correction ****

TITLE: Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof

DATE-ISSUED: October 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burke; James R.	Chapel Hill	NC		
Strittmatter; Warren J.	Durham	NC		
Nagai; Yoshitaka	Osaka			JP

US-CL-CURRENT: 435/7.1; 435/4, 435/6, 530/350

ABSTRACT:

Compounds that selectively bind to expanded polyglutamine repeats are disclosed. Such

compounds are characterized in that they bind to a first polyglutamine peptide consisting of 60 glutamine residues under conditions in which they do not bind to a second polyglutamine peptide consisting of 20 glutamine residues. Conjugates of such compounds, nucleic acids encoding the same, and methods of use thereof are also disclosed.

6 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 64. Document ID: US 6610820 B1

L4: Entry 64 of 79 File: USPT Aug 26, 2003

US-PAT-NO: 6610820
DOCUMENT-IDENTIFIER: US 6610820 B1

TITLE: Cell-permeable peptide inhibitors of the JNK signal transduction pathway

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bonny; Christophe	Morges			CH

US-CL-CURRENT: 530/300; 530/324, 530/326, 530/328

ABSTRACT:

The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells.

20 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 65. Document ID: US 6610542 B1

L4: Entry 65 of 79 File: USPT Aug 26, 2003

US-PAT-NO: 6610542
DOCUMENT-IDENTIFIER: US 6610542 B1
**** See image for Certificate of Correction ****

TITLE: Efficient ex vivo expansion of cd4+ and cd8- T-cells from HIV infected subjects

DATE-ISSUED: August 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bell; David N.	Oakville			CA
Rosenthal; Kenneth Lee	Ancaster			CA

US-CL-CURRENT: 435/377; 424/93.2, 424/93.21, 435/320.1, 435/325, 435/455, 514/44, 530/350, 530/351

ABSTRACT:

Methods for the expansion of CD4, CD8, and DP T-cells from HIV infected patients are disclosed which allow the maintenance of low levels of HIV. The invention further discloses methods for the inhibition of HIV gene expression. Also disclosed are methods for the rapid and efficient screening of cells derived from HIV-infected patients to assess the suitability of various antiviral treatments. The invention further provides a means for the generation of cell banks for use in immune reconstitution and means of treating or modifying expanded cell populations prior to infusion to enhance or modulate therapeutic effectiveness.

33 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 66. Document ID: US 6593292 B1

L4: Entry 66 of 79 File: USPT Jul 15, 2003

US-PAT-NO: 6593292
DOCUMENT-IDENTIFIER: US 6593292 B1

TITLE: Compositions and methods for enhancing drug delivery across and into epithelial tissues

DATE-ISSUED: July 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rothbard; Jonathan B.	Cupertino	CA		
Wender; Paul A.	Menlo Park	CA		
McGrane; P. Leo	Mountain View	CA		
Sista; Lalitha V. S.	Sunnyvale	CA		
Kirschberg; Thorsten A.	Mountain View	CA		

US-CL-CURRENT: 514/2; 514/11, 514/12, 514/15, 514/159, 514/16, 514/169, 514/17, 514/254.07, 514/263.31, 514/291, 514/423 , 514/456, 514/458, 514/634, 514/635, 514/636, 530/300, 530/321, 530/328, 530/329, 530/330, 544/366

ABSTRACT:

This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient

guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

134 Claims, 41 Drawing figures
Exemplary Claim Number: 61
Number of Drawing Sheets: 23

☐ 67. Document ID: US 6461822 B2

L4: Entry 67 of 79 File: USPT Oct 8, 2002

US-PAT-NO: 6461822
DOCUMENT-IDENTIFIER: US 6461822 B2

TITLE: Methods of screening compounds for their ability to inhibit the production of inflammatory cytokines

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gabel; Christopher A.	Ledyard	CT		
Griffiths; Richard J.	East Lyme	CT		
Eggler; James F.	Stonington	CT		
Dombroski; Mark A.	Waterford	CT		
Geoghegan; Kieran	Mystic	CT		

US-CL-CURRENT: 435/7.2; 435/7.1, 530/350, 536/23.5, 564/305

ABSTRACT:

The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1.beta..

24 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 13

☐ 68. Document ID: US 6451601 B1

L4: Entry 68 of 79 File: USPT Sep 17, 2002

US-PAT-NO: 6451601
DOCUMENT-IDENTIFIER: US 6451601 B1

TITLE: Transiently immortalized cells for use in gene therapy

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baetge; Edward E.	St. Sulpice			CH
Wong; Shou	Verona	WI		
Dupraz; Philippe	Crissier			CH
Thorens; Bernard	Epalinges			CH

US-CL-CURRENT: 435/366; 435/377, 435/405, 530/350, 536/23.4

ABSTRACT:

The invention provides methods and compositions for expanding cells that are not abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region containing a translocation carrier moiety having the function of a transport polypeptide amino acid sequence from, e.g., herpesviral VP22, HIV TAT, Antp HD, Arg repeats, or a cationic polymer, or from homologues or fragments thereof, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

12 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 69. Document ID: US 6451579 B1

L4: Entry 69 of 79 File: USPT Sep 17, 2002

US-PAT-NO: 6451579
DOCUMENT-IDENTIFIER: US 6451579 B1

TITLE: Regulated expression of recombinant proteins using RNA viruses

DATE-ISSUED: September 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jessee; Joel A.	Mount Airy	MD		
Ciccarone; Valentina C.	Gaithersburg	MD		

US-CL-CURRENT: 435/235.1; 424/94.5, 435/15, 435/320.1, 435/440, 435/455, 435/6, 435/69.1, 514/44, 530/350

ABSTRACT:

The present invention describes cells and constructs for a regulated viral (e.g. alphavirus) expression system, where gene expression is controlled by controlling expression of replicases or nonstructural proteins and/or controlling the amount of such proteins introduced in a cell, which in turn regulates RNA replication and

subsequently gene expression. Particularly, this system takes advantage of the high level expression of the alphavirus systems for recombinant protein production and allows for large scale applications without biosafety concerns.

9 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 70. Document ID: US 6399075 B1

L4: Entry 70 of 79 File: USPT Jun 4, 2002

US-PAT-NO: 6399075
DOCUMENT-IDENTIFIER: US 6399075 B1

TITLE: Compositions and methods for treating Papillomavirus-infected cells

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howley; Peter M.	Wellesley	MA		
Benson; John	Brookline	MA		
Kasukawa; Hiroaki	Princeton	NJ		

US-CL-CURRENT: 424/204.1; 514/12, 530/321, 530/325, 530/326, 530/350, 530/388.4, 536/23.74

ABSTRACT:

By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

32 Claims, 24 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 71. Document ID: US 6375952 B1

L4: Entry 71 of 79 File: USPT Apr 23, 2002

US-PAT-NO: 6375952
DOCUMENT-IDENTIFIER: US 6375952 B1
**** See image for Certificate of Correction ****

TITLE: Immunological herpes simplex virus antigens and methods for use thereof

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Koelle; David M.	Seattle	WA		
Corey; Lawrence	Seattle	WA		

US-CL-CURRENT: 424/186.1; 424/192.1, 424/199.1, 424/231.1, 435/235.1, 435/252.3, 435/320.1, 435/325, 435/69.3, 435/69.7 , 530/350, 536/23.4, 536/23.7

ABSTRACT:

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

39 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 72. Document ID: US 6358739 B1

L4: Entry 72 of 79 File: USPT Mar 19, 2002

US-PAT-NO: 6358739
DOCUMENT-IDENTIFIER: US 6358739 B1
**** See image for Certificate of Correction ****

TITLE: Transiently immortalized cells

DATE-ISSUED: March 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baetge; Edward E.	St. Sulpice			CH
Wong; Shou	Lausanne			CH
Dupraz; Philippe	Crissier			CH
Thorens; Bernard	Epalinges			CH

US-CL-CURRENT: 435/377; 530/350

ABSTRACT:

The invention provides methods and compositions for expanding cells that are not

abundant or are difficult to obtain in pure form in culture, are in short supply (e.g., human cells), or have brief lifetimes in culture, using fusion polypeptide. The fusion polypeptide has a first region having the transport function of herpesviral VP22 protein or human immunodeficiency virus (HIV) TAT protein, and a second region with a polypeptide having cell immortalization activity, a polypeptide having telomerase-specific activity, or a polypeptide having telomerase gene activation activity. The resulting cells of the invention are suitable for use in cell therapy.

12 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

---

☐ 73. Document ID: US 6316252 B1

L4: Entry 73 of 79 File: USPT Nov 13, 2001

US-PAT-NO: 6316252
DOCUMENT-IDENTIFIER: US 6316252 B1

TITLE: Biotherapeutic delivery system

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Harms; Jerome S.	Madison	WI		
Splitter; Gary A.	Brooklyn	WI		

US-CL-CURRENT: 435/320.1; 435/69.7, 530/350, 530/826, 536/23.4, 536/23.72

ABSTRACT:

Disclosed herein are fusion proteins, nucleotide sequences for creating them, and vectors containing the nucleotide sequences. The fusion proteins have a bovine herpesvirus protein linked to a biotherapeutic protein or reporter protein. They rapidly spread biotherapeutic or reporter protein throughout mammalian cells.

4 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

---

☐ 74. Document ID: US 6313269 B1

L4: Entry 74 of 79 File: USPT Nov 6, 2001

US-PAT-NO: 6313269
DOCUMENT-IDENTIFIER: US 6313269 B1

TITLE: Tumor necrosis factor related receptor, TR6

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Deen; Keith C.	Glenmore	PA		
Young; Peter R.	Lawrenceville	NJ		
Marshall; Lisa A.	Wyndmoor	PA		
Roshak; Amy K.	East Norriton	PA		
Tan; Kong B.	Philadelphia	PA		
Truneh; Alemseged	West Chester	PA		

US-CL-CURRENT: 530/350; 435/69.1

ABSTRACT:

TR6 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing TR6 polypeptides and polynucleotides in the design of protocols for the treatment of chronic and acute inflammation, arthritis, septicemia, autoimmune diseases (e.g. inflammatory bowel disease, psoriasis), transplant rejection, graft vs. host disease, infection, stroke, ischemia, acute respiratory disease syndrome, restenosis, brain injury, AIDS, Bone diseases, cancer, atheroschlerosis, and Alzheimers disease, among others and diagnostic assays for such conditions.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 75. Document ID: US 6251398 B1

L4: Entry 75 of 79 File: USPT Jun 26, 2001

US-PAT-NO: 6251398
DOCUMENT-IDENTIFIER: US 6251398 B1
**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 424/186.1; 424/192.1, 424/204.1, 424/208.1, 424/248.1, 424/263.1, 435/235.1, 435/252.3, 435/317.1, 435/325, 530/350, 530/826, 536/23.4

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide

proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumor antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides, vectors and host cells.

19 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 76. Document ID: US 6200577 B1

L4: Entry 76 of 79 File: USPT Mar 13, 2001

US-PAT-NO: 6200577
DOCUMENT-IDENTIFIER: US 6200577 B1

TITLE: Anti-herpesviral agents and assays therefor

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McLauchlan; John	Glasgow			GB
McGeoch; Duncan James	Glasgow			GB
Hope; Ralph Graham	Glasgow			GB
Rixon; Helen Winton McLaren	Strathblane			GB

US-CL-CURRENT: 424/229.1; 424/204.1, 424/231.1, 435/5, 435/7.93, 435/975, 530/300, 536/23.72

ABSTRACT:

There is described an antiviral agent capable of disrupting the association of two viral structural proteins required for maturation, replication and infection of herpesviruses. The agents are based upon VP22 and disrupt the normal association of that protein with VP16 and/or gB. Suitable agents are peptides having the amino acid sequences TPRVAGFNKRVFCAAVGRLAAMHARMAAVQLW or ITTIRVTVCEGKNLLQRANE. The agents are suitable for combatting infection of herpesviruses and thus for the treatment of cod sores, genital herpes, chickenpox and shingles. An assay to test for agents able to disrupt VP22/V16 and/or VP22/gB association is also described.

13 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 77. Document ID: US 6184038 B1

L4: Entry 77 of 79 File: USPT Feb 6, 2001

US-PAT-NO: 6184038
DOCUMENT-IDENTIFIER: US 6184038 B1
**** See image for Certificate of Correction ****

TITLE: Transport proteins and their uses

DATE-ISSUED: February 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/455; 435/468, 435/471, 530/300, 530/350

ABSTRACT:

The present invention relates to transport proteins, in particular VP22 and homologues thereof, and to methods of delivering these proteins and any associated molecules to a target population of cells. This transport protein has applications in gene therapy and methods of targeting agents to cells where targeting at high efficiency is required.

8 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 78. Document ID: US 6086900 A

L4: Entry 78 of 79 File: USPT Jul 11, 2000

US-PAT-NO: 6086900
DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3, 435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

☐ 79. Document ID: US 6017735 A

L4: Entry 79 of 79 File: USPT Jan 25, 2000

US-PAT-NO: 6017735
DOCUMENT-IDENTIFIER: US 6017735 A
**** See image for Certificate of Correction ****

TITLE: Materials and methods for intracellular transport and their uses

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Hare; Peter Francis Joseph	Oxted			GB
Elliott; Gillian Daphne	Oxted			GB

US-CL-CURRENT: 435/69.7; 435/252.3, 435/317.1, 435/320.1, 435/325, 435/69.3, 530/350, 536/23.4, 536/23.5

ABSTRACT:

Coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use, include (i) an aminoacid sequence with the transport function of herpesviral VP22 protein (or a homologue, e.g. from VZV, BHV or MDV) and (ii) another protein sequence selected from (a) proteins for cell cycle control; (b) suicide proteins; (c) antigenic sequences or antigenic proteins from microbial and viral antigens and tumour antigens; (d) immunomodulating proteins; and (e) therapeutic proteins. The coupled proteins can be used for intracellular delivery of protein sequences (ii), to exert the corresponding effector function in the target cell, and the fusion polypeptides can be expressed from corresponding polynucleotides. vectors and host cells.

19 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L3 AND VP22	79

Display Format: - Change Format